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Abstract: 
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High interstitial fluid pressure (IFP) in tumours is recognized as a barrier to 
drug delivery resulting in reduced efficacy. High IFP impedes the normal 
process of convective fluid flow (CFF) from blood vessels into the interstitium. 
The aim of this study was to develop an in vitro model that could be used to 
measure CFF and to study its effects on drug delivery. The model consists of 
a transwell cell culture insert which supports the growth of multicell layers 
(MCL) on collagen coated membranes. A graduated tube is inserted into the 
transwell and a pressure gradient is applied across the membrane by raising 
the volume of medium in the tube above that of the bottom chamber. CFF is 
determined by measuring the weight of medium in the bottom chamber as a 
function of time. CFF was inversely proportional to MCL thickness and 
41.1±3.6µm thick MCL has completely stopped CFF. Using a physiologically 
relevant hydrostatic pressure of 28mmHg, a CFF of 21µL/min was recorded 
using a DLD-1 MCL that was 12.21±3.2µm thick. Under these conditions, the 
rates of penetration of doxorubicin, imatinib and gefitinib were respectively 42, 
26 and 13 folds greater than when no CFF exists. Reversing the CFF so that it 
opposed the drug diffusion gradient significantly impairs drug penetration. In 
conclusion, a novel in vitro model for assessing the impact of CFF on drug 
delivery has been developed. This model could be used to evaluate strategies 
designed to increase drug delivery to solid tumours by modifying the CFF.   
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1. INTRODUCTION: 
1.1 General introduction to the cancer problem: 
Cancer is a cellular disease characterized by a shift in control mechanisms 
that govern the balance between cell proliferation, cell death and 
differentiation. In this disease, cancer cells grow abnormally and form a mass 
or tumour (Weinberg, 1996). Tumours can be benign or malignant. Benign 
tumours may grow but they do not invade surrounding normal tissue, spread 
to other tissues and are usually not life threatening. On the other hand, 
malignant tumours are life threatening. They grow, invade and spread 
(metastasise) to other tissues in the body.  
In comparison to normal cells, cancer cells acquire six essential hallmarks or 
traits (Figure1-1). The first hallmark is self-sufficiency in growth signals, the 
second is insensitivity to growth-inhibitory (antigrowth) signals, the third is 
evasion of programmed cell death (apoptosis), the fourth hallmark is limitless 
replicative potential, the fifth is sustained angiogenesis and finally the sixth 
hallmark is tissue invasion and metastasis, (Hanahan and Weinberg, 2000). 
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Figure 1-1: Essential Hallmarks of Cancer Cells (Hanahan and Weinberg, 2000). 
 
These hallmarks were updated in 2011. Two emerging hallmarks and two 
enabling characteristics were added to the current hallmarks (Figure1-2). The 
emerging hallmarks are the ability of cancer cells to avoid immune destruction 
and their ability to deregulate cellular energetics. The first of the enabling 
characteristics is the development of genomic instability in cancer cells which 
generates random mutations and the second is tumour-promoting 
inflammation. Tumour microenvironment plays a major role in enabling cancer 
cells to acquire these hallmarks (Hanahan and Weinberg, 2011).  
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Figure 1-2: Emerging hallmarks and enabling characteristics of cancer (Hanahan and 
Weinberg, 2011). 
 
Several factors may cause cancer. Environmental factors (Montesano and 
Hall, 2001), heredity, immune deficiency, some viral infections and 
carcinogenic agents are all linked to various cancers (Fagan-Dubin, 1979). 
Doll and Peto have listed various factors that may lead to cancer. These 
factors included tobacco, alcohol, diet, food additives, reproductive and sexual 
behaviour, occupation, pollution, industrial products, medicines and medical 
procedures and infections (Doll and Peto, 1981).  Knowledge of and a close 
understanding of how exposure to these risk factors can be reduced is an 
important weapon in the war on cancer. A detailed account of this is however 
beyond the scope of this thesis. 
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Overview of the molecular basis of cancer:  
Cancer can be considered a genetic disease. Oncogenes and tumour 
suppressor genes play a major role in the pathogenesis of cancer. DNA 
damage can lead to the activation of oncogenes and loss of tumour 
suppressor genes. Oncogenes can be considered tumour inducing factors and 
they develop from normal genes called proto-oncogenes. They have important 
roles in all phases of carcinogenesis. Activated oncogenes can produce 
excessive amounts of the normal gene product or an abnormal gene product. 
This can result in an abnormal cell growth and proliferation. The platelet 
derived growth factor receptor (PDGFR), epidermal growth factor receptor 
(EGFR), tyrosine kinases and apoptosis regulator BCL2 are examples of 
oncogenic proteins. These oncogenes can be targeted by cancer therapies 
(Croce, 2008). Imatinib is a prime example of a cancer therapy that targets a 
cancer causing oncogene in order to treat chronic myelogenous leukaemia. 
Imatinib is a small molecule that targets the tyrosine kinases ABL and C-KIT 
and the PDGFR. It is used in the treatment of chronic myelogenous leukaemia 
(Goldman and Melo, 2001) and gastrointestinal stromal tumours (GIST) 
(Cohen et al., 2010). Cetuximab is a monoclonal antibody which targets EGFR 
and is used in the treatment of colorectal cancer (Scartozzi et al., 2011). In 
contrast, tumour suppressor genes regulate and inhibit inappropriate cellular 
growth and proliferation. Mutation or loss of this gene can result in loss of 
normal cell growth control. P53 is an example of a tumour suppressor gene. 
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Mutation of P53 is one of the most common genetic changes associated with 
cancer. In addition, alteration in DNA repair genes can lead to cancer. DNA 
repair genes encode for protein that corrects errors that may occur during DNA 
duplication  (Weinberg, 1996). Cancers evolve as a result of a series of 
mutations in both oncogenes and tumour suppressor genes, the classic 
example of this being the Fearon-Vogelstein model of colorectal cancer 
(Fearon and Vogelstein, 1990). 
Incidence and Mortality Figures of cancer: 
About 12.7 million cancer cases and 7.6 million cancer death are estimated to 
have occurred in 2008 according to GLOBOCAN 2008. GLOBOCAN is an 
estimate of cancer incidence and mortality worldwide produced by the 
International Agency for Research on Cancer (IARC), which is a part of the 
World Health Organization (WHO). According to the same agency, the most 
frequently diagnosed and the leading cause of cancer death in female is the 
breast cancer which accounts for 23% of the total cancer cases and 14% of 
cancer death. However, in males, lung cancer was the leading cancer site 
accounting for 17% of total new cancer cases and 23% of the total cancer 
death (Jemal et al., 2011). 
In the European Union (EU), 1,281,436 is the predicted total number of cancer 
deaths in 2011. As the total number of cancer deaths in the (EU) was 
1,256,071 in 2007, there is an increase in the number of cases by 25,365. In 
2011, the estimated standardized cancer death rates in (EU) also are 
expected to be 142.8/100,000 men and 85.3/100,000 women compared with 
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153.8/100,000 men and 90.7/100,000 women in 2007 (figure 1-3) (Malvezzi et 
al., 2011). 
 
Figure 1-3: Cancer statistics in Europe: Bar plots of standardized death rates per 100 000 
population and certified deaths for the year 2007 (dark grey) and the predicted death rates 
and number of deaths for 2011 (light grey) for total cancer mortality in the (EU) in men and 
women (Malvezzi et al., 2011). 
 
In the United States, cancer is considered the second leading cause of death 
after cardiovascular disease. In 2010, more than 1.5 million new cancer cases 
were predicted to be diagnosed and about 569,490 cancer deaths are 
expected to be recorded in the United States. The overall survival rate from 
1999 to 2005 for all types of cancer was 68% and the five most common 
causes of death from cancer in men in the United States in 2007 were lung, 
prostate, colorectal, pancreas and leukaemia and in women they were lung, 
breast, colorectal, pancreas and ovarian cancer. Figure-1-4 represents the ten 
leading cancer types for the estimated new cancer cases and deaths in male 
and female in 2010 in the United States  (Jemal et al., 2010). 
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Figure 1-4: Ten leading cancer types for the estimated new cancer cases and deaths in men 
and women in 2010 in the United States (Jemal et al., 2010). 
 
These statistics are essential for evaluating the current cancer prevention and 
management strategies. It is clear from the current statistics that there is a real 
need for new therapies for treating cancer and/or new strategies to make the 
current available treatment modalities work better. 
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1.2 Treatment modalities of cancer: 
Surgery, radiotherapy and systemic therapy are the main cancer treatment 
modalities. 
Surgery: Surgery is the oldest modality available to treat patients with cancer. 
It is highly effective at treating cancer that have not metastasized and in these 
cases, treatment can be curative. Catching the disease early therefore is 
important but for many cancers, the disease has already disseminated at the 
time of diagnosis. Patients with limited metastatic disease may still benefit 
from surgical resection of the metastasis. Furthermore, in patients with 
advanced metastasis, surgery can be used to relieve pain, improve functional 
abnormalities (e.g. gastrointestinal obstruction) and may improve the patient’s 
quality of life (Nagula et al., 2010).   
Radiation therapy: Radiation therapy can be used to eradicate localized 
tumour masses or disseminated disease (leukaemia) with bone marrow or 
stem cell transplants. Radiation can also be used for tumours located at non-
operable areas of the body. The usefulness of radiation can be limited by its 
toxic effects on normal tissues that are located beside the tumour (Camma et 
al., 2000; Higgins et al., 1986). 
Systemic therapy: Not all cancers can be cured by surgery or radiation 
therapy, especially metastatic cancers. In these cases, systemic treatment is 
essential. These include chemotherapy (both traditional cytotoxics and 
molecularly targeted therapies), hormonal therapy and biological therapy. 
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Chemotherapy is the mainstay of systemic therapies and its origins go back to 
observations made in the middle 1940s, when mustard gas was shown to 
produce bone marrow suppression and lymphoid hypoplasia in service men 
exposed to the gas. This incident led to the use of mustard gas derivatives 
(nitrogen mustard alkylating agents) in the treatment of Hodgkin’s disease and 
other lymphomas (Joensuu, 2008). Since the use of nitrogen mustards 
emerged, a series of cytotoxic agents were developed, the vast majority of 
which kill cancer cells mainly by damaging DNA, interfering with DNA 
synthesis or inhibiting cell division. Cytotoxic chemotherapy agents have been 
classified by their effect on the cell cycle or their mechanism of action (Gilman, 
2006). Agents that affect the cell only during a specific phase of the cell cycle 
often are referred to as phase specific agents or schedule dependent agents. 
On the other hand, agents that affect the cell during any phase of the cell cycle 
are often referred to as phase non-specific agents or dose dependent agents. 
Figure 1-5, shows the mechanism of action and the effects of the cytotoxic 
drugs on phases of cell cycle. It does also show examples of phase specific 
and phase non-specific cytotoxic agents (Kimble, 2004). 
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Figure 1-5: Effects of cytotoxic drugs on phases of the cell cycle (Kimble, 2004). 
Cancer chemotherapy may be used as a primary, palliative, adjuvant or 
neoadjuvant treatment modality. It is considered a primary or a curative 
modality in some diseases like leukaemias, lymphomas and testicular cancer. 
Chemotherapy is initiated for palliative purposes in most of solid tumours to 
relieve symptoms either because of the nature of the tumour or because of 
advanced disease at time of treatment (Sepulveda et al., 2002). Adjuvant 
therapy is defined as the use of systemic chemotherapy to eradicate micro-
metastatic disease following surgery or radiotherapy or both of them. The main 
purpose of chemotherapy in this situation is to reduce tumour recurrence rates 
and prolong patient’s long term survival (Mazzeo et al., 2003). Chemotherapy 
may also be given in neoadjuvant or preoperative setting.  The purpose in this 
case is to make other treatment modalities like surgery more effective by 
reducing tumour burden and to destroy micro-metastases (Mauriac et al., 
1999). 
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With increased understanding of cancer cell biology, other systemic 
therapeutic agents have been introduced. The following section describes the 
key mechanisms of action and provides a few examples of hormonal, 
biological and molecular targeted agents used for the treatment of cancer.  
Hormonal therapy is type of anti-neoplastic therapy currently in the clinic. The 
drugs related to this group oppose or alter the effect of male or female 
hormones in hormone dependent tumours. This group of drugs inhibits tumour 
growth by blocking the receptors or by eliminating the endogenous hormone 
which feeds the tumour. The problem with this group is resistance where not 
all the tumours arising from hormone sensitive tissue respond to hormonal 
therapy. Examples of hormones used as anti-neoplastic drugs include the 
progestin hydroxyprogesterone, the anti-estrogen tamoxifen and the anti-
androgen flutamide (Ali and Coombes, 2002). 
Biological therapy is another form of systemic cancer therapy. In this group a 
protein, antibody or gene can be administered to the cancer patient in order to 
kill cancer cells or to support the patient immune system (Mihich, 2000; 
Rochlitz, 2001). The immune system plays an important role in determining 
cancer development. Immune-suppressed patients like AIDS patients face an 
increased risk of developing cancer compared to immune-competent 
individuals (Franceschi et al., 1998). Supporting the immune system can help 
prevent or treat cancer. Biological therapies aim to support individual immune 
response as well as providing selective anti-tumour effects. Immunotherapy is 
an example on biological systemic therapy and it usually involves stimulating 
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the host’s immune system to fight the cancer cells. The agents used in 
immunotherapy are naturally occurring cytokines which have been produced 
by the aid of the recombinant DNA technology. Examples of agents used in 
immunotherapy include interferons and interleukins (ILs). The proposed 
mechanism of action of Interferon-α for example is direct anti-proliferative 
efficacy, an immunomodulatory effect on natural killer cells, T cells, B cells and 
macrophages, anti-angiogenic efficacy and a differentiating effect on tumour 
cells (Kirkwood, 2002). Interleukin-2 (IL-2) is a recombinantly produced 
lymphokine with an immunoregulatory action and its use in patients with 
advanced renal cell carcinoma has induced tumour regression and increased 
patient survival with a favourable toxicity profile when used in low doses 
(Bleumer et al., 2006).  
The new generation of targeted therapeutic drugs: 
By understanding the mechanisms by which cancer cells exhibit abnormal 
growth, angiogenesis, apoptosis and metastasis, it has been possible to 
design drugs that inhibit these processes (Hanahan and Weinberg, 2011). 
Molecular targeted therapeutic agents were introduced to kill tumour cells 
without disrupting the physiological functions of normal cells (Eckhardt, 2006). 
Bevacizumab, cetuximab, trastuzumab, erlotinib, gefitinib and dasatinib are 
examples of clinically used molecular targeted agents (Soria et al., 2011). A 
list of them and other molecular targeted agents, their targets and clinical uses 
is available in table 1-1. Bevacizumab is a monoclonal antibody with 
antiangiogenic activity. It targets the vascular endothelial growth factor (VEGF) 
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(Zondor and Medina, 2004). Bevacizumab is available in the clinic for the 
treatment of non-small-cell lung cancer (Herbst et al., 2011) and colorectal 
cancer (Tol and Punt, 2010). The other monoclonal antibodies cetuximab and 
trastuzumab are also used clinically (Syed et al., 2004) for the treatment of 
solid tumours including colorectal cancer and breast cancer. They inhibit 
growth factor receptors leading to decreasing cell proliferation and increasing 
death of tumour cells (Yarden, 2001). Cetuximab targets the epidermal growth 
factor receptor (EGFR). It was reported as active and save option for the 
treatment of colorectal cancer (Roca et al., 2010). Trastuzumab is now a 
standard drug for Her-2 positive breast cancer patients (Slamon et al., 2011). 
Other examples of targeted drugs are erlotinib and gefitinib which inhibit the 
epidermal growth factor receptor tyrosine kinase (EGFR). They are used for 
the treatment of different types of solid tumours including non-small cell lung 
cancer (Herbst et al., 2011; Maemondo et al., 2010). Dasatinib also is another 
example of molecular targeted agents. It has the advantage of being used for 
the treatment of leukemias. It targets and inhibits the BCR-ABL tyrosine 
kinase. Dasatinib can be used for the treatment of patients with chronic 
myelogenous leukaemia (CML) or Philadelphia positive acute lymphoblastic 
leukaemia (ALL). It has shown efficacy in patients with CML or Philadelphia-
positive (ALL) patients who are resistant to imatinib as it inhibits imatinib BCR-
ABL mutations (Kantarjian et al., 2010; Talpaz et al., 2006). 
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Table 1-1: List of some molecular targeted agents currently in the clinic: 
Generic 
name 
Trade 
name 
Molecular 
Target 
Clinical use Reference 
Bevacizumab Avastin VEGF 
CRC, NSCLC, 
mBC, RCC 
1, 2, 3 
Cetuximab Erbitux EGFR CRC 4, 5, 6 
Panitumumab Vectibix EGFR CRC 11 
Trastuzumab Herciptin HER-2 BC 4, 5, 7 
Imatinib Glivec PDGFR 
ALL, CML, 
GIST 
9, 10 
Gefitinib Iressa EGFR NSCLC 2, 8 
Erlotinib Tarceva EGFR NSCLC 2, 8 
Dasatinib Sprycel BCR-ABL ALL, CML 9, 10 
Sorafenib Nexavar EGFR HCC, RCC 12, 13 
Sunitinib Sutent 
PDGFR, 
VEGF 
GIST 11 
Lapatinib Tyverb HER-2 NSCLC 14 
VEGF= Vascular endothelial growth factor, EGFR= Epidermal growth factor receptor, 
PDGFR= Platelet derived growth factor receptor, ALL= Acute lymphoblastic leukaemia, BC= 
Breast cancer, mBC= Metastatic breast cancer, HER-2= Human epidermal growth factor 2, 
CML= Chronic myelogenous leukaemia, CRC= Colorectal cancer, HCC= Hepatocellular 
carcinoma, RCC= Renal cell carcinoma, GIST= Gastro intestinal stromal tumour, NSCLC= 
Non-small-cell lung carcinoma.  
References: 1= (Zondor and Medina, 2004), 2= (Herbst et al., 2011), 3= (Tol and Punt, 2010), 
4= (Syed et al., 2004), 5= (Yarden, 2001), 6= (Roca et al., 2010), 7= (Slamon et al., 2011), 8= 
(Maemondo et al., 2010), 9= (Kantarjian et al., 2010), 10= (Talpaz et al., 2006), 11= (Soria et 
al., 2011), 12= (Kane et al., 2009),  13= (Chowdhury et al., 2008), 14=  (Kim et al., 2008). 
 
Current cancer treatment modalities can produce good cure and survival rates 
in some types of cancers such as certain types of leukaemia and testicular 
cancer (Brenner, 2002). But unfortunately, limitations that reduce the 
effectiveness of systemic therapy exist and these are discussed in the 
following section. 
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1.3 Limitations of chemotherapy: 
Cancer chemotherapy can be limited by several factors. These factors include 
administration technique problems, adverse effects, patient performance 
status and resistance, details of which are summarised below.  
Administration techniques: Administration techniques including dose 
intensity and the schedule of chemotherapy are considered among the 
limitations of the efficacy of cancer therapy. Dose intensity is defined as the 
amount of drug administered per unit of time. (Gianni and Piccart, 2000). 
Lengthening the interval between successive courses of chemotherapy or 
decreasing the dose can negatively affect treatment outcomes. The dose 
intensity for most chemotherapy regimens is limited by major dose-related 
toxicities such as bone marrow suppression (Lewis et al., 1997).  
The schedule of chemotherapy administration is also an important determinant 
of response. The optimal schedule is influenced by the pharmacokinetic 
properties of the anticancer agent. For example, phase-specific agents have 
cytotoxic effects only when the cell is in a particular phase of the cell cycle.  If 
a phase-specific agent with a short half-life is administered by a bolus 
injection, it may not affect all the cells. On the other hand, if it was given by 
continuous infusion, more cancer cells may be exposed to its cytotoxic effect 
(Lokich and Anderson, 1997). Increasing the duration of exposure is of course 
limited by toxicity to normal tissues. 
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Adverse effects: Adverse effects of systemic therapy are among the most 
important treatment limitation factors. Several adverse effects are common to 
most conventional chemotherapeutic agents. These adverse effects include 
nausea, vomiting, myelosuppression (including anaemia, neutropenia and 
thrombocytopenia), mucositis, alopecia, infertility and secondary malignancies. 
Some of these adverse effects like meylosuppression for example and some 
drug specific cytotoxicities like cardiotoxicity induced by doxorubicin, are  dose 
limiting side effects (Gharib and Burnett, 2002). Compared to conventional 
therapy, molecular targeted agents on the other hand, offer potential for 
improved efficacy and less toxicity as they act more selectively against cancer 
cells than normal cells (Soria et al., 2011).    
Patient performance status: Patient performance status, tolerance and 
specific factors also can play a major role in the usefulness of a 
chemotherapeutic course. Patient specific factors (e.g. performance status, co-
morbidities, renal and hepatic function, and pharmacogenomics), tumour-
specific factors (e.g. pathology, stage, and molecular profile), and treatment 
goals (e.g. palliation or cure) in addition to the cost of the treatment are all 
considered when determining the treatment option (Wedding et al., 2007).  
Resistance: Cancer cell resistance to systemic therapy is one of the most 
important limitation factors of cancer chemotherapy. Resistance can be 
classified into primary, acquired or multi drug resistance (MDR) and apparent 
resistance caused by limited drug delivery to the solid tumour. Drug resistance 
may be either inherent in cancer cells (primary) or acquired i.e. develop over 
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time during chemotherapy even after dramatic initial response. Some cell lines 
that became resistant to single chemotherapy agents may also be resistant to 
other agents that can be structurally non-related. This phenomenon is called 
multidrug resistance (MDR). The primary mechanism believed to be 
responsible for MDR is an increase in P-glycoprotein in the cell membrane. 
This protein mediates efflux of the chemotherapy agent causing a decreased 
accumulation of drug within the cells (Gottesman, 1993). Other mechanisms of 
resistance include alterations in metabolic pathways that influence drug 
metabolism, DNA repair, or apoptosis (Regev et al., 2007; Tannock and Rotin, 
1989). As for conventional chemotherapy, molecular targeted agents have 
also shown to develop resistance (Nishida et al., 2008). The most widely 
studied cause of resistance is cell related. However, a neglected type of 
resistance is generated by the inability of drugs to penetrate into the solid 
tumour efficiently. Numerous studies support this proposal (Eytan, 2005; Hicks 
et al., 2003; Kyle et al., 2007; Sutherland et al., 1979; West et al., 1980) but 
the seminal work was done by Sutherland (1979).  
Sutherland and his group studied resistance to doxorubicin using multicellular 
spheroids as an in vitro model. They used EMT-6 mammary tumour cell 
spheroids which were resistant to different exposure doses of doxorubicin. 
Compared to monolayer cultures, EMT-6 spheroids were exposed to different 
doxorubicin concentrations for different periods and a concentration gradient 
of fluorescence was observed from the outside to the centre of the intact 
spheroids. In addition, intact spheroids took up less doxorubicin compared 
with dissociated spheroids. Intact spheroid cells have also shown resistance 
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compared with dissociated cells when surviving fraction was plotted versus 
absorbed doxorubicin. Sutherland and his group also proved that the inner 
spheroid cells were the most resistant. They concluded that a diffusion barrier 
is present in the EMT-6 spheroids and they proposed that other factors related 
to the metabolic state of the cells, the microenvironment or the formation of 
different drug products must account for the observed resistance. (Sutherland 
et al., 1979).  
This field has developed over the years and more recently, Hicks and 
colleagues (Hicks et al., 2003) developed a pharmacokinetic 
(PK)/pharmacodynamic (PD) model for the hypoxia selective drug 
tirapazamine (TPZ) which is currently in clinical trials (Rischin et al., 2010). 
Through this model, TPZ diffusion through HT-29 colon carcinoma multi-cell 
layers (MCL) was measured. In this model, TPZ PK was represented by its 
transport through the MCLs whereas its PD was represented by its cytotoxicity 
using the clonogenic assay. Cytotoxicity of transported TPZ through different 
thicknesses of anoxic HT-29 MCLs was proportional to the measured values 
of TPZ in the medium of the diffusion model. These values on the other hand 
were inversely proportional to the MCL thickness. Hicks and colleagues 
concluded that inefficient transport was responsible for tirapzamine resistance 
in multicell layers of HT-29 (Hicks et al., 2003). 
Other studies have shown that drug resistance depends on the solid tumour 
microenvironment (Heldin et al., 2004) and pharmacological factors related to 
drug and/or on problems related to the delivery of anticancer drugs to the 
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tumour cells (Baxter and Jain, 1989; Cowan et al., 1996; Cowan and Tannock, 
2001; Kyle et al., 2004; Kyle et al., 2007; Phillips et al., 1998; Primeau et al., 
2005; Tannock et al., 2002; Tunggal et al., 1999). Details of some of these 
studies will be discussed later in this thesis. Results of all these studies 
suggest that optimization of transport properties of anticancer drugs may 
improve their therapeutic efficacy. Although the results of these studies have 
shown that limited drug delivery is one of the expected causes of 
chemotherapy resistance, an argument can be raised here that drugs such as 
doxorubicin are available in the clinic for treating several types of cancer so 
must be delivered well enough to have efficacy. The following section will 
discuss whether or not limited drug delivery to solid tumours is considered a 
clinical problem. 
1.4 Limited drug delivery to solid tumours as a form of drug 
resistance: 
To answer this question it is essential to consider specific therapeutic 
compounds, key questions to be addressed include; are the successful 
compounds able to efficiently penetrate their target tissue and is there 
evidence that ineffective agents fail due to limited penetration?  
The best characterised drug in terms of its distribution is the anti-cancer agent 
doxorubicin, as its natural fluorescence facilitates its easy detection within 
tissues. A variety of different experiments show that doxorubicin penetrates 
tumours poorly. For example, the drug shows weaker activity against the cells 
in the centre of spheroid preparations (Durand, 1990; Kerr and Kaye, 1987) 
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and in the deeper layers of MCLs (Kyle et al., 2004). This is also the case in 
vivo, with Lankelma and colleagues (1999) showing with laser scanning 
microscopy that cells which are remote from the microvessels are exposed to 
lower doxorubicin concentrations (Lankelma et al., 1999). 
The taxanes paclitaxel and docetaxel are microtubule-disrupting agents that 
are used to inhibit the growth of solid tumours. Similar distribution in tumours 
has been found for these drugs as for doxorubicin (Kuh et al., 1999; Kyle et 
al., 2007). Paclitaxel showed poor penetration in tumour sections which were 
incubated at 37°C in medium containing different paclitaxel concentrations for 
various times. (Kuh et al., 1999; Li et al., 2000) and both drugs showed 
inefficient distribution in MCL and tumour xenograft models (Kyle et al., 2007). 
These results clearly demonstrate that at least several anti-cancer drugs 
penetrate solid tumours to a very limited degree. However, these agents are 
relatively successful in the treatment of cancer, questioning the necessity of 
efficient drug penetration in order to produce a therapeutic effect. It is still 
possible that these drugs could still be successful even if they cannot reach 
the cells that reside some distance from the blood supply (Minchinton and 
Tannock, 2006). For example, it may be that killing the cells that are close to 
blood vessels progressively renders more cells distant from blood vessel 
susceptible to the drug. Chemotherapy is typically given in repeated cycles, 
and so it could be that more and more of the tumour is destroyed with each 
treatment cycle (Minchinton and Tannock, 2006). Alternatively, it is possible 
that just killing the cells in the proximity to blood vessels is sufficient to result in 
tumour regression, possibly because the cells that are distant from blood 
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vessel are necrotic and therefore cannot sustain tumour growth. This might 
suggest that widespread distribution of chemotherapeutic agents throughout 
solid tumours is not critical for their therapeutic success. 
In reality, it is hard to argue against the fact that these drugs would be 
considerably more effective if they were able to distribute more thoroughly 
throughout the tumour mass. This seems logically far more likely, and there 
are a few lines of evidence that may support this view. Some tumours develop 
resistance to these agents, and, although this is often attributed to efflux 
mechanisms or the acquisition of new mutations (McGrogan et al., 2008), it 
may be that inefficient killing of cells in the tumour interior allows the tumour to 
re-grow when the drug is removed. Moreover, there are many examples of 
anti-cancer compounds that are ineffective, and which can be demonstrated to 
penetrate tumours poorly. For instance, tirapazamine (TPZ), a drug designed 
to be activated once it reaches the hypoxic core of a tumour (Hicks et al., 
2004) as mentioned above, is comparatively ineffective, probably because it 
cannot reach deep into tumours (Hicks et al., 2003). The other example is the 
well-known anti-cancer agent 5-flourouracil (5-FU). It was proved that the 
concentration of 5-FU in tumour is directly proportional to its therapeutic effect 
(Muller et al., 1997; Presant et al., 1994). There is also evidence that efficient 
tissue distribution of drugs is crucial for successful treatment of other diseases. 
Drugs that act on the central nervous system (CNS) are an example (Upton, 
2007). The inability of some of them to cross the blood brain barrier (BBB) and 
distribute through the cerebrospinal fluid makes the pharmacological targeting 
of the brain difficult (Liu et al., 2008). 
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Considering limited drug delivery to solid tumours as one of the causes of 
chemotherapy resistance, it is essential to be familiar with different factors 
which may interfere with drug delivery process. The following section 
discusses the factors which influence drug penetration into cancerous tissues 
and cause limited drug delivery. 
1.5 Factors influencing drug penetration into solid tumours: 
The effectiveness of cancer treatment depends on adequate delivery of the 
anticancer agent to tumor cells. Once it has reached the tumour cell, how it 
interacts with cellular macromolecules will also determine response. Many 
factors influence how much drug reaches tumours, the major ones have been 
summarized by Minchinton and Tannock (2006) into supply, flux and 
consumption (figure 1-6) (Minchinton and Tannock, 2006).  
 
Figure 1-6: "Factors determining drug distribution in tissue. (a) Supply. The supply of a drug to 
the tissue will depend on its initial dose and its pharmacokinetics (PK). (b) Flux. After leaving 
the vasculature, flux through tissue can occur through extracellular or trans-cellular pathways, 
depending on relative solubility in water and lipids. Although diffusion through water will vary 
with size or molecular weight (mw), movement will be hindered by interactions with 
extracellular and cellular components, and the barrier posed by the cell membrane. (c) 
Consumption. Tissue penetration will be determined by the balance between delivery (supply 
and flux) and consumption. Cellular metabolism will reduce drug penetration and build-up 
within the tissue, and binding and sequestration can increase net tissue levels of a drug but 
limit its penetration. " (Minchinton and Tannock, 2006). 
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Drug supply: The cytotoxic effects of chemotherapy agents are related to the 
time the tumour is exposed to an effective concentration of the agent 
(Alagkiozidis et al., 2011). A multitude of factors determine how much drug 
reaches the tumour. These include the dosage regimen or schedule 
employed, the actual dose administered, the type of administration (e.g. 
infusion or bolus) and route of administration. These factors can influence the 
concentration of the drug at the tumour site. In addition to the initial dose of 
administered drug, the pharmacokinetic (PK) processes of absorption, 
distribution, metabolism and excretion of the administered drug affect its 
concentration in the plasma (Rentsch et al., 1998). Some other 
pharmacological factors can also affect the drug distribution in normal or 
cancerous tissue. These factors are host related and they can affect the basic 
elements of pharmacokinetics and hence influence the supply of drugs to solid 
tumour, Table 1-2, (Garattini, 2007). 
The vasculature of tumours is a critical factor that influences drug supply. It is 
well known that the vascular network which develops within tumours is poorly 
organised, inefficient and not extensive and this has a significant impact upon 
the supply of drugs to tumours (Brown and Wilson, 2004).   
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Table 1-2: Host factors influencing PK profiles and drug supply to tumours (Garattini, 
2007). 
• Age, Sex, Body weight, Race, Co-morbidity  
• Genetic differences in cytochrome P450 and drug 
efflux and uptake transporters. 
• Interactions with herbal remedies, food and drugs. 
ABSORPTION 
• Nausea, vomiting. 
• Gastric acid secretion. 
• Dissolution of tablets. 
DISTRIBUTION 
• Ascites or pleural effusion. 
• Plasma albumins and α1-acid-glycoprotein. 
• Amount of body fat. 
• Blood brain barrier (BBB). 
METABOLISM 
• Liver dysfunction. 
• Altered hepatic blood flow. 
• Reduced liver mass. 
• Inflammation. 
EXCRETION 
• Altered biliary flow. 
• Renal insufficiency. 
• Urinary pH. 
 
Drug flux through the tissue: Once a drug reaches the tumour, it has to 
leave the blood vessel (extravasate) and penetrate through several layers of 
cells. This process is called flux. There are two key processes by which drugs 
move through tissues; diffusion down a concentration gradient and convection 
which refers to the flow of fluid driven by differences in fluid pressure. Small 
molecules are mainly transported through tissue by diffusion whereas large 
molecules are transported by convection (Bobo et al., 1994). Drug diffusion 
depends mainly on the concentration gradient whereas convection depends 
on hydraulic conductivity and pressure differences (Jang et al., 2003). Drug 
flux through the tissue also depends on physicochemical properties such as 
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molecular weight, hydro or lipophilicity, and the charge of the drug. For 
example, the larger the drug molecule, its penetration through the extracellular 
matrix (ECM) is likely to be hindered. This applies to therapeutic agents such 
as antibodies (Garattini, 2007)  
Drug consumption in the tissue: The last determinant factor of drug 
distribution in tissues is drug consumption, binding or sequestration in the 
targeted tissue. Drug can be consumed in the tissue in different ways. 
Consumption can occur through drug binding to receptor in the tissue. Whilst 
this type of binding can increase the deposition of the drug in the tissue, 
sequestered drugs will not be able to move to other cells within the tissue.  
Metabolism can lead to inactivation or degradation of the drug in preparation 
for it to be excreted. Consumption can also remove free drug by inhibiting 
further permeation (Baxter and Jain, 1991; Minchinton and Tannock, 2006).   
In case of solid tumours, drug distribution in tissues can also be affected by 
other physiological factors related to the tumour microenvironment. These 
factors include irregular tumour vasculature, extracellular matrix (ECM) 
components, high interstitial fluid pressure (IFP) and cell to cell adhesion. The 
influence of physiological factors related to the characteristics of the tumour 
microenvironment on drug delivery and chemoresistance is discussed below. 
Heterogenous angiogenesis and blood flow in tumours: Solid tumours 
have a unique physiology that is generated as a result of a chaotic and poor 
blood supply. During tumour development, the process of angiogenesis is 
“turned on” but the blood supply that develops is very different from that found 
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in normal tissues. Blood vessels in solid tumours are often highly abnormal 
with distended capillaries, leaky walls and sluggish flow (Figure-1-7) (Brown 
and Wilson, 2004; Shubik, 1982). In addition, the compression of blood 
vessels caused by cancer cells, increase resistance to blood supply and 
impair blood supply to the tumour. All this can result in reducing the delivery of 
nutrients and the clearance of metabolism products leading to hypoxic and 
acidic regions in the tumour, increased interstitial fluid pressure (IFP), 
abnormal extracellular matrix and establishing a microenvironment that has a 
direct impact on the delivery of anticancer drugs (Jain and Baxter, 1988; 
Padera et al., 2004). 
 
Figure 1-7:  "The main differences between the vasculature of normal and malignant 
tissue. Whereas normal tissues have relatively uniform and well-ordered blood vessels that 
are sufficiently close together to oxygenate all of the tissues, blood vessels in tumours are 
tortuous, have incomplete vessel walls, have sluggish and irregular blood flow, and have 
regions of hypoxia between the vessels" (Brown and Wilson, 2004). 
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As stated above, poor and inefficient blood supply can lead to the presence of 
hypoxic regions within solid tumour tissues. In solid tumours, hypoxia has a 
significant role in enhancing resistance to both radiotherapy and 
chemotherapy (Brown, 1999). As the oxygen concentration decreases with 
increasing distances from the capillary, both cell proliferation rates and drug 
concentration also decrease (Figure 1-8). As a consequence of hypoxia, the 
fraction of proliferating cells will be decreased. The inhibition of cell 
proliferation can cause a decrease in the efficacy of most anticancer drugs 
because they are effective against rapidly dividing cells (Brown and Wilson, 
2004; Minchinton and Tannock, 2006).  
 
Figure 1-8: "Reasons why cells distant from blood vessels might be resistant to treatment. (a)  
Cords of cells surrounding a blood vessel in a xenograft of a cervix cancer. (b) Cords of cells 
surrounding a blood vessel in a xenograft of colon cancer. More cells are proliferating 
(bromodeoxyuridine-labelled black cells) close to the blood vessel. Green staining indicates 
hypoxic regions identified by pimonidazole. Proliferation occurs primarily close to blood 
vessels. Endothelial cells are coloured blue. (c) A diagrammatic representation illustrating the 
gradients in oxygen, nutrients and energy, and drug concentration." (Minchinton and Tannock, 
2006). 
46 
 
 
The pH within the tumour microenvironment can also influence chemotherapy 
resistance or delivery of anticancer agents to cancer cells. Drug molecules 
depend mainly on passive diffusion to cross the cell membrane and diffusion 
will depend upon factors such as charge on the molecule. In the tumour 
microenvironment, the extracellular pH is low and the intracellular pH is neutral 
to alkaline (Kozin et al., 2001). Based on that, weakly basic drugs such as 
doxorubicin are protonated and show limited cellular uptake. On the other 
hand, weakly acidic drugs such as cyclophosphamide can be concentrated in 
the neutral intracellular space (Gerweck et al., 2006; Tannock and Rotin, 
1989). In summary, a drug resistance in hypoxic and acidic regions of the solid 
tumour microenvironment may be related to a one of the following reasons, 
first, some drugs may be less effective in hypoxic, acidic, or nutrient deprived 
microenvironment, and second, cells in hypoxic areas may be exposed to low 
concentrations of drug because of limited drug access (Brown and Wilson, 
2004; Tannock and Rotin, 1989).  
Extracellular matrix (ECM) components: Solid tumours are composed of 
cancer cells and stromal cells including fibroblasts and inflammatory cells. 
Cancer cells and stromal cells are surrounded by an extracellular matrix 
(ECM) and are nourished by a vascular network. The ECM of solid tumours is 
composed of fibrous proteins such as collagen and polysaccharides like 
hyaluronan and proteoglycan. The role of ECM in normal tissue is to maintain 
homeostasis, generate tissue cohesiveness, act as a barrier to bacterial 
invasion and regulate macromolecule transport through interstitium (Heldin et 
al., 2004). Compared with normal tissues, tumour cells and stromal cells are 
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associated with an abnormal or altered ECM (Jang et al., 2003). The 
composition of extracellular matrix ECM in tumour can slow down the 
movement of molecules within the tumour and form a transport barrier against 
therapeutic drug penetration (Jain, 1998). Presence of glycosaminoglycan and 
collagen in the ECM can lower the hydraulic conductivity and lower convective 
fluid flow (CFF) through the interstitium (Netti et al., 2000).  
Cell to cell adhesion: Cell-cell adhesion is another characteristic of the 
tumour microenvironment which acts as a barrier to drug delivery. The role of 
cell adhesion molecules (CAMs) in morphology, locomotion, mitosis, 
cytokinesis, phagocytosis and maintenance of cell polarity have been studied 
(Pavalko and Otey, 1994). CAMs are glycoproteins found on the cell surface  
and act as a receptor for cell-to-cell and cell-to-ECM adhesions (Hynes and 
Zhao, 2000). CAMs can be divided to integrins, cadherins, selectins and the 
immunoglobulin superfamily (Dunehoo et al., 2006). Targeting or modifying 
CAMs such as integrins to disrupt cell-cell adhesion can be exploited to 
enhance drug delivery to solid tumours (Chen and Chen, 2011). 
High interstitial fluid pressure (IFP) and convective fluid flow (CFF): 
Another feature of solid tumours is the absence of a widespread lymphatic 
supply which is essential for returning the interstitial fluid to the blood 
circulation. In normal tissue, tissue fluid and macromolecules are drained via 
the lymphatic system. An impaired lymphatic system is a characteristic of solid 
tumours (Leu et al., 2000) which can lead to the retention of fluid and 
macromolecules in the tumour interstitium. The lack of a functional drainage 
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system causes the accumulation of fluids and contributes to increased 
interstitial fluid pressure (IFP) (Heldin et al., 2004; Hicks et al., 2006). This in 
turn can limit drug penetration into solid tumours in spite of leaky 
microvasculature because high IFP reverses the direction of CFF and fluid 
moves from the tumour into the blood vessel. This inhibits the transvascular 
transport of molecules and inhibits transport in the interstitial space (Jain, 
1998; Padera et al., 2004). This issue will be discussed in detail in the 
following section as it is one of the key objectives of this project. 
1.6 Impact of interstitial fluid pressure (IFP), hydrostatic 
pressure (HP) and convective fluid flow (CFF) on drug 
penetration: 
One of the main objectives of this project is to assess the impact of convective 
fluid flow (CFF) on drug penetration. This section will discuss the impact of 
IFP, hydrostatic pressure (HP) and CFF on drug distribution in tissue as they 
are all related to each other. As explained earlier, one of the consequences of 
elevated IFP in solid tumours is that the normal process of CFF through tissue 
is impeded. This is now recognised as a major barrier to drug uptake leading 
to reduced drug efficacy (Heldin et al., 2004). Drugs are transported out of 
capillaries to the tissue by diffusion and/or convection. They are transported 
through the interstitial space then into the lymphatic system or venous part of 
the vasculature to be drained or excreted. Transcapillary pressure is 
determined by the HP and colloid osmotic pressure in capillaries and in the 
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interstitium, together with hydraulic conductivity and the plasma protein 
reflection coefficient (Figure 1-9) (Heldin et al., 2004).  
 
Figure 1-9: Factors regulating drug transcapillary transport in normal and cancerous tissue: In 
normal tissue, the hydrostatic pressure is greater than the IFP; therefore there is a net outward 
filtration of 1-3 mm Hg. In tumour tissue, the hydrostatic pressure is less than or slightly 
greater than the IFP therefore there is a net inward or outward pressure of -18-2mm Hg  
(Heldin et al., 2004). Figure’s abbreviations: COP= Colloidal osmotic pressure, P= Hydrostatic 
pressure, IF= Interstitial fluid, CAP= Capillary.  
 
In normal interstitium, the transcapillary flow is outward from the vessel into 
the interstitium. In case of tumour tissue however, the transcapillary flow or the 
filtration pressure is either inward or outward pressure. In case of solid tumour, 
HP and IFP are often increased (Jain, 1987b). This was noticed in breast 
cancer, colorectal cancer (Less et al., 1992) and head and neck cancer 
(Gutmann et al., 1992). IFP values in solid tumours may reach up to 38 mmHg 
(table 1-3) (Jain, 1998).  
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Table 1-3: Values of IFP (mmHg) in normal and neoplastic tissues, (Jain, 1998).  
Tissue type N Mean IFP (mmHg) 
Normal skin 5 0.4 
Normal breast 8 0.0 
Head/neck carcinomas 27 19 
Cervical carcinomas 26 23 
Lung carcinomas 26 10 
Metastatic melanomas 14 21 
Breast carcinomas 13 29 
Brain tumours 17 7 
Colorectal liver metastasis 8 21 
lymphomas 7 4.5 
Renal cell carcinoma 1 38 
 
IFP can be measured using the wick-in needle technique or the micropuncture 
technique. Wick-in needle technique is performed by inserting a fine steel 
needle filled with a wick into the tissues to measure the fluid pressures. The 
needle is connected to pressure sensors that can read the pressure. The 
micropuncture technique is performed using a sharpened glass capillary. The 
capillary is connected to a counter pressure system to measure the fluid 
pressures in the tissues. This technique is more reliable than the wick-in 
needle as it is less traumatic. However, wick-in needle technique reserves the 
advantage of being able to measure fluid pressures in deep tissues (Aukland 
and Reed, 1993; Heldin et al., 2004). 
Elevated IFP occurs in solid tumours due to blood-vessel leakiness, abnormal 
lymphatic system, interstitial fibrosis and contraction of the interstitial space 
caused by stromal fibroblasts (Heldin et al., 2004). High IFP which is a 
characteristic of solid tumours can limit drug delivery to solid tumours. 
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Evidence for this is provided in several studies. One of them revealed that 
patients with melanoma or lymphoma who showed low IFP responded better 
to the treatment whereas those with high IFP did not respond to the treatment 
(Curti et al., 1993). Resistance and bad progression in these tumours were 
expected by the author to be due to the high IFP. However, the author did not 
specify clearly that resistance noticed with high IFP was due to limited delivery 
of chemotherapeutic agents to theses tumours. In another study, high IFP in 
patients with cervical cancer caused high recurrence rate and poor prognosis 
(Milosevic et al., 2001).  
Large molecules such as proteins are transported in the interstitium by CFF. 
On the other hand, low molecular weight compounds such as oxygen and 
glucose are mainly transported by diffusion (Jang et al., 2003). High IFP can 
impede CFF and hence limit the delivery of drugs that depend on CFF to be 
delivered to the solid tumour. For this reason lowering IFP to turn CFF on 
again might be an effective strategy to improve drug delivery to solid tumours.  
Utilizing convection (CFF) to deliver drugs to solid tumours has been tested in 
several studies (Baxter and Jain, 1989; Bobo et al., 1994; Chary and Jain, 
1989; Mardor et al., 2005; Swabb et al., 1974). Chary and Jain (1989), used 
fluorescence photobleaching to measure interstitial convection and diffusion of 
albumin in normal and neoplastic tissues grown in a thin, transparent window 
chambers in the ear of a rabbit. Average albumin velocity and albumin 
diffusion coefficient were measured. The results of this study provided impetus 
for further investigation into convection and diffusion in different normal and 
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neoplastic tissues (Chary and Jain, 1989). Another study investigated the use 
of convection as a mean to enhance the distribution of the large and small 
molecules in the brains of anesthetized cats. Convection-enhanced distribution 
of transferrin as macro and sucrose as micro molecules into the white matter 
of these anesthetized cats was produced through maintaining a pressure 
gradient during interstitial infusion. Using interstitial infusion to enhance drug 
delivery to brain, transferrin and sucrose brain concentrations were >100-fold 
higher than systemic concentrations. Results of this study showed that 
enhanced distribution of large and small molecules can be obtained in the 
brain through maintaining convection. This in turn can result in achieving high 
drug concentrations in the brain as well (Bobo et al., 1994). A clinical trial has 
been conducted to study the safety and efficacy of the use of intratumoural 
convection-enhanced delivery (CED) of paclitaxel for the treatment of patients 
with recurrent malignant gliomas. CED of paclitaxel was associated with high 
(73%) antitumour response rates in patients included in this study (Lidar et al., 
2004). Mardor and his group used magnetic resonance imaging (MRI) to 
assess convection efficiency and cytotoxic tissue response to different 
anticancer agents in a rat brain model. Using convection for direct delivery of 
drugs to brain based on delivering a continuous infusion via intracranial 
catheter is a novel drug delivery approach. Using this method to deliver 
different anticancer agents including taxol and carboplatin was assessed and 
showed efficient distribution in the brain. This method can be applied to other 
anticancer agents especially those with high molecular weights (Mardor et al., 
2005).  
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The results of these studies support the usefulness of utilizing CFF as a tool to 
improve drug delivery to solid tumours. Utilizing the knowledge gained from 
the factors that limit drug penetration and drug delivery to solid tumours can 
help designing methods, experiments and techniques to study this problem. 
The following section will discuss these techniques. 
1.7 Methods used to study drug penetration into solid 
tumours: 
A wide range of in vitro and in vivo techniques have been used to examine 
drug penetration in solid tumours. These techniques include the use of 
multicellular spheroids (MCS), (MCLs) and animal's studies, details of which 
are outlined below.  
1.7.1 In vitro techniques: 
Multicellular spheroids: Multicellular spheroids (Figure 1-10a), are spherical 
aggregates of cells. MCS were first described by Sutherland’s group in the 
1970’s and it provides one of the first 3 dimensional culture models which 
could be used to study drug resistance and tumour biology (Inch et al., 1970). 
Drug penetration studies employed MCSs as a reasonable model for solid 
tumours with similarities to solid tumours environment (Nederman and 
Twentyman, 1984). Similarities of MCSs to solid tumours environment are 
represented by the ability of MCSs to generate an ECM, presence of tight 
junctions between cells, gradients of cell proliferation, gradients of nutrient 
concentration, gene expression, and biological behaviour of cells (Durand, 
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1989; Nederman and Carlsson, 1984; Sutherland, 1988; Sutherland et al., 
1979; West et al., 1980). Using fluorescent or radiolabeled drugs, studies have 
shown limited penetration of doxorubicin, vinblastine, paclitaxel and 
methotrexate into the deeper layers of spheroids (Minchinton and Tannock, 
2006; Sutherland et al., 1979; West et al., 1980). Analysis of drug penetration 
into MCS is however restricted to those drugs that are naturally fluorescent or 
can be radiolabeled. The multi-cell layer model (Figure 1-10b) described below 
circumvents this limitation as a wide range of analytical techniques can be 
applied.   
Multicell layers: The multicell layer model was initially described by Wilson 
and his colleagues (Cowan et al., 1996; Hicks et al., 2006) and it provides a 
quantitative method that permits direct assessment of drug penetration 
through cell layers (Tannock and Rotin, 1989). The apparatus is shown in 
(figure 1-10c) and tumour cells are grown on collagen coated micro porous 
Teflon membrane to form the MCL. The resulting MCLs have a symmetrical, 
planar structure. To examine penetration, a drug is added to one side of the 
MCL (donating chamber) and its appearance on the other side of the MCL 
(receiving reservoir) is measured as a function of time using an appropriate 
analytical method, (Figure 1-10d). MCL is similar to MCS in sharing several 
properties of solid tumours derived from the same cell type, including a similar 
ECM, and tight junctions between epithelial cells. Studies conducted using 
MCLs have shown poor penetration of many anticancer agents through them 
(Kyle et al., 2004; Kyle et al., 2007; Phillips et al., 1998; Primeau et al., 2005; 
Tunggal et al., 1999). Phillips and his team described and characterized a 
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modified version of the assay published by Cowan et al in 1996, (Cowan et al., 
1996). This study also illustrated the application of this assay for evaluating 
the ability of bioreductive drugs such as EO9 and tirapazamine to penetrate 
multicell layers. Results of this study showed limited penetration of these 
drugs especially EO9 through the MCLs of DLD-1 which suggested that the 
failure of EO9 in the clinic was mainly due to combination of poor delivery and 
rapid in vivo elimination of the drug (Phillips et al., 1998). Tunggal and his 
team used the MCLs to quantify the penetration of four widely used anticancer 
drugs. The penetration of doxorubicin and mitoxantrone was limited and very 
slow compared to the penetration of methotrexate and 5-FU. MCLs have been 
shown to act as a substantial barrier to the effectiveness of these drugs 
(Tunggal et al., 1999). Tannock has also used MCLs to study the penetration 
of some anticancer drugs and suggested that the limited ability of anticancer 
drugs to reach tumour cells that are distant from blood vessels might be an 
important cause of clinical resistance of solid tumours to chemotherapy 
(Tannock et al., 2002). Using MCLs, different analytical techniques can be 
used such as high-performance liquid chromatography and mass 
spectrometry. The application of these techniques provides many advantages 
including the ability to differentiate between the parent compound and any 
metabolic products formed. This feature is not possible with spheroids 
(Minchinton and Tannock, 2006). 
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Figure 1-10: "Multicellular models used to study drug penetration. (a) Multicellular spheroids 
are grown in spinner culture to form spherical aggregates. (b) Multilayered cell cultures 
(MCCs) are grown on permeable support membranes; proliferating cells are located 
predominantly close to the upper and lower surfaces. (c)  Studies of drug penetration are 
usually performed by separating two reservoirs with an MCC (left) or by floating an MCC on a 
medium with the drug of interest added to the small compartment above the MCC, and 
sampling from the lower receiving reservoir (right). (d)  The penetration of a drug through an 
MCC (lower curves) is usually compared to penetration through the support membrane alone 
(upper curves), as shown for doxorubicin (left) and 5-fluorouracil (right)." (Minchinton and 
Tannock, 2006). 
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1.7.2  In vivo techniques: 
Different in vivo methods can be used to study drug penetration into solid 
tumours. These include:  
Window chambers: In vivo techniques can be performed in animals directly in 
a model called window chambers. In this technique, tumour is implanted under 
the skin of an experimental animal. The tumour is then covered with a 
translucent window. In this in vivo model, tumours are observed directly in the 
living animals prior to and after drug administration. Direct assessment of 
fluorescent drug penetration or distribution into tissue can be achieved using 
this technique (Chary and Jain, 1989; Dreher et al., 2006; Netti et al., 2000). 
This technique can also give information about the in vivo effect of an 
anticancer agent (Chary and Jain, 1989; Helmlinger et al., 1997). 
Tumour sections: In vivo techniques can also be performed through using 
sections of tumours taken either from animal (Figure 1-11) or human (Figure 1-
12) treated tissues. Using these sections, drug distribution in tumour can be 
studied using direct fluorescence or immunohistochemistry. Direct visualisation 
of fluorescent drugs like doxorubicin in a tumour microenvironment was 
studied using this technique (Henneberry and Aherne, 1992; Ozols et al., 
1979). Drug distribution in tumours in relation to blood supply or hypoxia can 
also be studied using fluorescent-labelled antibodies (Lankelma et al., 1999; 
Primeau et al., 2005) as seen in figures 1-11 and 1-12.  
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Figure 1-11: Doxorubicin distribution into sections of tumour tissue: Perivascular distribution 
of doxorubicin (blue) in relation to hypoxic regions (green) and blood vessel (red) in tissue 
sections of mouse mammary adenocarcinoma (16C). Bar, 100 µm. (Primeau et al., 2005). 
 
Figure 1-12: Doxorubicin distribution in human tissue: Doxorubicin distribution (red) at 2 h 
after doxorubicin injection of patient. Immunostaining vessels with an antibody to CD31 
(green), both colours yields (yellow) when superimposed. Doxorubicin nuclear concentrations 
were highly observed near the microvessles. Magnifications: x10 (A); x40 (B and C).  
(Lankelma et al., 1999). 
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Non-invasive imaging techniques: The development of non-invasive 
imaging techniques such as magnetic resonance imaging (MRI) and positron-
emission tomography (PET) for studying drug distribution in tissues of animals 
or humans are promising tools. The only problem facing these methods is the 
resolution which is not yet able to assess drug distribution in solid tumours. 
However, with the development of more advanced technology, these 
techniques might improve in the future and become useful tools for 
researchers who are interested in this field (Brindle, 2008). 
There are advantages and disadvantages of using in vivo methods to study 
drug penetration. The advantage of using in vivo methods is that they are 
more realistic than in vitro methods as they represent the whole factors that 
affect drug distribution in tissues including drug metabolism which is not 
present in the in vitro techniques. On the other hand, the high cost, time 
consumption and the extensive use of animals are the most important 
disadvantages of in vivo techniques. 
These in vitro and in vivo methods can be exploited to design experiments and 
models to study drug penetration and to develop strategies to improve drug 
delivery to solid tumours. These strategies are discussed in the following 
section. 
60 
 
 
1.8 Strategies used to improve drug penetration into solid 
tumours: 
Understanding the barriers to drug delivery to solid tumours is central to the 
development of strategies that are designed to improve drug delivery to cancer 
cells. Several strategies have been developed and these include; manipulating 
tumour vasculature, reducing IFP, manipulation of tumour pH, modification of 
the ECM, modifying drug administration regimens, and modifying drug 
pharmacokinetics or physicochemical properties of compounds. These 
strategies with some examples are explained below:  
1.8.1 Manipulating tumour vasculature: 
Pre-treating solid tumours with anti-angiogenic therapy: Anti-angiogenic 
agents such as the monoclonal antibody bevacizumab that targets vascular 
endothelial growth factor (VEGF), seems to improve the effect of cancer 
chemotherapy mainly by normalizing the vascular architecture in tumours,  
improving blood flow and reducing the IFP (Jain, 2001, 2005; Tong et al., 
2004). Experimental studies showed that combining anti-VEGF target drugs 
with other chemotherapeutic agents increased the responses of experimental 
tumours (Segers et al., 2006; Wildiers et al., 2003). Using bevacizumab in 
clinical trials for the treatment of patients with metastatic colorectal cancer 
(Arkenau et al., 2009; Hurwitz et al., 2004), non-small-cell lung cancer (Herbst 
et al., 2011; Herbst et al., 2007; Sandler et al., 2006) and malignant gliomas 
(de Groot and Yung, 2008), prolonged survival rates when combined with 
other chemotherapeutic agents have been recorded.   
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Use of vascular disrupting agents: A number of agents have been 
developed to directly target the vasculature of tumours with the aim of either 
cutting off the blood supply to the tumour or trapping drug inside the tumour by 
collapsing the vasculature when the drug concentration in the tumour is at its 
maximum (Curnis et al., 2002; Siemann et al., 2005). Drugs in this class 
include tumour necrosis factors, flavone acetic acid, dimethylxantheone acetic 
acid, and the tubulin binding agents like combretastatin-A4 disodium 
phosphate (Horsman and Siemann, 2006; Siemann, 2011). The effect of these 
agents on the tumour vasculature include elevation of vessels permeability, 
reducing tumour blood flow, reducing drug clearance from tumour and hence 
increasing drug accumulation at the tumour site. On the other hand, if vascular 
disrupting agents were given before chemotherapy they may cause reduction 
in blood flow which in turn can increase the IFP which leads to a decrease in 
drug delivery to the tumour (Horsman and Siemann, 2006). Some of the 
vascular disrupting agents are being or have been tested in clinical trials. The 
most important of them are the tubulin-depolymerizing vascular disrupting 
agent combretastatin A-4 phosphate CA4P (Fosbretabulin) and the flavonoid 
vascular disrupting agent ASA404 (Vadimezan) (Siemann, 2011). In a phase II 
clinical trial, ASA404 in combination with carboplatin and paclitaxel has given 
5 month patient survival advantage when it was given to patients with non-
small cell lung cancer (McKeage, 2011; McKeage et al., 2009). 
Combretastatin A-4 phosphate has been tested in phase II and III clinical trials 
for the treatment of anaplastic thyroid cancer and phase II clinical trial for the 
treatment of non-small cell lung cancer with promising results (Siemann, 2011; 
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Siemann et al., 2009). Other randomized phase II and phase III clinical trials 
using combretastatin and ASA404 combined with standard chemotherapy in 
advanced non-small cell lung cancer are currently on-going. The results of 
these clinical trials are expected to be reported shortly (McKeage, 2011). If 
successful, these agents could be used to develop strategies that may 
enhance the delivery of partner therapeutics. 
Modulating muscle tone of the blood vessel: Using histamine or a selective 
endothelin receptor-A antagonist like Botulinium neurotoxin type-A which relax 
the blood vessel and increase tumour blood flow which in turn can reduce the 
IFP and improve drug delivery (Brunstein et al., 2006). Histamine showed 
synergistic antitumour effect when combined with melphalan as perfusion for 
the treatment of experimental rats with soft tissue sarcoma liver metastasis. 
The technique used in this experiment is called Melphalan-based isolated 
hepatic perfusion (M-IHP). The author concluded that the results of this 
experiment are encouraging and that phase I-II study to explore the efficacy in 
the clinic is worthwhile (Brunstein et al., 2007). Injecting botulinium neurotoxin 
type-A locally into mouse tumours increased tumour oxygenation and 
perfusion. The tumour has also shown improvement by responding to 
radiotherapy and chemotherapy. The significant increase in tumour 
oxygenation and perfusion is expected to be due to the botulinium neurotoxin 
relaxation of the tumour vessels. The results of this experiment can be applied 
in clinical trials to improve drug delivery and reduce chemotherapy resistance 
(Ansiaux et al., 2006; Ansiaux and Gallez, 2007). In another study, botulinium 
neurotoxin type-A has significantly increased the uptake of gemcitabine in 
63 
 
 
hepatomas implanted in mice. Compared with two other perfusion-enhancing 
vascular modifiers (BQ123 and thalidomide), botulinium neurotoxin type-A has 
significantly enhanced tumour growth inhibition when combined with 
gemcitabine in the same study (Cron et al., 2008). The results of this study 
and the previous study are promising for preclinical and clinical evaluation of 
botulinium neurotoxin type-A as a vascular modifier to enhance drug delivery 
to solid tumours. 
1.8.2 Reducing interstitial fluid pressure (IFP): 
Because of the higher IFP in tumours compared to normal tissues, the net 
convection flow in tumour interstitium is outward from the core of a tumour 
(Jang et al., 2003). Reducing IFP using one of the previous methods or 
through the use of one of the following methods can potentially improve drug 
delivery to the tumours via re-instating the normal convective fluid flow from 
the blood vessel into the interstitium. 
Use of platelet derived growth factor (PDGF) inhibitors: PDGF mediates 
high IFP in tumours through stimulating cells contractility and through 
promoting interactions between the extracellular matrix molecules and the 
integrins of stromal fibroblasts (Heldin et al., 2004). For this reason, using a 
PDGF inhibitor such as imatinib might decrease IFP in tumours and hence 
enhances drug delivery (Pietras et al., 2002). PDGF antagonists have lowered 
tumour IFP, increased drug uptake and increased treatment efficiency in 
preclinical models. Imatinib through inhibiting PDGF and reducing tumour IFP 
increased the therapeutic index of the epothilone B microtubule stabilizing 
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agent EPO906 (Patupilon) through increasing EPO906 uptake into human 
anaplastic thyroid carcinomas implanted into mice (Pietras et al., 2003). 
Another study showed that the PDGF receptor beta (PDGFR-β) inhibitor 
CDP860 caused fluid accumulation and increased vascularized volume in 
patients with advanced ovarian or colorectal cancer. Although this clinical trial 
was stopped early because of the fluid accumulation noticed in most of the 
patients, however, its results suggested that inhibiting PDGFR-β might 
improve the delivery of anti-cancer agents (Jayson et al., 2005). The concept 
of adding a PDGF antagonist to reduce IFP and improve drug uptake and 
efficacy was applied in a clinical trial conducted by Starling and his group 
(Starling et al., 2011). This clinical trial aimed to define safe doses of 
gemcitabine plus oxaliplatin combined with imatinib in patients with advanced 
gemcitabine-refractory pancreatic cancer. Gemcitabine and oxaliplatine were 
safely and feasibly combined with imatinib given every other week.  
Use of transforming growth factor β (TGFβ) inhibitors: TGFβ inhibitors are 
expected to decrease amount of extracellular matrix molecules and hence 
reduce IFP in tumours which in turn can enhance drug delivery (Lammerts et 
al., 2002). Lammerts and his colleagues reported that a decrease in tumour 
IFP was noticed in mice after 5-10 days of treatment with TGFβ inhibitor. It 
was also observed in Lammerts study that using TGFβ inhibitor leads to a 
reduction in the amount of collagen but not in hyaluronan content which 
suggests that the reduction of IFP in tumours was due to the inhibition of 
collagen synthesis (Jacobson et al., 2003).  Inhibiting TGFβ lowered IFP in 
KAT-4 experimental model for anaplastic thyroid carcinoma. Pre-treating KAT-
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4 carcinomas with TGFβ inhibitor increased cytotoxicity of doxorubicin against 
KAT-4 carcinoma cells (Salnikov et al., 2005). LY2109761 and 1D11 are TGFβ 
inhibitors which were tested preclinically and showed the ability to reduce 
tumour burden and metastasis in vivo (Ganapathy et al., 2010; Melisi et al., 
2008).  
Use of tumour necrosis factor α (TNFα): TNFα is an inflammatory cytokine. 
It is expected to cause reduction in IFP due to its vasodilatory effect which is 
mainly mediated by the release of nitric oxide (NO) from endothelial cells or 
macrophages (Baudry and Vicaut, 1993). Use of TNFα in 
immunocompromized mice bearing human melanoma caused 64% decrease 
in tumour IFP and reduced the mean arterial pressure by 70% (Kristensen et 
al., 1996). Using isolated limb perfusion, melpahlan concentrations in tumour 
tissues implanted in rats were six fold higher when combined with TNFα which 
indicates the synergistic anti-tumour effect between TNFα and melphalan (de 
Wilt et al., 2000). In humans, TNFα has enhanced the anti-tumour activity of 
chemotherapeutic agents when combined together through isolated limb 
perfusion for the treatment of patients with melanoma or sarcoma of the 
extremities (Grunhagen et al., 2006). Long term outcome of isolated limb 
perfusion with TNFα for patients with melanoma has proved long term local 
control in selected patients (Deroose et al., 2011).   
Use of corticosteroids: Corticosteroids are expected to reduce IFP due to 
their anti-inflammatory action which can cause growth arrest and apoptosis 
induction as well as their ability to reduce stromal contents of the extracellular 
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matrix (ECM) (Li et al., 2004). Dexamethasone which is a corticosteroid has 
significantly reduced the IFP of human colon carcinoma xenograft implanted in 
mice (Kristjansen et al., 1993). This reduction in IFP was mainly due to a 
reduced microvascular permeability and vascular hydraulic conductivity in the 
tumours and due to decreased amounts of ECM contents. Dexamethasone 
has significantly reduced IFP, reduced the tumour growth and augmented the 
effect of 5-fluorouracil in rats bearing mammary tumours (Stuhr et al., 2006). 
The author reported that this reduction in IFP was mainly due to the anti-
inflammatory effect of dexamethasone and due to inhibiting the production of 
ECM stromal contents. 
Use of chemotherapy itself: The use of chemotherapy itself in a concept 
called low dose chemotherapy causes limited cell killing but in addition, it can 
reduce the tumour cell density, decompress blood vessel, decrease 
microvascular pressure and decrease the IFP (Jang et al., 2003). The use of 
low dose paclitaxel increased cells apoptosis and reduced the IFP which 
enhanced the delivery of paclitaxel in tumours implanted in mice (Griffon-
Etienne et al., 1999). In another study, paclitaxel decreased IFP and improved 
oxygenation in breast cancer in patients treated with neoadjuvant 
chemotherapy (Taghian et al., 2005). Another study showed that treatment 
with imatinib in non-small-cell lung cancer (NSCLC) is associated with 
decrease of IFP and improved oxygenation in A549 human lung 
adenocarcinoma xenografts grown in mice (Vlahovic et al., 2006). 
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Use of vasodialating agents: Use of vasodialating agent like hydralazine can 
also reduce the IFP through decreasing tumour blood flow which in turn can 
reduce flow resistance and increase transcapillary pressure gradient (Zlotecki 
et al., 1995). Zlotecki (1995) and his group reported that hydralazine reduced 
IFP by 50% in mice bearing human colon adenocarcinoma xenograft. In 
another study, hydralazine has significantly reduced IFP by 31% and 14% 
from the initial value in two different solid tumour models implanted in mice 
(Podobnik et al., 2001). Other vasodilators such as bradykinin agonists, 
nicotinamide and prostaglandin E1 (PGE1) have also been reported to lower 
IFP and hence enhance drug uptake by tumours. In addition to its 
vasodialating effect, labradamil which is a bradykinin agonist can increase 
vascular permeability through increasing vasculature pore size and increasing 
vascular surface area which at the end reduces IFP and improves blood flow 
(Emerich et al., 2001a). Labradamil was reported to increase the tumour 
uptake of other chemotherapeutic agents such as carboplatin and doxorubicin 
in rats (Emerich et al., 2001b). A recent study reported that bradykinin 
agonists have improved the uptake of the MRI contrast Agent Gd-DTPA, into 
rodents bearing malignant brain tumours (Sarin et al., 2009). 
Nicotinamide which is a water soluble vitamin lowers the mean arterial blood 
pressure which cause a decrease in the flow resistance in tumour which in 
turn reduce IFP and enhance drug uptake (Lee et al., 1992). Intraperitoneal 
injections of nicotinamide were found to reduce tumour IFP by about 40% in a 
study conducted by Lee and his group using mice bearing tumours. It is 
expected that lowering of IFP was due to lowering of the vascular resistance 
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as mentioned above and due to tumour ulceration which resulted in increasing 
tissue hydraulic conductivity (Lee et al., 1992).  In another study, nicotinamide 
reduced IFP in a dose and time dependent manner when tested in mice 
bearing tumours (Peters et al., 1997). Prostaglandin E1 (PGE1) which is a 
proinflammatory factor has also been shown to reduce IFP through decreasing 
the contractility of stromal fibroblasts by decreasing fibroblasts-mediated 
collagen (Rubin et al., 2000). PGE1 significantly reduced IFP and enhanced 
the anti-tumour efficacy of 5-FU in rats bearing colonic and mammary tumours 
(Salnikov et al., 2003). 
1.8.3 Manipulation of tumour pH: 
Low pH of extracellular environment is a characteristic of solid tumours (Kozin 
et al., 2001). Low pH can lead to a decrease in the ionization of weak acids 
and increase the ionization of weak bases. For this reason lower extracellular 
pH leads to increased activity and cellular uptake of weak acids and 
decreased activity and cellular uptake of weak bases as they will be 
sequestered in acidic pH (Tannock and Rotin, 1989; Vukovic and Tannock, 
1997). This hypothesis was proved as the basic anticancer agents, e.g. 
doxorubicin and mitoxantrone were found to have difficulty in penetrating 
MCLs because they concentrate in perinuclear acidic endosomes. For this 
reason, addition of competing weak bases such as chloroquine, or the addition 
of a proton pump inhibitor such as omeprazole to convert the perinuclear 
endosomes pH from acidic to basic significantly helped those drugs to 
penetrate the MCLs (Lee and Tannock, 2006). The other effect of low pH is 
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that it can affect cellular uptake of some drugs which depend on active 
transport process such as methotrexate (Cowan and Tannock, 2001). 
Methotrexate is a weak acid. It is a well-known anticancer agent. It is actively 
transported into cells mainly through active transport mechanism depending 
on a transporter protein. This protein is inhibited at low pH. Using MCLs, this 
hypothesis was proved when the activity and cellular uptake of methotrexate 
were inhibited in acidic pH induced by adding folic acid (Cowan and Tannock, 
2001).  The explanation here was that low pH inhibited the energy dependent 
active transport process which in turn reduced cellular uptake of methotrexate. 
An in vitro preclinical study conducted to reduce the intracellular pH using 
cariporide and S3705 in order to enhance the pH-dependent cytotoxic effect of 
melphalan for human breast cancer cells. Lowering intracellular pH enhanced 
cell killing after multiple courses of melphalan. This study concluded that 
intracellular pH manipulation can influence the effect of chemotherapy (Wong 
et al., 2005). An in vivo study tested the effect of pH change -using glucose- 
on the efficacy of the weak acid chlorambucil and the weak base doxorubicin 
against lung carcinoma implanted in mice. A minor change in the intracellular-
extracellular pH gradient by 0.2 units increased tumour growth delay induced 
by the weak acid chlorambucil by 2.3 folds compared to the weak base 
doxorubicin (Gerweck et al., 2006). This indicated that pH gradient difference 
between normal and tumour tissue may be exploited and targeted for the 
treatment of cancer through developing weak acid chemotherapeutic agents.  
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1.8.4 Remodelling the extracellular matrix (ECM): 
Extracellular matrix (ECM) is known to limit drug penetration through either 
directly binding to the drugs or through its acidic pH as explained above. In 
addition, ECM has an adhesive effect. Tumour and stromal cells produce an 
ECM consisting of collagens, proteoglycans and other molecules that limit the 
transport of molecules. This adhesive effect can limit drug penetration into 
solid tumours (Netti et al., 2000).  
Using hyaluronidase: Hyaluronidase which has anti-adhesive effect through 
breaking hyaluronic acid down has enabled drugs to permeate through the 
extracellular matrix component more freely (Heldin et al., 2004). Pre-treating 
multicellular tumour spheroids of squamous carcinoma with hyaluronidase 
enhanced doxorubicin penetration and cell killing (Kohno et al., 1994). 
Treating multicellular spheroids with hyaluronidase as an anti-adhesive agent 
allowed drugs such as cyclophosphamide to permeate the extracellular matrix 
more freely (Croix et al., 1996). In a pilot study, hyaluronidase improved the 
penetration of carboplatin and other standard chemotherapy used for the 
treatment of children with brain tumour (Pillwein et al., 1998). In a number of 
preclinical and clinical trials, adding hyaluronidase enhanced the efficacy of 
cytotoxic agents as it may decrease intratumoural pressure and loosen cell to 
cell contact which in turn enhances drug penetration (Baumgartner et al., 
1998). Hyaluronidase has also improved the distribution and uptake of 
liposomal doxorubicin in human osteosarcoma xenografts implanted in mice 
(Eikenes et al., 2005). Although hyaluronidase enhanced penetration and 
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efficacy of some chemotherapeutic agents, however, this technique may not 
be applicable systemically. In addition it is expected that penetration might 
have been enhanced by mechanisms other than modulating the extracellular 
matrix (Croix et al., 1996).  
Using collagenase: Collagen is expected to be a major determinant of 
resistance of drug transport in solid tumours as it hinders the transport of 
macromolecules. Tumours contain much denser collagen network which is 
thicker than that of normal tissue. In addition to this, tumours contain 
increased number of fibroblasts which are usually bound to the collagen fibres 
which create more tension between the fibres and this contributes towards 
increased IFP in tumours (Heldin et al., 2004). Reduction of collagen content 
in tumours using collagenase can be used as a method for enhancing drug 
delivery to solid tumours because it reduces IFP and loosen the interstitium of 
the solid tumour  (Netti et al., 2000). Human osteosarcoma xenografts treated 
with collagenase improved the distribution of monoclonal antibodies (Eikenes 
et al., 2004). Collagenase also increased viral vectors transport in human 
melanoma xenografts (McKee et al., 2006). Collagenase has significantly 
increased nanoparticle penetration in collagen-treated multicellular spheroids 
(Goodman et al., 2007). In a recent study, ultrasound-guided administration of 
the collagen-2 selective collagenase-2 improved liposomal doxorubicin 
accumulation and distribution in solid tumour xenografts. Intratumoural and 
intravenous administration of collagenase-2 reduced IFP by 35 and 40% 
respectively compared to control (Zheng et al., 2011). Despite the results of 
this study and the previous studies which have shown the ability of 
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collagenase to enhance drug delivery to solid tumours but this strategy has not 
yet translated into clinical trials mainly because of the danger of affecting 
normal tissues and to avoid metastasis that can be created by the use of 
collagenase (Tredan et al., 2007). Developing types of collagenases that can 
selectively act only on the tumour collagen will make this strategy more 
attractive but this is challenging. 
Using relaxin: The use of relaxin which is a hormone secreted by women 
during pregnancy has been shown to degrade the tumour ECM and to improve 
macromolecular diffusion in tumours (Brown et al., 2003). Relaxin is expected 
to inhibit collagen synthesis, increase collagen turnover and up-regulates the 
matrix metalloproteinases (Jain and Stylianopoulos, 2010; Seibold et al., 
2000). Through these mechanisms relaxin enhanced the diffusion of IgG by 
twofold and increased the diffusion of dextran by threefold in human soft tissue 
sarcomas (Hsts26t) xenografts (Jain and Stylianopoulos, 2010; Perentes et 
al., 2009). More preclinical in vivo studies are required to prove the success of 
the use of relaxin as one of the strategies to improve drug delivery. These in 
vivo studies should of course show that relaxin has improved the delivery of 
some well-known anti-cancer agents such as doxorubicin. 
1.8.5 Modifying drug administration technique: 
The use of continuous infusion instead of bolus injections can maintain 
diffusion and convection for prolonged periods and achieve more uniform 
distribution in the tumour area compared to single bolus injection. The efficacy 
of 5-FU was better and its toxicity was less when administered as continuous 
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infusion compared to bolus injection in a multicentre study for patients with 
advanced colorectal cancer (de Gramont et al., 1997). Another study showed 
that weekly 24 hours infusion has enhanced 5-FU therapeutic index and 
reduced toxicity (O'Dwyer et al., 2001). 
1.8.6 Modifying drug pharmacokinetics and nanoparticle delivery: 
The use of liposomes or nanoparticle carriers can increase the half-life of the 
anticancer agent and enhance its passing through fenestrations in the tumour 
blood vessels (Jain and Stylianopoulos, 2010). In addition, coating the drug 
carrying liposomes with antibodies to specific tumour antigens can facilitate 
targeting malignant cells (Kontermann, 2006). Changes in the formulation of 
an existing anticancer agent like doxorubicin can help its penetration into solid 
tumours. Encapsulating doxorubicin into liposomes can alter the 
pharmacokinetics of the free drug and exploit tumour vessels permeability to 
liposomal profiles (Di Paolo, 2004; Vail et al., 2004). Another example of drug 
formulation change is the use of a nanoparticle formulation of paclitaxel bound 
to albumin. This modification might result in improving its ability to penetrate 
into solid tumours as it evades the delivery and adverse effect problems 
caused by the original hydrophobic formula because it is known that paclitaxel 
is a poorly water soluble drug. For this reason it is originally solubilised in a 
polyoxyethylated castor oil and ethanol formula. This formula causes 
hypersensitivity reactions and causes paclitaxel entrapment in plasma as 
micelles. Micelles alter the drug efficacy and affect its pharmacokinetics 
through decreasing its clearance and its volume of distribution. These 
74 
 
 
pharmacokinetic changes can also increase drug adverse effects. The 
pharmaceutical company (American BioScience, Santa Monica, CA) 
introduced a novel, solvent free, albumin bound, 130 nm particle form of 
paclitaxel. Albumin has the ability to bind to specific proteins in the tumour and 
hence transport paclitaxel to cancer cells. This formula has reduced adverse 
effects of paclitaxel as well (Nyman et al., 2005). Its mechanism exploits the 
enhanced permeability and retention effect (EPR) (Maeda, 2010b). Exploiting 
EPR effect has shown safety and improved delivery and efficacy of drugs such 
as doxorubicin and paclitaxel (Iyer et al., 2006; Maeda, 2010a; Torchilin, 
2011). 
1.9 Synopsis and objectives of the project: 
Impaired drug delivery to solid tumours is a significant factor that limits curative 
potential. The effectiveness of cancer treatment depends on the delivery of the 
anticancer agent to all tumour cells located in different regions of the tumour 
because unaffected cells may act as clones that result in tumour re-growth 
and development of resistance (Hicks et al., 2003). Different drug penetration 
barriers exist in solid tumours and hence can cause chemotherapy resistance 
(Tredan et al., 2007). Drug penetration studies have demonstrated that a 
variety of anti-cancer drugs are indeed unable to penetrate fully into solid 
tumours, suggesting that an improved clinical response might be generated if 
the distribution of these drugs could be improved (Minchinton and Tannock, 
2006). Elevated interstitial fluid pressure (IFP) in solid tumours is considered 
one of the barriers to drug penetration. High IFP is one of the characteristics of 
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solid tumours (Heldin et al., 2004). One of the consequences of IFP elevation 
in solid tumours is that it impedes the convective fluid flow (CFF) process 
through which drugs are transported to tumours (Heldin et al., 2004). This in 
turn can reduce drug uptake and resistance can then develop. Different 
strategies have been developed to study and to overcome barriers to drug 
transport in order to improve drug distribution to vascular and avascular 
regions of tumour. This requires the development of different in vivo and in 
vitro methods that can be used to study drug penetration. A variety of in vitro 
and in vivo techniques have been developed over the past couple of decades 
such that the concentration of therapeutic agents in tissues and tumours can 
now be measured (Minchinton and Tannock, 2006). However, Experimental 
models used to study IFP in solid tumours are mostly in vivo models. These 
models are expensive, time consuming and extensively using animals. The 
use of animal models also restricts the type of experiments that can be done. 
For example, it is difficult to systematically dissect individual 
pathways/mechanisms involved in maintaining high IFP due to the inherent 
complexity of the in vivo model. Developing an in vitro based assay to study 
the effect of IFP on drug penetration can overcome the disadvantages of using 
the in vivo models. In addition, it can be used to study the ability of several 
anticancer drugs to penetrate through tumours and can be utilized to develop 
strategies to overcome barriers and to improve drug penetration in order to 
reduce chemotherapy resistance.  
The long term objective of this project is based on the hypothesis that 
understanding the pharmacological and biological factors that control drug 
76 
 
 
delivery to solid tumours especially those related to the tumour 
microenvironment such as IFP, can be exploited to develop methods and 
strategies to overcome limited drug penetration into solid tumours. Hence this 
will improve drug delivery in order to allow drugs to exert their therapeutic 
effect.  
The specific objective of this project is to utilize the penetration model used by 
Phillips and his team (Phillips et al., 1998) to develop and evaluate novel 
models for assessing the impact of IFP on drug penetration. The traditional 
approach uses MCL systems where the fluid level in the upper and lower 
chambers is equal and the initial part of this thesis describes studies designed 
to optimise analytical techniques and characterise drug penetration rates when 
there is no pressure gradient across the MCL. By modifying the upper 
chamber to allow fluid levels to be raised above that of the bottom chamber, a 
pressure gradient will be established and this should drive convective fluid flow 
(CFF). This model will be characterised and its impact upon drug 
delivery/penetration determined.  
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2. MATERIALS AND METHODS: 
2.1 Chemicals and reagents: 
Doxorubicin was purchased from Sigma (Sigma Aldrich, Pool, UK). Epirubicin 
was purchased from Euroasiarnd (Euroasian Chemicals PVT.LTD, India). 
Imatinib and gefitinib were purchased from LC Laboratories (Woburn, MA, 
USA). For in vitro experiments, all drugs were dissolved in dimethyl sulphoxide 
(DMSO) (Sigma Aldrich) to provide stock solutions of 10mM which were 
subsequently aliquoted into 1.5 mL microcentrifuge tubes (Costar, USA) and 
stored at -20°C until required. Chemical structures and molecular weights of 
doxorubicin, imatinib and gefitinib are presented in appendix 1.  
All chemicals used were of analytical grade and all solvents were HPLC grade 
unless otherwise stated. All reagents were purchased from Sigma Aldrich 
(Poole, Dorset, UK) unless otherwise stated. 
2.2 Cell lines and cell culture conditions: 
All cell lines were purchased from American Type Culture Collection (ATCC) 
or European Collection of Cell Culture (ECACC). A list of selected cell lines 
used in this study is presented in table 2-1. Cell lines were chosen based on 
their ability to form spheroids (Friedrich et al., 2007) and previous experience 
in this laboratory. Cells were routinely maintained at 37oC in a CO2 enriched 
(5%) humidified atmosphere as monolayer cultures in T-75 flasks (Corning, 
NY, USA). Cells were grown in RPMI-1640 culture medium containing 25 mM 
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HEPES buffer and supplemented with 10% Foetal Bovine Serum (FBS), 
Sodium Pyruvate (1 mM) and L-Glutamine (2 mM). Cells were routinely 
passaged when they reached 70-80% confluent by trypsinisation. Cells were 
washed 3 times with 10 mL of Hanks balanced salt solution (HBSS) prior to 
the addition of 3 mL of Trypsin-EDTA (0.25% Trypsin-EDTA). 
Table 2-1: List of used cancer cell lines and their tissue of origins 
CELL LINES ORIGIN REFERENCE 
DLD-1 (ATCC) Human colorectal adenocarcinoma  (Dexter et al., 1979) 
MCF7 (ATCC) Human breast adenocarcinoma  (Soule et al., 1973) 
SiHa (ATCC) Human cervix carcinoma (Friedl et al., 1970) 
Panc-1 (ATCC) Human Pancreatic adenocarcinoma (Lieber et al., 1975) 
Caski (ATCC) Human cervix epidermoid carcinoma (Pattillo et al., 1977) 
A2780 (ECACC) Human ovarian carcinoma (Newman et al., 1988) 
M14* Human melanoma (Mouches and Bove, 1983) 
SK-MEL 23* Human melanoma (Pankovich and Jimbow, 1991) 
HT29 (ATCC) Human colorectal adenocarcinoma  (Fogh et al., 1977) 
 
A549 (ATCC) Human lung carcinoma (Giard et al., 1973) 
PC3 (ATCC) Human prostate adenocarcinoma (Kaighn et al., 1979) 
786-0 (ATCC)  Human renal cell adenocarcinoma (Williams et al., 1976) 
* Obtained from the University of Leeds.  
Following incubation at 37°C for 5 minutes or until cells became detached from 
the flask surface, 10 mL of complete media was added and the cell 
suspension was centrifuged (Heraeus megafuge 1.0, Thermo Electron 
Corporation) at room temperature for 5 minutes at 1000g. The supernatant 
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was discarded and the cell pellets were re-suspended in 10 mL of fresh RPMI 
medium. From the re-suspended cells, 2x105 cells were added to a new non-
vented T-75 flask. Cells were discarded after 10 passages and replaced with 
fresh cultures obtained from liquid nitrogen stocks. All cell lines were proved to 
be free of mycoplasma by regular screening with mycoplasma detection kit 
(Roche, Mannheim, Germany). For cell counting, cells were trypsinized and re-
suspended in fresh medium as described above. From the cells suspension, 
10 µL was then placed into a haemocytometer chamber. The haemocytometer 
contains 2 chambers, which are divided into 9 major squares. Each of these 
has a volume of 0.1 mm3 or 1 x 10-4 mL. Average cell counts were taken from 
a total of 10 grid counts using a low-power (10X) objective. The cell 
concentration was expressed as mean cell count x 104 cells/mL.   
2.3  Growth curves: 
The growth characteristics of DLD-1 and MCF-7 cells were determined as 
these two cell lines formed the mainstay of experiments performed in this 
thesis. Their selection was based on previous studies which demonstrated that 
they readily formed multicell layers (Phillips et al., 1998). Cells were harvested 
as mentioned previously and the cell suspension was split into 8 T-25 flasks 
(Corning, NY, USA). On day 0, total number of cells in each flask was 1x105 
cells/mL in a final volume of 10 mL per flask. Every day, cells were trypsinised 
and the total number of cells in each flask counted using a haemocytometer. 
Growth curves were constructed by plotting total cell number against time. 
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2.4  Growth characteristics of cells on transwell membranes: 
2.4.1 Apparatus characteristics and MCLs formation: 
The apparatus used for drug penetration assays is the transwell culture insert 
that has previously been used for multicell culture formation (Phillips et al., 
1998). This apparatus (figure 2-1) consists of a transwell insert (TransWell-
COL plastic insert, Corning Costar incorporated, NY, USA), containing a 
collagen-coated microporous polytetrafluroethylene (PTFE) membrane (pore 
size 0.4 µm, diameter 6.5 mm, thickness 30 µm and surface area 0.33 cm2), 
placed into one well of a 24 well plate. The micro porous membrane forms a 
barrier between the top and the bottom chamber and a surface upon which 
cells can be seeded to form MCLs. To initiate MCL formation, a total of 3x105 
cells in no more than 200 µL of RPMI-1640 culture medium was added to the 
top chamber of the transwell. Transwells were then incubated at 37°C for 2 
hours to allow cells to attach to the membrane before the addition of 2 mL of 
RPMI-1640 medium to the bottom chamber and flooding the top chamber with 
1 mL of the same medium. Cells were incubated at 37°C in an atmosphere 
containing 95% air and 5% CO2 for up to 7 days with medium being changed 
every other day in both the top and bottom chambers.   
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Figure 2-1: Schematic representation of the conventional drug penetration system which was 
considered model 1 (diffusion only D↓) in this study. The transwell insert is placed into one 
well of a 24 well plate and cells (3x10
5
cells) are seeded into the top chamber to form MCL. 
Drug at selected concentrations is added to the top chamber and samples are withdrawn from 
the bottom chamber at different times for analysis. (Phillips et al., 1998). 
 
2.4.2  Processing MCLs for thickness measurement: 
2.4.2.1 Transwell fixation and membrane embedding: 
At several time points, transwells were collected and fixed in order to measure 
the thicknesses of the MCLs. Transwells were fixed in Bouin’s solution for one 
hour, then rinsed three times with 70% ethanol and stored at room 
temperature in 70% ethanol until required for measurement of the thickness of 
the multicell layer. The transwell was removed from ethanol and with a sharp 
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scalpel blade; the membrane was carefully detached from the plastic insert. 
The membrane was placed with labelled paper into a microsette processing 
embedding cassette with lid (Simport, Canada) and placed in an automatic 
tissue processor (Leica TP1020, Leica instruments GmbH, Germany). The 
following settings were used on the processor: 
- 70% ethanol for 1 hour 
- 80% ethanol for 30 minutes 
- 95 % ethanol for 30 minutes 
- 100% ethanol for 30 minutes (3 times, in 3 different tanks) 
- Histoclear for 30 minutes (3 times, in 3 different tanks) 
- Paraffin wax for 45 minutes 
- Paraffin wax for 1 hour 
Finally, each membrane was embedded into a labelled plastic mould 
(Disposable Embedding Molds, (Peel-A-Way), Polysciences, Inc., USA). The 
plastic mould was filled with fresh wax and the membrane was allowed to rest 
horizontally on the bottom of the mould and positioned at one edge to facilitate 
sectioning. It was then left to set on a refrigerated surface. Once set, wax 
blocks were kept at room temperature until required for sectioning. 
2.4.2.2 Sectioning: 
The wax block containing the membrane was incubated at 4-8°C for at least 
30 minutes in order to increase the rigidity of the wax before sectioning. Wax 
blocks were then cut into sections using a Leica RM2155 microtome (Leica 
instruments GmbH, Germany). Sections (5 µm thick) were collected and 
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placed on APES (3-aminopropyltriethoxysilane) coated slides and stored at 
room temperature until required for Haematoxylin and Eosin staining. From 
each wax block, 3 sections were collected. 
2.4.2.3 Haematoxylin and eosin staining: 
Sections were de-waxed and re-hydrated according to the following schedule: 
- Xylene for 5 minutes (twice, two different tanks) 
- Xylene/ethanol 50:50 for 5 minutes 
- Ethanol 100% for 5 minutes (Twice, 2 different tanks) 
- Ethanol 90% for 5 minutes 
- Ethanol 70% for 5 minutes 
Slides were then stained in Harris haematoxylin for 10 minutes, washed with 
running tap water, then immersed in acidic alcohol (0.25% v/v conc. HCL in 
70% ethanol) for 5 seconds. This step is performed to remove the excess 
haematoxylin from the cells leaving the nuclei strongly stained but not the 
cytoplasm. After that, slides were washed briefly in running tap water then 
stained in Scott's tap water substitute (3.5g sodium bicarbonate and 20g 
magnesium sulphate dissolved in 1000 mL H2O) for 2 minutes. This solution is 
strongly alkaline and turns the section blue. Sections were counterstained in 
1% (w/v) aqueous eosin for 1 minute then washed briefly in tap water and 
drained for 1 minute to let excess water run out. Sections were then 
dehydrated as follow: 
- Ethanol 100% for 1 minute, then ethanol 100% in a different tank for 3 
minutes. 
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- 50% xylene/ethanol for 3 minutes 
- Xylene for 3 minutes 
- Clean xylene for 5 minutes 
Sections were then mounted using DPX medium (VWR international Ltd. 
Poole, England), a cover slip was added and left to dry at room temperature.  
2.4.2.4 MCL thickness measurement: 
The average thickness of the multicell layer was determined by taking 5 
random measurements from each section under a 20X objective lens using a 
LEICA (DMRB, Germany) microscope connected to a camera (Leica MPS52, 
Q Imaging, Germany) and using AcQuis, (Annotating acquisition system (32 
bit), from syncroscopy) software. The microscope was automatically calibrated 
for a 20X objective lens using the software contained within the AcQuis 
program. 
2.4.3 Ability of cell lines to form MCLs: 
The cell lines listed in table 2.1 were all evaluated to determine if they formed 
MCLs. In all cases, 3x105 cells were added to each transwell and the protocol 
described in 2.4.1 and 2.4.2 was followed. After 5 days of culture, transwells 
were fixed and processed as described above. Cell lines were judged to have 
formed MCLs based upon histological analysis of the cross sections (e.g. gaps 
in the MCL). 
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2.4.4 Collagen expression in the MCL using immunohistochemistry: 
Collagen is an essential component of the extracellular matrix and digesting or 
modifying it is a potential strategy for altering IFP and therefore enhancing 
drug delivery. To determine whether MCL express collagen, preliminary 
immunohistochemical studies were performed according to the following 
protocols. DLD-1 MCL (Day-7) sections were used and DLD-1 tumour 
xenograft sections were used as positive control. The first step in the protocol 
was to de-wax and rehydrate the paraffin embedded sections as follow: 
- Xylene - 10 mins x 2 
- 50% xylene/ethanol – 5 mins 
- Absolute ethanol – 5 mins x 2 
- 90% ethanol – 5 mins 
- 70% ethanol – 5 mins 
- Distilled water – 5 mins 
Rehydrated sections were placed in 1% H2O2 for 30 minutes to quench 
endogenous peroxidase. Sections were then washed in PBS for 10 minutes. 
Antigen retrieval was performed in citrate buffer at medium-high microwave for 
20 minutes. Sections were allowed to cool down for 30 minutes then washed 
in PBS for 10 minutes. Sections were then covered for 20 minutes with normal 
goat blocking serum (IVD, Vector laboratories Inc. Burlingame, CA), diluted 
15:1000 in PBS. Excess serum was shaked off then sections were covered for 
one hour with the primary antibody (Rabbit Polyclonal to Collagen IV, ab 
(6586), Abcam, PLC, UK), which was diluted 1:500 in PBS. Negative control 
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sections were covered with the blocking serum for the same length of time. 
Primary antibody was shaked off then sections were washed in PBS for 10 
minutes. Sections were then covered for 30 minutes with the secondary 
antibody (Biotinylated Anti-Rabbit IgG made in goat, IVD, Vector laboratories 
Inc., Burlingame, CA) which was diluted 1:200 in PBS. Secondary antibody 
was washed off then sections were washed in PBS for 10 minutes prior to 
incubation with ABC reagent (Vectastain ABC Kit, Peroxidase standard PK 
4000, Vector laboratories Ltd.) for 30 minutes. After 30 minutes incubation with 
ABC reagent, sections were washed in PBS for 10 minutes then incubated 
with DAB (DAB Peroxidase Substrate kit, Vector laboratories, CA) for 5 
minutes. DAB was washed off then sections were washed in distilled water for 
5 minutes. Sections were counterstained in Harris Haematoxylin solution for 
20 seconds then washed in tap water. Sections were then placed in Scott’s tap 
water for 2 minutes. This step was followed by dehydration using: 
- 70% ethanol  
- 90% ethanol  
- Absolute ethanol X2  
- 50% xylene/ethanol  
- Xylene II  
for 2 minutes each; then clean xylene for 5 minutes. At the end, sections were 
mounted in DPX, cover slips were added then slides were left to dry at room 
temperature. Immunohistochemical staining was evaluated under a 20X lens 
using a LEICA (DMRB, Germany) microscope connected to a camera (Leica 
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MPS52, Q Imaging, Germany) and using Acquits, (Annotating acquisition 
system (32 bit), from syncroscopy) software. 
2.4.5 Testing the ability of the MCL to form a barrier using trypan blue:  
To determine whether molecules can cross MCLs by moving in between cells 
(i.e. via intracellular spaces) rather than through cells, trypan blue was added 
to the top chamber and its appearance in the bottom chamber was measured 
spectorphotometrically. As trypan blue will not cross intact membranes, the 
only way it can reach the bottom chamber is via movement through 
intercellular spaces. In this experiment, 0.2% (w/v) of trypan blue was added 
to the top chamber in a volume of 100 µL in PBS and the bottom chamber 
contained 600 µL of PBS which was constantly stirred. Following 3 minutes 
incubation at 37°C, the transwell was removed and 500 µL was collected from 
the bottom chamber and stored at 4°C until required for analysis. This 
experiment was performed in triplicate using DLD-1 MCL on day 1 of growth 
on the membrane and blank (cells-free) transwells. Samples collected were 
analysed using a spectrophotometer (Varian, CARY- 50 Bio, UV-Visible 
Spectrophotometer, Oxford, UK). For each sample and calibration standard, 
50 µL was added to 950 µL of PBS to give a final volume of 1 mL. Calibration 
samples were 2X serial dilutions of 0.2% trypan blue. Samples and calibration 
standards were placed in disposable cuvettes (1.5 mL semi-micro Plastibrand, 
Germany) and absorbance was read at 590 nm. 
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2.5 Analysis of doxorubicin: 
Before experiments designed to measure the ability of doxorubicin to 
penetrate MCLs were conducted, the following procedures were performed to 
establish robust experimental methodologies: 1) Establishment of a HPLC 
method to analyse doxorubicin and the internal standard; 2) Establishment of 
methods for extracting doxorubicin from cell culture media, analysis of 
extraction efficiencies and limit of detection of each technique; 3) Testing inter 
and intra-day experimental variations; 4) Drug stability studies in cell culture 
medium at 37 °C. 
2.5.1 HPLC analysis of doxorubicin: 
Sample analysis was performed using high performance liquid 
chromatography system (HPLC). A C18 HIRPB, Hichrom column, 250mm x 
4.6mm i.d. (inner diameter), was used for separation. A Waters 2996 
photodiode array and a Shimadzu RF-10 AXL Fluorescence detector at an 
excision of 480 nm and an emission of 560 nm, with Masslynx 4.0 software 
(Micromass Ltd.) were used for spectral analysis of the peaks of interest. An 
isocratic separation was performed using 60% of mobile phase-A composed of 
90% 5mM Ammonium formate buffer and 10% Acetonitrile, and 40% of mobile 
phase-B composed of 40% 5mM Ammonium formate buffer and 60% of 
Acetonitrile. Ammonium formate buffer was prepared by dissolving 0.315g of 
Ammonium formate in 1L of distilled water and its pH was adjusted to 3.55 
using formic acid (VWR International Ltd, UK). The flow rate was set at 1.5 
mL/min using a Waters 2795 (Alliance HT) separations module system. The 
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total running time of each sample was 10 minutes and the volume of injection 
was 10 µL unless otherwise stated. The structurally related epirubicin was 
used as an internal standard (Zheng et al., 2001). 
2.5.2  Extraction techniques and extraction efficiency test: 
As it was expected that a wide range of drug concentrations to be present 
from the penetration assays, different extraction techniques were used in order 
to analyse these concentrations and identify a suitable extraction method. A 
suitable extraction method is the one which is the most convenient and yet 
provides sufficient sensitivity. Therefore, the method chosen is dependent on 
the concentration of drug being investigated. In addition to these 
characteristics, the extraction technique used should be inexpensive and not 
time consuming. Extraction efficiency is measured by dividing the peak areas 
of extracted samples by the peak areas of non-extracted samples. Samples 
were extracted using three different extraction techniques as follows: 
2.5.2.1 Doxorubicin extraction from tissue culture medium (TCM) 
using protein precipitation technique without 
evaporation: 
These experiments were conducted using 500 nM doxorubicin. In this 
technique, 200 µL of acetonitrile was added to 100 µL of phenol red-free 
medium containing doxorubicin (500 nM) to give a final volume of 300 µL. The 
sample was then mixed for a few seconds then centrifuged at 10,000g for 5 
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minutes at 4°C. The supernatant was then carefully removed and 50 µL was 
injected into the (HPLC). 
2.5.2.2   Doxorubicin extraction from tissue culture medium 
(TCM) using protein precipitation technique with 
evaporation and reconstitution: 
In this technique, the same steps used in the previous method were used 
except that the supernatant was evaporated at room temperature using an EZ-
2 Plus evaporator (Genevac Limited, Ipswich, UK). The sample was then 
reconstituted in 300 µL of mobile phase A. The reconstituted sample was then 
centrifuged for 2 minutes at 10,000g. Finally 50 µL was injected into the HPLC. 
2.5.2.3 Doxorubicin extraction from tissue culture medium (TCM) 
using solid phase extraction (SPE): 
In this technique, samples were extracted using Isolute (IST) C18 EC SPE 50 
mg cartridges (Biotage, EU). Cartridges were placed on an AASP VAC-ELUT 
system (Analytichem International) and each cartridge was primed by adding 1 
mL of methanol under vacuum.  1 mL of 0.02% formic acid was then added to 
the cartridge and passed through the cartridge very slowly. Samples (300 µL, 
composed of 200 µL of phenol red free medium added to 100 µL of 
doxorubicin (500 nM) prepared in the same medium) were added to each 
cartridge and passed through very slowly. The cartridge was then washed with 
1 mL of 0.02 % formic acid solution and dried under vacuum (DA7C, Charles 
Austen pumps Ltd. Surrey, England). Finally, 1 mL of propan-2-ol (Fisher 
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Scientific, UK): methanol (3:1) solution was added and passed through each 
cartridge very slowly collecting samples in labelled tubes. The final eluent was 
evaporated at room temperature using EZ-2 Plus evaporation machine 
(Genevac Limited, Ipswich, UK) and the dry sample was reconstituted into 300 
µL of mobile phase A, mixed, centrifuged for 2 minutes at 10,000g and 
transferred to HPLC vials. 50 µL was injected into the HPLC. 
2.5.3 Extraction efficiencies, intra-day and injection reproducibilities: 
Extraction efficiency of each extraction technique was calculated by dividing 
the peak areas of the extracted samples by the peak areas of non-extracted 
standards. The extraction efficiency (EE) was calculated as follows: 
     
                                               
                                                     
      
The extraction efficiency was calculated based on 6 readings injected from 6 
independent samples and 6 readings injected from the same vial. The results 
of those injections were also used to test intra-day and injection 
reproducibilities by using the (coefficient of variation [CV]). Intra-day 
reproducibility is used to check the human sampling error and it is tested by 
injecting 6 injections from 6 independent vials having the same concentration 
and prepared in the same way on different occasions whereas injection 
reproducibilities are used to check the reproducibility of the HPLC by injecting 
6 samples from the same vial that contain a specific concentration of drug. 
Intra-day and injection reproducibility variations (coefficient of variation [CV]) 
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are calculated based on the mean peak areas and the standard deviation of 
the injected samples using the following equation:  
     
                   (  )                              
                             
       
 
2.5.4 Calibration curves and limit of detection: 
Calibration curves were prepared on the same day of each experiment using 
the same stock of doxorubicin for both calibration curve and experimental 
samples. All standard concentration used were prepared using a stock 
solution of doxorubicin at 10 mM in DMSO which was diluted in complete 
phenol red-free RPMI-1640 medium or mobile phase to give 100 µM. This was 
further diluted to prepare the required concentrations of standards in tissue 
culture medium or mobile phase as required. Because of the different 
extraction techniques used and variations in experimental protocols during 
optimisation phases of the project, the concentration range for calibration 
curve standards varied to cover the expected minimum and maximum 
concentrations. The linear regression analysis of the ratios of peak area of the 
drug versus internal standard was plotted against concentration.  In all cases, 
the calibration curves used were linear. The equation used for calculating the 
unknown concentration was the linear regression equation as follow: 
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where: 
x:  is the unknown concentration 
y: is the relative ratio (Doxorubicin peak area/Internal Standard Peak area) 
X1000 
yº: is the y-intercept, and        
a: is the slope.  
The limit of detection for doxorubicin using HPLC was calculated using signal 
to noise (S/N) ratios (>5) and exploiting the results of these calibration curves. 
2.5.5 Doxorubicin stability at 37°C: 
Doxorubicin stability under the experimental conditions used, i.e. tissue culture 
medium at 37°C for 30 minutes or 1 hour, was determined according to the 
following procedure. Three different  doxorubicin (1 µM) standards in complete 
phenol red-free RPMI-1640 medium were prepared and placed in three 
different eppendorf tubes, each containing 1 mL of drug solution. 100 µL 
aliquots were taken from each tube and labelled as time point 0. The 
remaining solution (900 µL) was then transferred to three different wells of a 
24 well plate and incubated at 37°C. At various time intervals (15, 30, 60 and 
120 minutes), 100 µL samples were collected from each well and placed into 
an eppendorf tube. Acetonitrile (200 µL containing 500 nM epirubicin) was 
added immediately to each sample, mixed for few seconds and centrifuged for 
5 minutes at 10,000g at 4°C (Heraeus Labofuge 400R, Kendro Laboratory 
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Products, Germany). The supernatant was removed carefully, transferred into 
short thread vial (9 mm PP, Kinesis Inc., Malta, USA) and injected directly into 
the HPLC system (50 µL injection volume). 
2.6 Analysis of imatinib and gefitinib:  
2.6.1 HPLC, LC/MS, and LC/MS/MS analysis of imatinib and gefitinib: 
For imatinib and gefitinib, HPLC, LC/MS and LC/MS/MS were used for 
analysis depending on the expected concentration of each experiment. In case 
of analysis using HPLC, isocratic separation was performed using 55% of 
mobile phase-A (MPA) which consisted of 90% distilled water and 10% 
methanol and 45% of mobile phase-B (MPB) which composed of 10% distilled 
water and 90% methanol. Formic acid (0.1%) was used to adjust the pH in 
both mobile phases to 3.5. The column used was a C18 HIRPB, Hichrom 
column, 250mm x 4.6mm i.d. (inner diameter) and compounds were detected 
at 265 and 343 nm for imatinib and gefitinib respectively using a Waters 2996 
photodiode array detector. The flow rate was set at 1.2 mL/min using a Waters 
2795 (Alliance HT) separations module system. The total running time of each 
sample was 10 minutes and the volume of injection was 50 µL. HPLC was 
used for analysing samples that were expected to contain high concentrations 
of drug.  
For analysis using LC/MS, the same column mentioned above was used for 
separation. A Waters 2996 photodiode array and a Micromass ZMD single 
quadruple mass spectrometer (Micromass, Manchester UK) with Masslynx 
software were used for spectral analysis and mass analysis of the peaks of 
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interest. An isocratic separation method was performed using 50% of mobile 
phase-A (MPA) which composed of 90% distilled water and 10% methanol 
and 50% of mobile phase-B (MPB) which composed of 10% distilled water and 
90% methanol. Formic acid (0.1%) was used to adjust the pH in both mobile 
phases to 3.5. The MS Parameters were optimised to: desolvation gas flow 
506 lit/hr, cone gas flow 35 lit/hr, capillary 3.5 kV, sample cone 45 V, 
extraction cone 5 V, RF lens 0.20 V, source block temperature 100°C and 
desolvation temperature 150 °C. Drugs were detected as singularly charged 
ions using selected ion recording (SIR). The flow rate was set at 1 mL/min 
using a Waters 2695 separations module system. The total running time of 
each sample was 10 minutes and the volume of injection was 30 µL.  
LC/MS/MS settings were as follows: An ACQUITY UPLC® BEH C18 1.7 µm 
column was used for separation. A Waters Acquity photodiode array and a 
Waters Quattro Premier XE triple quadruple mass spectrometer, with Mass 
Lynx 4.1 software were used for spectral analysis of the peaks of interest. An 
isocratic separation method was performed using 65% of mobile phase A 
(MPA) which composed of 90% distilled water and 10% methanol and 35% of 
mobile phase B (MPB) which composed of 10% distilled water and 90% 
methanol. The MS/MS parameters were optimized to: Ionization mode ES+, 
Capillary (KV) 3.75, Cone (V) 40, Extractor (V) 4, RF Lens (V) 1.0, Source 
temperature (°C) 130, Desolvation temperature (°C) 250, Cone Gas Flow 
(L/Hr) 50, Desolvation Gas Flow (L/Hr) 697, Collision 30, Multiplier (V) 650, 
Syringe Pump Flow (µL/min) 20, Pressure (mbar) 8.79e-3, Collision Gas Flow 
(mL/min) 0.35. Drugs were detected as singularly charged ion using selected 
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ion recordings (SIR) or monitoring fragmentations using multiple reaction 
monitoring (MRM). The flow rate was set at 0.35 mL/min using a Waters 
Acquity UPLC (Ultra High Pressure Liquid Chromatography) module. The total 
running time of each sample was 4 minutes and the volume of injection was 
10 µL. In all cases, gefitinib was used as internal standard for imatinib which in 
turn was also used as an internal standard for gefitinib. 
2.6.2  Extraction of imatinib and gefitinib from TCM: 
Unless otherwise stated, all samples created containing imatinib and gefitinib 
were extracted from TCM using protein precipitation without evaporation by 
adding 300 µL of methanol to 100 µL of imatinib or gefitinib in phenol red free 
medium. Samples were vortexed for few seconds centrifuged at 10,000g for 5 
minutes at 4°C. Supernatant was then carefully removed and 50 µL was 
injected into the (HPLC) and LC/MS and 10 µL was injected into LC/MS/MS. 
This extraction technique was selected for all three analytical techniques 
described above except in the case of low gefitinib concentrations which were 
extracted using SPE as explained earlier (section 2.5.2.3). 
2.6.3  Calibration curves and limits of detection: 
As in the case of doxorubicin, calibration curves were prepared based on the 
expected concentrations of analysed drug depending on the penetration assay 
method used. Different calibration curve standards were used ranging from 10 
nM to 100 µM. The same method used for calculating the unknown 
concentrations of doxorubicin was applied for imatinib and gefitinib. The limit 
of detection for imatinib and gefitinib using LC/MS/MS, LC/MS and HPLC 
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respectively were calculated using signal to noise (S/N) ratios (> 5) and 
exploiting the results of these calibration curves. 
2.6.4  Stability test of imatinib and gefitinib at 37°C: 
The stability of imatinib and gefitinib at 37°C in cell culture medium was 
determined according to the following procedure. Three different (1 µM) 
preparations of each drug were made in complete phenol red-free RPMI-1640 
medium and 100 µL aliquots were taken from each tube and labelled as time 
point 0. The remaining solution of each tube (900 µL each) was placed at 37°C 
and 100 µL sample was collected from each tube and placed into an 
eppendorf tube at 15, 30, 60 and 120 minute intervals. Methanol (300 µL 
containing 500 nM internal standard either imatinib or gefitinib) was added 
immediately to each sample, mixed for few seconds and centrifuged for 5 
minutes at 10,000g at 4°C. Supernatant was removed carefully, transferred 
into short thread vials (9 mm PP, 0.3mL,  Kinesis Inc., Malta, USA) and 
injected directly into the HPLC system (50 µL injection volume). 
2.7 Drug penetration assays using model-1: 
Following validating the analytical procedures, drug penetration assays were 
performed using the conventional drug penetration system which was 
considered model-1, diffusion only (D↓), described in section 2.4. To examine 
drug penetration, an anticancer agent can be added to the top chamber and 
the concentration that migrates to the bottom chamber can be measured as a 
function of time using an appropriate analytical method. Drug penetration 
assays were performed using two strategies. The first, termed variable 
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concentration gradient (VCG) is where a defined concentration is added to the 
top chamber and is not replenished during the experiment. In this case, the 
concentration in the top chamber will decrease whilst the concentration in the 
bottom chamber increases until equilibrium is established. The second, termed 
‘constant concentration gradient’ (CCG) is where the concentration of drug in 
the top chamber is maintained at a constant concentration by replacing the top 
chamber with fresh media containing drug every time a sample is taken. In this 
case, the concentration in the top chamber remains approximately constant. 
Details of these two different assays are explained below. 
2.7.1  Drug penetration assays using variable concentration gradient 
(VCG) technique:  
Drug penetration assays were carried out after 1, 3, 5 and 7 days of growth of 
DLD-1 and/or MCF-7 cells on the membrane considering seeding day as day 
0. When required, medium was removed from the top chamber of the transwell 
and replaced with 100 µL of phenol red-free RPMI-1640 medium 
supplemented with 10% foetal bovine serum, 1 mM Sodium Pyruvate, 2 mM L-
glutamine and contained working drug concentration at 100, 50 or 25 µM. The 
transwell was then inserted into one well of a 24-well plate containing 600 µL 
of phenol red-free medium and incubated at 37°C with the bottom chamber 
being constantly stirred. At two minutes interval for the first 10 minutes and five 
minutes intervals thereafter for the next 50 minutes, 10 µL of medium was 
removed from the bottom chamber and added to a micro centrifuge tube 
containing 290 µL of phenol red free media containing 0.5 µM epirubicin (as an 
internal standard). Samples were then mixed and stored at -80°C until 
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required for HPLC analysis. At each time point, 10 µL of fresh medium was 
added to the bottom chamber to maintain the volume at 600 µL. At the end of 
the experiment, transwells were fixed in Bouin’s solution for one hour then 
rinsed 3 times with 70% ethanol and stored at room temperature in 70% 
ethanol until required for histological analysis of multicell layer thickness as 
described earlier. All experiments including blank (cell-free) transwells were 
repeated independently three times. 
2.7.2 Calculating drug penetration rates using variable concentration 
gradient (VCG) technique: 
To calculate the penetration rates using penetration assay with VCG-
technique, concentration values of the first 6 sampling points were converted 
into amounts and expressed as (nmoles). Penetration rate was calculated 
based on fitting a linear regression to the first 6 sampling points on the curve 
which represents the initial linear component of the amount versus time curve 
using the linear regression equation. The slope of the linear regression 
equation was considered the penetration rate. Penetration rates were 
expressed as nmoles/minute. 
2.7.3 Drug penetration assays using constant concentration gradient 
(CCG) technique: 
In this technique, drug was added to the top chamber in a volume of 100 µL 
(concentrations varied depending on the drug and the specific experiment) 
and the bottom chamber contained 600 µL of complete phenol red free media 
which was constantly stirred as before. At various time intervals, the contents 
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of the top chamber were removed and replaced with 100 µL of media 
containing fresh drug at the original concentration. At the same time, the 
transwell was removed and transferred to a new well of the 24 well plates that 
contained 600 µL of complete phenol red free media. In this way, the 
concentration gradient between the top and bottom chambers remained 
constant. From the bottom chamber, 500 µL was collected and added to a 
micro centrifuge tube, mixed and stored at -80°C until required for analysis. 
This procedure was repeated every 5 minutes for 30 minutes. This experiment 
was performed in triplicate using blank (cell-free) transwells and cell seeded 
transwells (i.e. MCLs) with 3 different working concentrations (25, 50 and 100 
µM). To analyse samples created using this method, the 500 µL sample which 
was removed from the bottom chamber was added to 100 µL of phenol red-
free medium containing 500 nM of the internal standard to give a final volume 
of 600 µL. Samples were then extracted using solid phase extraction following 
the same steps as explained in section 2.5.2.3.  
2.7.4 Calculating drug penetration rates using constant concentration 
gradient (CCG) technique: 
Using penetration assay with CCG-technique, cumulative drug concentration 
values which were plotted versus time and expressed as µM were converted 
into amounts and expressed as (nmoles). The penetration rate was calculated 
based on fitting a linear regression to the plotted curve which represents the 
drug amounts (nmoles) versus time (min.). The slope of the linear regression 
equation was considered the penetration rate and expressed as (nmoles/min). 
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2.8 Impact of hydrostatic pressure (HP), on convective fluid 
flow (CFF) and drug penetration using models 2 and 3: 
As described in the introduction, tumours have high IFP which affects drug 
delivery and distribution through solid tumour tissue. To assess the impact of 
IFP on drug penetration, the drug penetration apparatus was modified. 
Modifications to the penetration assays apparatus were conducted and three 
models were generated. The first is the one described previously where there 
is no difference in the height of medium between the top and bottom chamber 
of the transwell apparatus. There is therefore no pressure gradient across the 
membrane and in this case, it is equivalent to an in vivo situation where HP = 
IFP i.e. no convective fluid flow (CFF). In this model, drug penetration to the 
bottom chamber will occur mainly by diffusion. This model was named 
‘diffusion only’ and denoted (D ↓). The second system is where the fluid height 
in the top chamber is much greater than that in the bottom chamber. In this 
case, a pressure gradient is established across the membrane and this drives 
CFF. This model is equivalent to a situation in vivo where the HP is greater 
than IFP. This model was named ‘convection plus diffusion’ and denoted 
(C↓D↓). In the third model, the fluid height in the bottom chamber is raised 
above that of the top chamber. The pressure gradient and CFF is therefore 
reversed compared to model 2 and is equivalent to an in vivo situation where 
HP is less than the IFP. This model was named ‘diffusion opposing 
convection’ and denoted (D↓ C↑). In all three models, the arrows denote the 
direction of either diffusion (D) or convection (C). Full details of the second and 
third model are provided below. 
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2.8.1  Model 2, convection plus diffusion (C↓D↓): 
The apparatus used in this model is presented in figure 2-2. Briefly, a 
graduated tube was inserted into the top chamber and this can be filled with 
media to different heights. The variable height enables different pressure 
gradients to be applied but typically, 13 mL of media containing working drug 
concentrations was used. This creates a physiologically relevant hydrostatic 
pressure equivalent to 28 mmHg across the transwell membrane. In the 
bottom chamber, 200 µL of Phenol Red Free tissue culture medium was 
placed. Samples (100 µL) were collected from the bottom chamber every 5 
minutes over a 30 minutes run time. Collected samples (100 µL) were added 
to 100 µL of internal standard (50 µM) and stored at -80°C until required for 
analysis. The medium in the top chamber was removed and replaced with 13 
mL of fresh medium containing the same working concentration i.e. the 
concentration at the top chamber was maintained constant. The same method 
was followed for blank samples where blank transwells (no cells) were used. 
Convective flow (CFF) was measured by weighing the bottom chamber every 
5 minutes and the rate of convective fluid flow was determined from linear 
regression analysis of weight of fluid in the bottom chamber plotted against 
time. Samples created from this method were extracted using SPE cartridges 
as described previously in case of doxorubicin. Imatinib and gefitinib were 
extracted using protein precipitation without evaporation. Samples were 
reconstituted in mobile phase and finally 10 µL in case of doxorubicin or 50 µL 
in case of imatinib and gefitinib were injected into HPLC. Penetration rates 
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using this model were calculated following the same method used in case of 
CCG technique.  
 
 
 
Figure 2-2: Schematic representation of model 2 (convection plus diffusion C↓D↓): A 
graduated tube was inserted into the transwell insert which was placed in a 24 well plate. Drug 
at selected concentrations is added to the top chamber (coloured in red to indicate where the 
drug is added) and samples are withdrawn from the bottom chamber at different times for 
analysis. Drug volume at the top chamber exerts a physiologically relevant pressure on the 
bottom chamber equivalent to 28 mmHg. Convection is measured by weighing the bottom 
chamber pre and post each time point. 
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2.8.1.1 Calculating hydrostatic pressure in model 2: 
As described previously, volume of medium at the top chamber of model 2 
creates a physiologically relevant hydrostatic pressure of 28 mmHg which is 
similar to that found in some solid tumours. This was calculated based on the 
following: Pressure = Force / Area 
The force in the system is applied by the weight of the medium placed at the 
top chamber. Force is calculated by multiplying the mass by the gravity, i.e. 
Force = weight of medium in the top chamber 
  = Mass * gravity (9.8 m /s2) 
As 1 Kg = 9.8 Newton, then 13 gm or 13 mL of medium at the top chamber 
equals (13 * 9.8) / 1000 = 0.1274 Newton. 
The area of the transwell = 0.33 cm2 which equals 3.32 x10-5 m2  
Pressure is measured by Pascal value which is calculated by dividing the 
mass expressed as Newton by the area2 expressed as m2: i.e. Pascal = N / m2 
In the model those two values were calculated, therefore,   
Pressure in Pascal = 0.1274 / 3.32 x10-5 = 3840.36 Pascal 
Pascal can be converted into mmHg as follow: 
1 Atmospheric pressure = 101000 Pascal = 1010 mbar = 760 mmHg 
Based on this, 3840.36 Pascal = 38.4 mbar = 28.8 mmHg  
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2.8.1.2 Influence of MCL thickness and hydrostatic pressure (HP) 
on CFF in model 2: 
The influence of the MCLs thicknesses and the influence of different 
hydrostatic pressure (ΔP) on CFF were assessed using several thicknesses of 
DLD-1 MCLs. By varying the volume of media in the top chamber, the effect of 
pressure on CFF could be determined. CFF versus MCL thickness was 
assessed on days 1-7 of growth of DLD-1 and/or MCF-7 on the membrane 
using (C↓D↓) penetration assay model. This experiment was conducted as 
described previously (see 2.8.1) and was performed in triplicate. CFF was 
measured by weighing the bottom chamber pre and post each time point. 
Weight differences were considered equivalent to volumes assuming medium 
density equals 1. Volumes were converted into µLs and CFF vs. thickness was 
plotted as µL/min vs. MCL thickness (µm). 
CFF vs. (ΔP) was also assessed using DLD-1 and MCF-7 MCLs on day one of 
growth on the membrane and utilizing the (C↓D↓) penetration assay model. 
This experiment was performed in triplicate using 5 different volumes of 
medium in the top chamber. Volumes used were 1, 4, 7, 10 and 13 mLs. Each 
one of these volumes created a different hydrostatic pressure at the top 
chamber and hence created different CFF. Hydrostatic pressures created by 
1, 4, 7, 10 and 13 mL of medium were 2.15, 8.61, 15.07, 21.53 and 28.8 
mmHg respectively. Each volume was allowed to convect through one day old 
MCL of DLD-1 over 5 minutes and convection to the bottom chamber was 
calculated by weighing the bottom chamber pre and post each time point. 
Weight differences were converted into volumes considering medium density 
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equals 1 as explained above and CFF (µL/min) was plotted versus volume 
(mL). 
2.8.2  Model 3, diffusion opposing convection (D↓C↑): 
Drug penetration and the convective flow from the bottom to the top chamber 
in this model was tested using the modified penetration system presented in 
figure 2-3. In this model, 100 µL of media containing drug at a working 
concentration was added to the top chamber and 20 mL of phenol red free 
tissue culture medium placed in the bottom chamber. Samples (900 µL) were 
collected from the bottom chamber every 5 minutes over 30 minutes. Top and 
bottom chambers were replaced with fresh drug and fresh medium 
respectively to maintain constant concentration and pressure gradient in the 
system every 5 minutes. The orientation of the transwell in this apparatus was 
inversed compared to the previous models such that the pressure gradient did 
not detach the MCL from the membrane. Collected samples for analysis were 
added to 100 µL of internal standard (500 nM), extracted using SPE, 
evaporated as explained above, reconstituted in 50 µL mobile phase and 
finally 10 µL was injected into HPLC in the case of doxorubicin or LC/MS/MS 
in the case of imatinib and gefitinib. 
Convective flow was measured by observing the tissue culture medium which 
was able to convect into the graduated tube every minute or by weighing the 
bottom chamber pre and post penetration. Penetration rates using this model 
were calculated following the same method described in section 2.7.4. 
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Figure 2-3: Schematic representation of model 3 (diffusion opposing convection D↓C↑): The 
graduated tube and the insert in model-2 were immersed into a cylindrical tube containing 
medium. Drug (100 µL) at selected concentrations is added to the top chamber and samples 
are withdrawn from the bottom chamber at different times for analysis. Medium volume at the 
bottom chamber creates a reverse physiologically relevant pressure on the top chamber. 
Convection is measured by weighing the bottom chamber pre and post each time point. 
 
2.8.3 Modified model 3, diffusion opposing convection (D↑C↓): 
A modified version of the previous model was also evaluated. It is similar to 
model 2 in construction but in this case, drug is added to the bottom chamber 
and the concentration of drug appearing in the top chamber is measured. By 
increasing the volume in the top chamber to produce a pressure gradient, the 
forces of diffusion and convection are in opposition (Figure 2-4). Samples (900 
µL) were collected from the top chamber every 5 minutes over 30 minutes. 
Top and bottom chambers were replaced with fresh medium and fresh drug 
Drug in top chamber  
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respectively to maintain constant concentration and pressure gradients in the 
system every 5 minutes. Collected samples for analysis were added to 100 µL 
of internal standard (500 nM), extracted using SPE, evaporated as explained 
above, reconstituted in 50 µL mobile phase and finally 10 µL was injected into 
HPLC. This model was tested using doxorubicin only. Convective flow was 
measured by weighing the bottom chamber pre and post penetration. 
Penetration rates using this model were calculated following the same method 
described in section 2.7.4. 
 
 
Figure 2-4: Schematic representation of modified model 3 (diffusion opposing convection 
D↑C↓): This system resembles model 2. The difference here is that the drug (200 µL) at 
selected concentrations is added to the bottom chamber and samples are withdrawn from the 
top chamber at different times for analysis. The graduated tube at the top chamber is filled 
with medium which creates a physiologically relevant hydrostatic pressure equivalent to 28 
mmHg that opposes the direction of diffusion. Convection is measured by weighing the bottom 
chamber pre and post each time point. 
 
Drug in bottom chamber  
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2.9 Penetration assay detailed methodology for all models 
and drugs: 
The three different penetration assay systems were tested and evaluated 
using doxorubicin, imatinib and gefitinib at 100 µM each on one day old DLD-1 
MCLs. A wide variety of extraction and analytical techniques were employed 
as described previously, full details of which can be found in summary form in 
appendix 2. 
2.10 Influence of penetration assays convection versus 
exposure time on cell survival: 
Each of these experiments generated concentrations versus time curves and 
to assess the effect of different exposures on cell kill, chemosensitivity studies 
were conducted. In vitro chemosensitivity of DLD-1 cells to the cumulative 
concentrations of doxorubicin, imatinib and gefitinib retrieved from the three 
different penetration systems (Table 2-2) was determined using the 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT assay) 
explained elsewhere (Mosmann, 1983). This experiment was conducted in 
triplicate by seeding DLD-1 in 96 well plates at density of 2x104 cells per well 
in a final volume of 100 µL in complete RPMI-1640 medium. After 24 hours of 
incubation at 37°C and 5% CO2, medium was removed, then cells were 
exposed to 100 µL of various concentrations of drug (Table 2-2) for 30 
minutes. After 30 minutes exposure, wells were washed with 200 µL of Hanks 
Balanced Salt Solution (HBSS) followed by adding 200 µL of medium to each 
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well. Cells were then incubated for 5 days at 37°C and 5% CO2. On the fifth 
day, 20 µL of a 5 mg/mL solution of MTT were added to each well then cells 
were incubated at 37°C and 5% CO2. After incubation for 4 hours, medium and 
MTT were removed and replaced with 150 µL of DMSO and absorbance was 
determined at 540 nm using multiskan Ex (Thermo electron corporation). 
Survival was calculated as the true absorbance of treated lanes divided by the 
true absorbance of control lanes and expressed as a percentage.  
 
Table 2-2: Doxorubicin, imatinib and gefitinib cumulative concentrations retrieved from the 
three different penetration models and used to assess the influence of those concentrations 
versus time on DLD-1 cells survival rates using MTT assay. 
  
C↓D↓ 
 
 
D↓ 
 
D↓C↑ 
 
Drug 
 
Conc (µM) 
 
 
Doxorubicin 
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2.8 
 
0.03 
 
Imatinib 
 
 
68.21 
 
2.73 
 
0.08 
 
Gefitinib 
 
 
61.34 
 
5.16 
 
0.03 
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3. RESULTS 
3.1 Growth curves in monolayer setting: 
The growth characteristic of DLD-1 and MCF-7 cells cultured as monolayers is 
presented in figure 3-1. In DLD-1cells, an initial lag period of 24 hours was 
observed before cells entered exponential growth. After 4 to 5 days in culture, 
cells entered plateau phase and cell numbers remained constant until the end 
of the experiment. No significant lag phase was observed in MCF-7 cells and 
these cells entered plateau phase between 5 and 6 days of culture.  
3.2 Growth characteristics of cell lines on the transwell’s 
membrane and MCL thickness measurements: 
3.2.1 Growth characteristics and thicknesses of DLD-1 and MCF-7 
MCLs: 
Growth characteristics and thicknesses of DLD-1 and MCF-7 MCLs are 
presented in figures 3-2 and 3-3. The average thickness of DLD-1 and MCF-7 
on day one of growth on the transwell microporous membrane was 12.9 ± 3.01 
µm and 12.2 ± 1.02 µm respectively. Coverage of the entire membrane was 
generally very good with only occasional gaps in the cell layer being visible 
under phase contrast microscopy. If gaps in the monolayer were, observed, 
these transwells were discarded. The thickness of the MCL increased as a 
function of time and on day 7, thickness of the MCLs were 69.40 ± 7.40 and 
61.28 ± 4.54 µm for DLD-1 and MCF7 cells respectively. 
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Figure 3-1: Growth curves of DLD-1(A) and MCF-7 (B). T-25 flasks were seeded with 1 x 10
5
 
cells and cultured in 10 mL complete growth medium for 8 days. Cells were trypsinised and 
counted using a haemocytometer. Each data point represents the mean ± SD for 3 
independent experiments. 
 
 
 
 
B 
A 
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Panel-1    Panel-2 
  
   
 
 
  
 
 
Figure 3-2: Histological sections through MCLs of DLD-1 (panel-1) and MCF-7 (Panel-2), 
on days 1(A), 3(B), 5(C) and 7(D) of growth on the transwell membrane. Bar = 30 µm. 
 
A 
C 
B 
D 
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Figure 3-3: Thicknesses of DLD-1 and MCF-7 MCLs. Each point represents the mean 
thickness ± SD for 15 measurements on a total of three histological sections of three separate 
experiments. 
3.2.2 The ability of a panel of cell lines to form MCLs: 
Based upon previous studies, DLD-1 and MCF7 cells were known to form 
MCL’s. The ability of other cell lines to form MCLs was determined and the 
results are presented in figures 3-4 and 3-5. The cell lines included SiHa, 
Panc-1, Caski, A-2780, M14, SK-MEL 23, HT-29, A549, PC3 and 786-0. 
These cell lines were processed in the same way as DLD-1 and MCF-7. They 
were all seeded at a density of 3 x 105 cells on the transwell membrane and 
allowed to grow for 5 days at 37°C and 5% CO2. Panc-1, SK-MEL 23, A-2780, 
M14, SiHa and Caski cell lines formed MCLs with thicknesses ranging from 20 
– 120 µm. However, A-549, 7860, HT-29 and PC3 formed thin MCLs with 
thickness ranging from 8 – 13 µm. Although SiHa and Caski formed a thin 
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MCL, the MCLs formed were uniform and tightly attached to the membrane 
with no gaps or holes. Panc-1 and SK-MEL 23 formed thicker MCLs compared 
to DLD-1 and MCF-7. The average thickness of DLD-1 and MCF-7 MCL on 
the 5th day of growth on the membrane was 47.6 ± 11.26 µm and 39.55 ± 8.81 
µm respectively. However, the MCL formed by Panc-1 and SK-MEL was 
 
 
 
 
 
 
  
      
 
 
 
 
 
 
Figure 3-4: Histological sections through Panc-1, SK-MEL 23, A-2780, M14, SiHa, Caski, A-
549, 7860, HT-29 and PC3 MCLs on day 5 of growth on the transwell membrane.  
Caski 
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three times thicker than that of DLD-1 and MCF-7 on the same day of growth. 
MCLs formed by A-549, 7860, HT-29 and PC3 were thin and there were gaps 
between the cells, particularly for HT-29 and PC3 cell lines. 
 
 
 
Figure 3-5: MCL thicknesses of Panc-1, SK-MEL 23, A-2780, M14, SiHa, Caski, A-549, 7860, 
HT-29 and PC3 after 5 days of growth on the transwell membrane. Results represent mean ± 
SD of 15 readings from 3 different sections of 3 different replicates. 
 
3.2.3 Testing the ability of the MCL to form a homogenous barrier using 
trypan blue:   
In order to determine whether drugs cross the MCL by penetrating through 
cells or via gaps between cells, the ability of trypan blue (which is excluded 
from cells with intact membranes) to cross DLD-1 MCLs was determined. 
Trypan blue was allowed to penetrate through DLD-1 MCL (Day-1) and 
through blank membrane (no cells) over 3 minutes at 37°C. Concentrations of 
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penetrating trypan blue to the bottom chamber were measured 
spectrophotometrically based on calibration curve standards (figure 3-6). 
 
Figure 3-6: Calibration curves used to calculate penetrating trypan blue concentrations. 
Results represent mean ± SD for three independent replicates. 
 
Penetrating trypan blue was calculated as concentration (% w/v) as in figure 3-
7. The significant difference in penetrating trypan blue through blank 
membrane compared to DLD-1 MCL can be clearly noticed where 0.0019 % 
(w/v) was measured in the bottom chamber in case of blank membrane 
compared with 0.0002 % (w/v) in case of DLD-1 MCL. These results show that 
trypan blue penetration through blank membrane was 10 times higher than 
that penetrated through DLD-1 MCL which indicates that trypan blue 
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penetrated the MCL through gaps between the cells and that the MCL had the 
ability to limit trypan blue penetration to the bottom chamber. 
 
Figure 3-7: Concentrations (% w/v) of penetrating trypan blue through blank membrane and 
through DLD-1 MCL. Results represent mean ±SD of three different replicates. (*) P<0.05. 
 
3.3  Analysis of doxorubicin: 
3.3.1 HPLC analysis of doxorubicin: 
Figure 3-8 shows the retention time and peak areas of doxorubicin and the 
internal standard epirubicin. Doxorubicin elutes first followed by epirubicin with 
one minute interval between them. The representative chromatograms 
presented in figure 3-8 were obtained using doxorubicin alone (A), doxorubicin 
and epirubicin mixed together (B) and epirubicin alone (C).  
119 
 
 
 
 
Figure 3-8: HPLC Chromatogram showing peak areas and retention times of doxorubicin and 
epirubicin. The concentrations of doxorubicin and epirubicin were 500 nM 
 
3.3.2 Calibration curves, limits of detection, extraction efficiencies, 
intra-day variations and injection reproducibility: 
Quantification of doxorubicin in tissue culture medium or in mobile phase was 
performed based on standard calibration curves prepared daily by linear 
regression of the ratio of drug to internal standard peak area versus 
concentration. The calibration curves used for the determination of doxorubicin 
in tissue culture medium were linear over the concentration range of 10 nM to 
100 µM. Correlation coefficient (r2) values ranged between 0.991 and 0.995. 
Doxorubicin 
 
Epirubicin 
Epirubicin 
Doxorubicin 
A 
B 
C 
120 
 
 
Figure 3-9 represents an example for one of the calibration curves which were 
used to determine doxorubicin. This calibration was used to analyse samples 
retrieved from the third penetration model (diffusion opposing convection 
D↓C↑), which usually permeates very low drug concentrations. Using 
calibration curves, the lower reproducible limit of quantification (LLOQ) for 
doxorubicin using HPLC was 10 nM.  
 
Figure 3-9: Calibration curve standards used to analyse samples created using model 3 
(diffusion opposing convection D↓C↑). Results represent mean ±SD of 3 replicates. 
 
Limits of detection, extraction efficiencies of extraction techniques obtained for 
doxorubicin and experimental variations due to human sampling error or due 
to machine error during analysis (% precision) are all summarized in table 3-1. 
Different extraction techniques were used to extract doxorubicin from tissue 
culture medium details of which were described previously. Solid phase 
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extraction (SPE) had an extraction efficiency of 55% and 10 nM limit of 
detection. Protein precipitation without evaporation and protein precipitation 
with further evaporation had extraction efficiencies of 77% and 51% 
respectively and limits of detection of 50 nM and 20 nM respectively. Although 
solid phase extraction had an extraction efficiency of 55%, however, it was 
considered to be the best method of extraction because of its selectivity 
compared to other methods and due to its better limit of detection. Intra-day 
variations and injection reproducibility and precision were calculated by 
injecting 6 quality control injections from 6 independent vials or from the same 
vial containing doxorubicin (500 nM) respectively. Precision was calculated 
using the coefficient of variation equation which was described in section 
(2.5.3). Precision values obtained using the three different extraction 
techniques were less than 15%. 
Table 3-1: Extraction efficiencies, limits of detection, intra-day variations and 
injection reproducibility (precision) of each extraction technique using HPLC.  
 
Comparison/Method Non 
extracted 
Solid 
Phase 
Extraction 
Protein 
precipitation 
without 
evaporation 
Protein 
precipitation 
with 
evaporation 
and 
reconstitution 
 
%Extraction 
efficiency 
(mean ±SD) 
n/a* 55.2 ± 9.7 77.3 ± 7 51.3 ± 3.8 
Limit of detection 
(nM) 
5 nM 10 nM 50 nM 20 nM 
Experimental 
precision  (%),(n=6) 
3.55 8.59 6.75 4.25 
Injection precision 
(%),(n=6) 
0.314 0.092 0.25 0.25 
* = Not applicable.  
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3.3.3 Doxorubicin stability at 37°C: 
Drug penetration assays are conducted at 37°C over a time period of 30 
minutes to 1hour. As a control experiment, the stability of doxorubicin under 
experimental conditions (phenol red free complete medium at 37°C) is 
presented in figure 3-10. Doxorubicin 1 µM was extracted using protein 
precipitation without evaporation and analysed by HPLC. The results 
demonstrate that doxorubicin is stable under these experimental conditions for 
at least 2 hours. 
 
Figure 3-10: Doxorubicin (1 µM in tissue culture medium) stability test at 37°C over 2 hours. 
Results represent mean ± SD for three different replicates.  
 
3.4 Analysis of imatinib and gefitinib: 
3.4.1 HPLC, LC/MS and LC/MS/MS analysis of imatinib and gefitinib: 
HPLC, LC/MS and LC/MS/MS were used to analyse imatinib and gefitinib. 
LC/MS/MS was reserved for samples which were expected to contain very low 
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concentrations i.e. those produced by the third model (diffusion opposing 
convection D↓C↑), LC/MS was used to analyse samples created from diffusion 
only model (D↓) and HPLC was used to analyse samples which were 
expected to contain high concentrations of drug i.e. those produced by the 
second model (convection plus diffusion C↓D↓). Figures 3-11 – 3-14 represent 
the chromatographic traces of imatinib and gefitinib using HPLC, LC/MS and 
LC/MS/MS. Panel (A) of  figure 3-11 shows the absorbance spectrum for 
imatinib and section (B) on the same figure represent the absorbance 
spectrum for gefitinib obtained using reverse-phase liquid chromatography. 
They were scanned across the wavelength range between 200 and 400 nm. 
Imatinib absorbance peaks occur at 265 nm while gefitinib absorbance peaks 
occur at 252 nm and 343 nm.  Panel (C) on the same figure represents HPLC 
chromatographic traces for gefitinib (10 µM) and imatinib (10 µM) separated 
using the HPLC analysis conditions described in section (2.6). Samples were 
extracted using simple protein precipitation with methanol. It is noticed from 
the chromatogram that gefitiinib eluted at 4.30 minute while imatinib eluted at 
7.55 minute. Figure 3-12 represents LC/MS chromatographic traces for 
imatinib (10 µM). Reverse-phase liquid chromatography with MS was used for 
the separation of imatinib. Panel (A) on the figure represents the diode array 
detection of imatinib at a wavelength of 265 nm and a retention time of 5.94 
minutes. Panel (B) represents an MS trace supporting correct identification of 
imatinib in MS detector. In this trace, total ion chromatogram (TIC) scanning of 
singularly charged ion [ES+] with retention time at 5.90 minutes. Panel (C) 
represents selected ion recording (SIR) of imatinib in specific [ES+] mass to 
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charge ratio (m/z) of 494 with retention time at 5.91 minutes. Finally, panel (D) 
on figure 3-12 represents spectral characteristics of imatinib at m/z of 494.11.  
Gefitinib (10 µM) LC/MS chromatogram traces on the other hand are 
presented on figure 3-13. Gefitinib was also separated using reverse-phase 
liquid chromatography with MS. Panel (A) on the figure represents the diode 
array detection of gefitinib at a wavelength of 343 nm and a retention time of 
3.16 minutes. Panel (B) represents an MS trace supporting correct 
identification of gefitinib in MS detector. In this trace, scanning of a singularly 
charged ion [ES+] is presented with retention time at 3.28 minutes. Panel (C) 
represents selected ion recording (SIR) of gefitinib in specific [ES+] mass to 
charge ratio (m/z) of 446.85 with retention time at 3.24 minutes. Finally, panel 
(D) on the same figure represents spectral characteristics of gefitinib at m/z of 
446.85. LC/MS/MS chromatograms of imatinib and gefitinib are presented in 
figure 3-14 which shows the chromatographic traces of imatinib 100 nM alone 
as seen on panel (A), gefitinib 500 nM alone panel (B) and both imatinib 100 
nM and gefitinib 500 nM together as on panel (C). As seen on panel (C), total 
ion chromatogram (TIC) scanning of singularly charged ion [ES+] with gefitinib 
eluted at minute 1.58 and imatinib eluted at minute 2.48. Total running time 
was 4 minutes with flow rate of 0.35 mL/min and an injection volume of 10 µL. 
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Figure 3-11: Detection of imatinib and gefitinib at (10 µM) using HPLC. Reverse-phase liquid 
chromatography was used for the separation of imatinib and gefitinib. Absorbance spectrum 
(range 200-400 nm) for imatinib (A) and gefitinib (B). Absorbance peaks occur at 265 nm for 
imatinib and at 252 nm and 343 nm for gefitinb. (C) Chromatograms of imatinib and gefitinib 
using diode array detection (DAD) at wavelength of 343 nm and retention times of 4.3 and 
7.55 minutes for imatinib and gefitinib respectively. 
 
50A50B1mlmin
nm
200 225 250 275 300 325 350 375 400
A
U
0.0
5.0e-3
1.0e-2
200.56
265.56
QC
nm
200 225 250 275 300 325 350 375 400
A
U
0.0
1.0e-2
2.0e-2
3.0e-2
203.56
252.56
343.56
A 
B 
C Gefitinib 
Imatinib 
 
 
126 
 
 
 
 
 
 
Figure 3-12: Detection of (10 µM) imatinib using LC/MS. Reverse-phase liquid 
chromatography was used for the separation of imatinib. (A) DAD trace representing peak and 
retention time at 5.94 minutes. (B) MS trace supporting correct identification of imatinib in MS 
detector. Total ion chromatogram (TIC) scanning of singularly charged ion [ES+] with retention 
time at 5.90 minutes. (C) Selected ion recording (SIR) of imatinib in specific [ES+] m/z of 494 
with retention time at 5.91 minutes. (D) Spectral characteristics of imatinib at m/z of 494.11.  
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Figure 3-13: Detection of (10 µM) gefitinib using LC/MS. Reverse-phase liquid 
chromatography was used for the separation of gefitinib. (A) DAD trace representing peak and 
retention time at 3.16 minutes. (B) MS trace supporting correct identification of gefitinib in MS 
detector. Trace represents scanning of singularly charged ion [ES+] with retention time at 3.28 
minutes. (C) Selected ion recording (SIR) of gefitinib in specific [ES+] m/z of 446.85 with 
retention time at 3.24 minutes. (D) Spectral characteristics of gefitinib at m/z of 446.85. 
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Figure 3-14:  Chromatographic traces of imatinib 100 nM (A) and gefitinb 500 nM (B) using 
LC/MS/MS. Panel (C) represents total ion chromatogram (TIC) and peak areas of both drugs 
together. Gefitinib eluted at minute 1.58 and imatinib eluted at minute 2.48. 
 
 
 
 
3.4.2  Calibration curves and limits of detection: 
As in case of doxorubicin, imatinib and gefitinb quantification in tissue culture 
medium or in mobile phase was performed based on standard calibration 
curves. Quantification was performed by linear regression of the ratio of dug to 
internal standard peak area versus concentration of at least ten concentration 
standards (in triplicate). The calibration curves used for the determination of 
imatinib and gefitinib in tissue culture medium were linear over the 
concentration range of 10 nM to 100 µM depending on the penetration model 
Imatinib 
Gefitinib 
Gefitinib 
Imatinib 
C 
B 
A 
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used with the correlation coefficient (r2) values ranging between 0.96 and 0.99. 
Calibration curve standards were selected depending on the penetration 
model used as each model operates over different ranges of drug 
concentrations. A series of calibration curves were generated, the details of 
which varied depending upon the specific experiment performed (appendix 2). 
Figures 3-15 and 3-16 represent typical examples of calibration curves used to 
quantify imatinib and gefitinib concentrations respectively. These calibration 
curves were used to analyse samples retrieved from the third penetration 
model (diffusion opposing convection D↓C↑), which usually permeates very 
low drug concentrations. Using calibration curves, the lower reproducible limit 
of quantification (LLOQ) for imatinib and gefitinb using LC/MS/MS was 1 nM. 
However, 100 nM and 1 µM were detected and quantified using LC/MS and 
HPLC respectively.  
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Figure 3-15: Imatinib calibration curve standards used to analyse samples created using 
model 3 (diffusion opposing convection D↓C↑). Results represent mean ±SD of 3 replicates. 
 
 
 
Figure 3-16: Gefitinib calibration curve standards used to analyse samples created using 
model 3 (D↓C↑). Results represent mean ±SD of 3 replicates. 
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3.4.3 Stability of imatinib and gefitinib at 37°C: 
The stability of imatinib and gefitinib in phenol red free complete medium at 
37°C are presented in figure 3-17. Imatinib and gefitinib 1 µM each were 
extracted using protein precipitation without evaporation and analysed by 
HPLC. The results demonstrate that they were both stable under these 
experimental conditions for at least 2 hours. 
 
 
Figure 3-17: Stability of imatinib and gefitinib 1 µM each in tissue culture medium at 37°C 
over 2 hours. Results represent mean ± SD for three different replicates.  
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3.5 Drug penetration assays using model-1: 
3.5.1 Drug penetration assay using variable concentration gradient 
(VCG) technique: 
The penetration of doxorubicin through blank transwells (no cells seeded) is 
presented in figure 3-18. In the absence of cells, doxorubicin at an initial 
concentration of 100 µM penetrated the membrane and reached a maximum 
concentration in the bottom chamber of 9.26 ± 2.21 µM after 45 minutes. 
Doxorubicin at 50 µM and 25 µM penetrated the membrane and reached 
concentrations of 4.41 ± 0.82 and 2.16 ± 0.26 µM respectively after 45 
minutes. It was clearly noticed that the penetration curves plotted using VCG-
technique showed considerable variation as indicated by “spiking” in the 
curves (Figure 3-18). In addition, the expected theoretical steady state (14 µM 
in case of using 100 µM at the top chamber) was not achieved.  
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Figure 3-18: Penetration of doxorubicin 100, 50 and 25 µM through non hydrated blank (no 
cells seeded) membranes using VCG-technique. Results represent mean ± SD for 3 
independent experiments.  
 
Inadequate hydration of the membranes could be a cause of this spiking and 
for this reason; penetration assay was performed using a hydrated transwell 
where the transwell was incubated in medium at 37°C for 24 hours prior to 
conducting the penetration assay. Penetration assay was conducted using 
doxorubicin at 100 µM only. The results are presented in (figure 3-19). 
Transwell hydration did not improve the variation observed and curve spiking 
still occurred.  
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Figure 3-19: Penetration of doxorubicin 100 µM through hydrated and non-hydrated blank (no 
cells seeded) membranes using VCG-technique. Results represent mean ± SD for 3 
independent experiments. 
 
The next potential source of error explored was the collagen which coats the 
membrane. It was expected that collagen may bind to doxorubicin and hence 
influences its penetration through the membrane. An experiment was 
conducted using a trypsinized transwell. To remove collagen, transwell 
membrane was trypsinized with 0.5 mL of trypsin for 5 minutes then rinsed 3 
times with HBSS solution prior to conducting the penetration assay. 
Penetration assay was conducted using doxorubicin at 100 µM. Although the 
resultant plotted curve came smoother and penetration rate was faster after 
trypsinization however, variation was still observed and curve spiking still 
occurred as shown on Figure 3-20.  
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Figure 3-20: Penetration of doxorubicin 100 µM through a trypsinized and non-trypsinized 
blank (no cells seeded) membrane using VCG-technique. 
 
The result of this experiment indicates that spiking and inherent variations in 
the plotted curves might not be due to the presence of collagen in the 
transwell. Although the variations and “spikes” noticed in the plotted curves 
using VCG technique through control transwells, penetration of doxorubicin 
through DLD-1 multicell layers was performed and it is presented in figure 3-
21. Penetration of doxorubicin through DLD-1 MCLs was performed using 
doxorubicin at 100, 50 and 25 µM on days 1, 3, 5 and 7 of growth of cells on 
the membrane. In the presence of cells, doxorubicin at 100 µM penetrated the 
multicell layer on the first day of growth on the membrane and reached a 
maximum concentration of approximately 3.79 ± 1.77 µM after 45 minutes. 
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Using 50 and 25 µM in the top chamber, doxorubicin reached concentrations 
of 1.41 ± 0.60 and 0.75 ± 0.46 µM respectively after 45 mins of incubation. 
The rate of penetration through a MCL of 14.3 ± 2 μm is therefore 
concentration dependent. Doxorubicin penetration on days 3 and 5 of growth 
on the membrane showed that as the thickness of the MCL increased, the rate 
of doxorubicin penetration decreased.  The inherent variations and spikes in 
the curves were still present as occurred with the control samples. Figure 3-21 
represent mean ± SD of doxorubicin 100, 50 and 25 µM penetration through 
blank transwells (no cells seeded) and through the multi cell layers on days 1, 
3 and 5 of growth on the membrane. Day 7 samples were not analysed 
because of the clear limited penetration noticed on day 5. Using penetration 
assay with VCG-technique, penetration rates were calculated based on fitting 
a linear regression to the first 6 sampling points on the curve which represents 
the initial penetration rate. The slope of the linear regression equation was 
considered the penetration rate. Concentration values were converted into 
amounts and the rate was expressed as nmoles/minute. Tables 3-2 to 3-4, 
and figures, 3-22 and 3-23 show the penetration rates through DLD-1 MCLs 
(days 1-5) and through blank membrane. Rates of doxorubicin penetration 
were inversely proportional to the thickness of multicell layer with penetration 
rate of 0.0622 ± 0.006 nmol/min on day 1 (thickness 14.3 ± 2 µm), 0.0288 ± 
0.007 nmol/min on day 3 (thickness 21.9 ± 2.7 µm) and 0.005 ± 0.002 
nmol/min on day 5 where the thickness of the multicell layer was (37.3 ± 4.5 
µm), for doxorubicin at 100 µM. Penetration rates of doxorubicin 50 and 25 µM 
using VCG are presented in tables 3-3 and 3-4. They show clear limited 
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penetration especially for doxorubicin at 25 µM on days 3 and 5 of growth on 
the membrane. Throughout all these experiments, considerable variation in 
data points was observed and ‘spiking’ of curves occurred frequently. Because 
of this, an alternative approach was employed where the concentration of drug 
in the top chamber was maintained at a constant value (the constant 
concentration gradient or CCG technique). 
Table 3-2: Penetration rates of doxorubicin 100 µM, through blank (no cells seeded) and 
through DLD-1 MCLs on days 1, 3 and 5 of growth on the membrane using VCG-technique. 
 
 
 
Doxorubicin 100 µM 
Penetration rate (nmoles/min) 
Blank membrane 
 (no cells) 
MCL 
(Day-1) 
MCL  
(Day-3) 
MCL  
(Day-5) 
Average Penetration 
rates (nmoles/min) 
0.2425 0.0622 0.0288 0.005 
SD 0.015 0.006 0.007 0.002 
Table 3-3: Penetration rates of doxorubicin 50 µM, through blank (no cells seeded) and 
through DLD-1 MCL on days 1, 3 and 5 of growth on the membrane using VCG-technique. 
 
 
 
Doxorubicin 50 µM 
Penetration rate (nmoles/min) 
Blank membrane 
 (no cells) 
MCL 
(Day-1) 
MCL  
(Day-3) 
MCL  
(Day-5) 
Average Penetration 
rates (nmoles/min) 
0.1125 0.0118 0.0073 0.004 
SD 0.015 0.006 0.0007 0.002 
Table 3-4: Penetration rates of doxorubicin 25 µM, through blank (no cells seeded) and 
through DLD-1 MCL on days 1, 3 and 5 of growth on the membrane using VCG-technique. 
 
 
 
Doxorubicin 25 µM 
Penetration rate (nmoles/min) 
Blank membrane 
 (no cells) 
MCL 
(Day-1) 
MCL  
(Day-3) 
MCL  
(Day-5) 
Average Penetration 
rates (nmoles/min) 
0.0633 0.0081 BLD* BLD 
SD 0.015 0.006 BLD BLD 
*BLD = Below the limit of detection. 
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Figure 3-21: Penetration of doxorubicin 100 (A), 50 (B) and 25 µM (C) through blank (no cells 
seeded) and through DLD-1 MCL on days 1, 3 and 5 of growth on the membrane using VCG-
technique. Legends in (A) represent (B) and (C). 
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Figure 3-22 (A): Penetrating amounts of doxorubicin (100 µM), through blank (no cells 
seeded) and through DLD-1 MCL on days 1, 3 and 5 of growth on the membrane using 
VCG-technique. Penetration rates were calculated from linear regression of the first 6 time 
points. Results represent mean ± SD of three independent replicates. 
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Figure 3-22 (B): Penetrating amounts of doxorubicin (50 µM), through blank (no cells 
seeded) and through DLD-1 MCL on days 1, 3 and 5 of growth on the membrane using 
VCG-technique. Penetration rates were calculated from linear regression of the first 6 time 
points. Results represent mean ± SD of three independent replicates. 
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Figure 3-22 (C): Penetrating amounts of doxorubicin (25 µM), through blank (no cells 
seeded) and through DLD-1 MCL on days 1, 3 and 5 of growth on the membrane using 
VCG-technique. Penetration rates were calculated from linear regression of the first 6 time 
points. Results represent mean ± SD of three independent replicates. 
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Figure 3-23: Penetration rates of doxorubicin 100, 50 and 25 µM, through blank (no cells 
seeded) and through DLD-1 MCLs on days 1, 3 and 5 of growth on the membrane using VCG-
technique.  
 
3.5.2 Drug penetration assay using constant concentration gradient 
(CCG) technique: 
Using CCG-technique, doxorubicin penetration through blank membranes 
(figure 3-24), DLD1 (figure 3-25) and MCF7 MCLs (figure 3.26) was 
performed. With the CCG technique, data output was linear and the graphs did 
not show the significant ‘spiking’ noticed with the VCG technique. In addition, 
penetration rates were easy to calculate and finally, results were reproducible. 
The next step was to calculate the penetration rates using this technique to be 
compared with the results of the previous technique. 
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Figure 3-24: Penetration of doxorubicin 100, 50 and 25 µM through blank (no cells seeded) 
membranes using CCG-technique. Results represent mean ± SD for 3 independent 
experiments. 
 
 
144 
 
 
 
Figure 3-25: Penetration of doxorubicin 100 µM through DLD-1 MCLs on days 1, 3, 5 and 7 of 
growth on the membrane using CCG-technique. Results represent mean ± SD for 3 
independent experiments. 
 
 
Figure 3-26: Penetration of doxorubicin 100 µM through MCF-7 MCLs on days 1, 3, 5 and 7 of 
growth on the membrane using CCG-technique. Results represent mean ± SD for 3 
independent experiments.  
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Penetration rates were determined by linear regression analysis as described 
previously. Penetration rates of doxorubicin through blank membranes, DLD-1 
and MCF-7 MCLs is presented in figures 3-27 to 3-29 and summarized in 
tables 3-5 to 3-10. The penetration rates were proportional to doxorubicin 
concentration, where 100 µM showed a penetration rate of 0.3774 ± 0.0122 
nmol/min, 50 µM showed a penetration rate of 0.1834 ± 0.0249 nmol/min and 
25 µM showed a penetration rate of 0.0699 ± 0.006 nmol/min through blank 
membranes. Penetration rates were also inversely proportional to the MCL 
thicknesses. Doxorubicin at 100 µM showed penetration rates of 0.1016 ± 
0.0095, 0.0160 ± 0.0079, 0.0107 ± 0.0041 and 0.0087 ± 0.0027 nmoles/min on 
days 1, 3, 5 and 7 respectively through DLD-1 MCLs. Penetration rates 
obtained using this technique, were more reliable because of the linearity of 
the data obtained compared to VCG technique. Figures 3-30 and 3-31 
summarize the penetration rates of doxorubicin 100, 50 and 25 µM through 
DLD-1 and MCF-7 MCLs respectively on days 1, 3, 5 and 7 of cells growth on 
the membrane.  
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Figure 3-27: Cumulative penetrating amounts of doxorubicin 100, 50 and 25 µM through 
blank membrane using CCG-technique. Results represent mean ± SD for 3 independent 
experiments. 
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Figure 3-28: Cumulative penetrating amounts of doxorubicin 100 µM through DLD-1 MCLs on 
days 1,3,5 and 7 of growth on the membrane using CCG-technique. Penetration rates were 
calculated from the linear regression of the time points on the curve. Results represent mean 
± SD for 3 independent experiments. 
 
 
 
Figure 3-29: Cumulative penetrating amounts of doxorubicin 100 µM through MCF-7 MCLs on 
days 1,3,5 and 7 of growth on the membrane using CCG-technique. Penetration rates were 
calculated from the linear regression of the time points on the curve. Results represent mean ± 
SD for 3 independent experiments. 
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Table 3-5: Penetration rates of doxorubicin 100 µM, through blank (no cells seeded) and 
through DLD-1 MCL on days 1, 3, 5 and 7 of growth on the membrane using CCG-technique. 
 
 
 
Doxorubicin 100 µM 
Penetration rate (nmoles/min) 
Blank 
membrane 
 (no cells) 
MCL 
(Day-1) 
MCL  
(Day-3) 
MCL  
(Day-5) 
MCL 
(Day-7) 
Average 
Penetration rates 
(nmoles/min) 
0.3774 0.1016 0.0160 0.0107 0.0087 
SD 0.0122 0.0095 0.0079 0.0041 0.0027 
 
Table 3-6: Penetration rates of doxorubicin 50 µM, through blank (no cells seeded) and 
through DLD-1 MCL on days 1, 3 and 5 of growth on the membrane using CCG-technique. 
 
 
 
Doxorubicin 50 µM 
Penetration rate (nmoles/min) 
Blank 
membrane 
 (no cells) 
MCL 
(Day-1) 
MCL  
(Day-3) 
MCL  
(Day-5) 
MCL 
(Day-7) 
Average 
Penetration rates 
(nmoles/min) 
0.1834 0.0223 0.0096 0.0062 0.0042 
SD 0.0249 0.0071 0.0019 0.0016 0.0016 
 
Table 3-7: Penetration rates of doxorubicin 25 µM, through blank (no cells seeded) and 
through DLD-1 MCL on days 1, 3 and 5 of growth on the membrane using CCG-technique. 
 
 
 
Doxorubicin 25 µM 
Penetration rate (nmoles/min) 
Blank 
membrane 
 (no cells) 
MCL 
(Day-1) 
MCL  
(Day-3) 
MCL  
(Day-5) 
MCL 
(Day-7) 
Average 
Penetration rates 
(nmoles/min) 
0.0699 0.0171 0.0052 0.0036 0.0012 
SD 0.0060 0.0049 0.0014 0.0013 0.0007 
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Table 3-8: Penetration rates of doxorubicin 100 µM, through blank (no cells seeded) and 
through MCF-7 MCL on days 1, 3 and 5 of growth on the membrane using CCG-technique. 
 
 
 
Doxorubicin 100 µM 
Penetration rate (nmoles/min) 
Blank 
membrane 
 (no cells) 
MCL 
(Day-1) 
MCL  
(Day-3) 
MCL  
(Day-5) 
MCL 
(Day-7) 
Average 
Penetration rates 
(nmoles/min) 
0.3774 0.0699 0.0131 0.0054 0.0034 
SD 0.0122 0.0105 0.0012 0.0008 0.0007 
 
Table 3-9: Penetration rates of doxorubicin 50 µM, through blank (no cells seeded) and 
through MCF-7 MCL on days 1, 3 and 5 of growth on the membrane using CCG-technique. 
 
 
 
Doxorubicin 50 µM 
Penetration rate (nmoles/min) 
Blank 
membrane 
 (no cells) 
MCL 
(Day-1) 
MCL  
(Day-3) 
MCL  
(Day-5) 
MCL 
(Day-7) 
Average 
Penetration rates 
(nmoles/min) 
0.1834 0.0351 0.0098 0.0069 0.0042 
SD 0.0249 0.0065 0.0015 0.0005 0.0006 
 
Table 3-10: Penetration rates of doxorubicin 25 µM, through blank (no cells seeded) and 
through MCF-7 MCL on days 1, 3 and 5 of growth on the membrane using CCG-technique. 
 
 
 
Doxorubicin 25 µM 
Penetration rate (nmoles/min) 
Blank 
membrane 
 (no cells) 
MCL 
(Day-1) 
MCL  
(Day-3) 
MCL  
(Day-5) 
MCL 
(Day-7) 
Average 
Penetration rates 
(nmoles/min) 
0.0699 0.0198 0.0086 0.0024 0.0009 
SD 0.0060 0.0019 0.0008 0.0003 0.00009 
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Figure 3-30: Penetration rates of doxorubicin 100, 50 and 25 µM, through blank (no cells 
seeded) and through DLD-1 MCL on days 1, 3, 5 and 7 of growth on the membrane using 
CCG-technique. Results represent mean ± SD for 3 independent experiments. 
 
 
 
Figure 3-31: Penetration rates of doxorubicin 100, 50 and 25 µM, through blank (no cells 
seeded) and through MCF-7 MCL on days 1, 3, 5 and 7 of growth on the membrane using 
CCG-technique. Results represent mean ± SD for 3 independent experiments. 
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3.6 Drug penetration assays using models 2 and 3:  
Model-1 (diffusion only D↓) was used at the beginning of this project for 
validating the sampling, analysis, extraction efficiencies, drugs stability and 
inter and intra-day experimental and injection variations. Details of those 
results were presented in the previous sections. As there is no hydrostatic 
pressure difference in this model, drugs penetrate through it by diffusion. After 
the introduction of models 2 and 3, penetration assays through model 1 were 
used as control to evaluate the effect of HP change on CFF and penetration 
rates. Penetration assays using doxorubicin, imatinib and gefitinib 100 µM 
each were conducted using these models. Details of these drugs penetration 
through models 2 and 3 compared to model 1 will be presented in the 
following sections. 
3.6.1 Model 2: Convection plus diffusion (C↓D↓) penetration assay: 
The transwell chamber was modified by inserting a 10 mL pipette into the top 
chamber and securing it in place with superglue. The fluid level in the top 
chamber was raised above the level in the bottom chamber and the rate of 
transfer of fluid (i.e. convective fluid flow) from the top to bottom chamber 
determined. The results are presented in Figure 3-32. Using 13 mL of medium 
in the top chamber, a physiologically relevant pressure of 28 mmHg is 
generated and a convective flow rate of 18 µL/minute was obtained. 
Convection was proportional to the volume of medium at the top chamber as 
noticed in figure 3-32.  
Similar experiment was performed using 13 mL of medium at the top chamber 
against different DLD-1 MCL thicknesses as presented in figure 3-33 which 
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shows the convection versus thickness measured using convection plus 
diffusion penetration assay model. CFF calculated on day 1 was 21 µL/minute 
which is mainly similar to the reading of the above experiment however, CFF 
was significantly reduced to 7 µL/minute on the second day with a DLD-1 MCL 
thickness of 25.1 µm. CFF dramatically reduced to 1 µL/minute on the third 
day where the MCL thickness was 31 µm. Four days old DLD-1 MCL with 
thickness of 41 µm was mainly able to stop convection completely. 
 
 
Figure 3-32: Convective fluid flow (CFF) through 12.21± 3.2 µm thick DLD-1 MCL. CFF was 
measured using convection plus diffusion penetration assay model (C↓D↓) against different 
volumes of medium at the top chambers creating different pressure gradients (ΔP). Results 
represent mean ± SD for 3 independent experiments. 
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Figure 3-33: Convective fluid flow (CFF) through several thicknesses of DLD-1 MCL 
measured using convection plus diffusion penetration assay model (C↓D↓). Results represent 
mean ± SD for 3 independent experiments. 
 
Figure 3-34 shows doxorubicin 100 µM penetration through DLD-1 MCLs 
using model 2 where drug penetration is driven by both convection and 
diffusion forces together (C↓D↓). Experiments were conducted using a 
physiologically relevant hydrostatic pressure applied to the top chamber of the 
penetration assay experimental system. A significant difference is clearly 
noticed in the cumulative concentrations which penetrate to the bottom 
chamber every 5 minutes compared to the previous technique (Model 1, 
diffusion only D↓) in which there is no hydrostatic pressure difference and 
hence no CFF. 
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Figure 3-34: Penetration of doxorubicin (100 µM) through DLD-1 MCL (Day-1) using model 
2 (C↓D↓) compared to model 1 (D↓). Results represent mean ± SD for 3 independent 
experiments. 
 
3.6.2 Model 3, diffusion opposing convection (D↓C↑): 
In this assay, the direction of CFF is reversed so that diffusion and CFF are 
opposing each other. The results of drug penetration through this model 
compared to model 1 are presented in Figure 3-35.  Using doxorubicin at 100 
µM and a 1 day DLD-1 MCL, drug penetration was significantly reduced 
compared to the same experiment conducted where CFF was zero. 
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Figure 3-35: Doxorubicin 100 µM penetration through DLD-1 MCL (Day-1) using model 3 
(D↓C↑) compared to model 1 (D↓). Reverse convection from the bottom chamber has 
significantly reduced drug penetration. Results represent mean ± SD for 3 independent 
experiments. 
 
This model was further modified as will be explained in the following section. 
3.6.3 Modified model 3, diffusion opposing convection (D↑C↓): 
In order to reduce variations in CFF, reduce materials and time consumed by 
model 3, it was further modified by adding the drug to the bottom chamber and 
measuring that diffusing to the top chamber i.e. (D↑ C↓) as presented in figure 
2-4. As in model 2, 13 mL of medium is placed at the top chamber to exert a 
physiologically relevant hydrostatic pressure from the top to the bottom 
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chamber. Using this model, CFF from top to bottom chamber was 26.7 ± 3.9 
µL/min. Doxorubicin penetrated from the bottom chamber to the top chamber 
at rates of 0.08 ± 0.02 nmoles/min as presented in figure 3-36. The penetration 
rate with this model was also significantly lower compared to the diffusion only 
model as presented in figures 3-37 and 3-38. 
 
Figure 3-36: Cumulative amounts of doxorubicin 100 µM through DLD-1 MCL (day 1) 
using original (D↓C↑) and modified model 3 (D↑C↓).  Slopes of the linear regressions were 
used for calculating penetration rates. Results represent mean ± SD for at least 3 
independent experiments. 
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Figure 3-37: Doxorubicin 100 µM penetration through DLD-1 MCL (Day-1) using modified 
model 3 (D↑C↓) compared to model 1 (D↓). Reverse convection from the top chamber has 
significantly reduced drug penetration. Results represent mean ± SD for 3 independent 
experiments. 
 
 
The penetration rates of doxorubicin were also significantly lowered compared 
to other models as presented on figure 3-38. 
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Figure 3-38: Doxorubicin 100 µM penetration rates through DLD-1 MCL (Day-1) using 
modified model 3 (D↑C↓) compared to other models. Results represent mean ± SD for 3 
independent experiments. 
 
Penetration models 1, 2 and 3 were validated using doxorubicin, imatinib and 
gefitinib where convection and penetration rates were calculated as will be 
presented in the following section. 
 
 
159 
 
 
3.7 Impact of CFF on drug penetration through MCLs using 
doxorubicin, imatinib and gefitinib: 
The three different penetration assay models were validated and evaluated 
using doxorubicin, imatinib and gefitinib. All drugs (100 µM) were tested for 
their ability to penetrate one day old DLD-1 MCLs using the three different 
penetration assay models in triplicate. Using penetration assay models 2 
(convection plus diffusion C↓D↓) and 3 (diffusion opposing convection D↓C↑), 
both convection and penetration rates were calculated and compared to the 
first model (diffusion only D↓) where no CFF exists. Convective fluid flow in 
case of (C↓D↓) and (D↓C↑) penetration models where doxorubicin, imatinib 
and gefitinib were used are presented in figures 3-39 and 3-40 and in table 3-
11. It is clear from the results that calculated CFF was similar in both models 
with the (D↓C↑) penetration model giving marginally higher readings than the 
(C↓D↓) model. Using doxorubicin, CFF result through (C↓D↓) model was 28.4 
± 2.97 µL/min compared to 45.57 ± 6.94 µL/min in case of (D↓C↑) model. 
Using imatinib, CFF result through (C↓D↓) model was 21.08 ± 9.48 µL/min 
compared to 60.23 ± 11.89 µL/min in case of (D↓C↑) model and finally using 
gefitinib , CFF result through (C↓D↓) model was 24.04 ± 5.49 µL/min 
compared to 44.90 ± 1.65 µL/min in case of (D↓C↑) model. Within each model, 
these differences in convection however were not statistically significant at 
P<0.05.   
With regards to drug penetration rates, the penetration of doxorubicin, imatinib 
and gefitinib at 100 µM, are presented in figures 3-41 to 3-45 and in table 3-
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12. Cumulative concentrations (figures 3-41, 3-42 and 3-43 for doxorubicin, 
imatinib and gefitinib respectively) were converted into amounts and 
expressed as (nmoles) as presented in figure 3-44. Slope of the linear 
regression of each experiment was considered the penetration rate. 
Penetration rate for doxorubicin (100 µM) was 1.53 ± 0.17 nmoles/minute in 
case of (C↓D↓). This rate dramatically reduced to 0.11 ± 0.04 nmoles/minute 
and 0.04 ± 0.00 nmoles/minute in case of D↓ and D↓C↑ models respectively. 
Penetration rate for imatinib 100 µM was 0.90 ± 0.24 nmoles/minute in case 
of (C↓D↓). This rate significantly reduced to 0.10 ± 0.04 nmoles/minute and 
0.04 ± 0.00 nmoles/minute in case of D↓ and D↓C↑ models respectively. 
Lastly, penetration rate for gefitinib 100 µM was 0.78 ± 0.17 nmoles/minute in 
case of (C↓D↓). This rate has been significantly reduced to 0.19 ± 0.04 
nmoles/minute and 0.03 ± 0.01 nmoles/minute in case of D↓ and D↓C↑ models 
respectively as presented in table 3-12 and figure 3-45.  
In case of model 2 (C↓D↓), doxorubicin, imatinib and gefitinib penetration rates 
have significantly increased by 42, 26 and 13 folds respectively compared to 
model 1 (D↓) penetration rates. Furthermore, when diffusion was opposed by 
convection as in case of model 3 (D↓C↑), penetration rates of doxorubicin, 
imatinib and gefitinib were dramatically reduced respectively by 100, 81 and 
195 folds compared to their penetration through model 1 (D↓). These results 
show the significant impact CFF has on drug penetration. 
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Figure 3-39 (a): Cumulative CFF calculated for doxorubicin (A), imatinib (B) and 
gefit inib (C) penetration through DLD-1 MCL (day-1) using C↓D↓ and D↓C↑ 
penetration  models. Slopes of the linear regressions were used for calculating CFF 
rates. Results represent mean ± SD for at least 3 independent experiments.  
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Figure 3-39(b):  Cumulative CFF calculated for doxorubicin , imatinib and gef it inib 
penetration through DLD-1 MCL (day-1) using C↓D↓ and D↓C↑ penetration  
models. Slopes of the linear regressions were used for calculating CFF rates. Results 
represent mean ± SD for at least 3 independent experiments.  
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Table 3-11: Convective fluid flow (CFF) calculated for doxorubicin, imatinib and gefitinib 100 
µM penetration through DLD-1 MCL using the three different penetration models. Results 
represent mean ± SD for at least 3 independent experiments. 
 
 C↓D↓ D↓ D↓C↑ 
CFF (µL/min) Average SD Average SD Average SD 
Control 20.10 1.75 0.00 0.00 40.44 3.00 
Doxorubicin 28.41 2.97 0.00 0.00 45.57 6.94 
Imatinib 21.08 9.48 0.00 0.00 60.23 11.89 
Gefitinib 24.04 5.49 0.00 0.00 44.90 1.65 
 
 
 
 
 
Figure 3-40:  Convective fluid flow (CFF) calculated for control (drug-free medium) and for 
doxorubicin, imatinib and gefitinib 100 µM penetration through DLD-1 MCL (day-1) using 
(C↓D↓) and (D↓C↑) penetration assay models. Results represent mean ± SD for at least 3 
independent experiments. P>0.05. 
 
 
 
  
C 
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  Model-1, (D↓)    Model-2, (C↓D↓) 
  
 
  Model-3, D↓C↑    Models together 
  
Figure 3-41:  Doxorubicin 100 µM penetration results through DLD-1 MCL (Day-1) using the 
three different penetration models expressed as cumulative concentrations in µM. Results 
represent mean ± SD for 3 independent experiments. 
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  Model-1, (D↓)    Model-2, (C↓D↓) 
  
 
  Model-3, D↓C↑    Models together 
  
Figure 3-42:  Imatinib 100 µM penetration results through DLD-1 MCL (Day-1) using the three 
different penetration models expressed as cumulative concentrations in µM. Results represent 
mean ± SD for 3 independent experiments. 
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  Model-1, (D↓)    Model-2, (C↓D↓) 
  
 
  Model-3, D↓C↑    Models together 
  
Figure 3-43: Gefitinib 100 µM penetration results through DLD-1 MCL (Day-1) using the three 
different penetration models expressed as cumulative concentrations in µM. Results represent 
mean ± SD for 3 independent experiments. 
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Figure 3-44: Doxorubicin (A), imatinib (B) and gefitinib (C) penetrating amounts through DLD-
1 MCL (Day-1) using the three different penetration models expressed as cumulative amounts 
in (nmoles). Penetration rates were calculated from these figures through their linear 
regressions (data presented in table 3-12). Results represent mean ± SD for 3 independent 
experiments. 
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Table 3-12: Penetration rates of doxorubicin, imatinib and gefitinib 100 µM through DLD-1 
MCL using the three different penetration models. Results represent mean ± SD for 3 
independent experiments. 
 
 
 
 
 
Figure 3-45: Penetration rates of doxorubicin, imatinib and gefitinib 100 µM using the three 
different penetration models. Results represent mean ± SD for 3 independent experiments. 
 
 C↓D↓ D↓ D↓C↑ 
Penetration rate 
(nmole/min) 
Average SD Average SD Average SD 
Doxorubicin 1.53 0.17 0.11 0.04 0.04 0.00 
Imatinib 0.90 0.24 0.10 0.04 0.04 0.00 
Gefitinib 0.78 0.17 0.18 0.04 0.03 0.01 
C 
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3.8 Influence of concentration versus exposure time on cell 
survival: 
To determine what impact CFF may have on chemosensitivity, cells were 
exposed to concentrations of drug that represent the amount or concentration 
of drug crossing the transwell during the experiment. For example, the data 
presented in figure 3-41 indicates that 112 μM of doxorubicin crossed the 
membrane within 30 min. Cells were therefore exposed to this concentration of 
doxorubicin for 30 minutes and cell survival determined by the MTT assay 
after a 4 day recovery period. Similar experiments were designed using data 
obtained from the other penetration models. The results of these studies are 
presented in figures 3-46 to 3-48. Doxorubicin cumulative concentration of 112 
µM from model 2 (C↓D↓) was cytotoxic to 76.6% of cells after 30 minutes 
exposure. For doxorubicin cumulative concentrations collected from the 
diffusion only model (D↓), were 2.80 µM and this was cytotoxic to 27% of cells. 
On the other hand doxorubicin cumulative concentration of 0.03 µM collected 
from model 3 (D↓C↑), did not cause a significant cytotoxicity to the same cell 
line (figure 3-46). Table 3-13 shows the used concentrations of doxorubicin, 
imatinib and gefitinb as well as the survival rate ±SD after the DLD-1 cells 
exposure to each one of them. Figures 3-47 and 3-48 represent the results of 
the same experiment using imatinib, and gefitinib respectively. It was noticed 
clearly through those figures that apart from gefitinib (C↓D↓) at 61 µM which 
was cytotoxic to 8% of cells, imatinib and gefitinib at all other concentrations 
did not cause any significant cytotoxicity.  
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Table 3-13: Doxorubicin, imatinib and gefitinib cumulative concentrations used for 
testing concentration VS time effect on DLD-1 survival rates using MTT assay. 
Those concentrations were retr ieved based on the cumulative concentra tions 
analysed post convection plus diffusion (C↓D↓), diffusion only (D↓) and diffusion 
opposed by convection (D↓C↑) penetration assays.  
 
C↓D↓ D↓ D↓C↑ 
 
Drug 
 
Conc. (µM) / Survival rate ±SD 
 
 
Doxorubicin 
 
112 / 23.40±4.68 
 
 
2.8 / 73.10±6.46 
 
0.03 / 98.95±7.16 
 
Imatinib 
 
68.21 / 99.16±3.52 
  
 
2.73 / 99.41±3.95 
 
0.08 / 97.46±4.06 
 
Gefitinib 
 
61.34 / 91.74±11.17 
 
 
5.16 / 94.39±11.15 
 
0.03 / 100.74±4.64 
 
 
 
 
Figure 3-46: Effect of 30 minutes exposure of DLD-1 cells to doxorubicin cumulative 
concentrations (retrieved from penetration assays) on the cells viability using MTT assay. 
Results represent mean ± SD for three independent experiments. 
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Figure 3-47: Effect of 30 minutes exposure of DLD-1 cells to imatinib cumulative 
concentrations (retrieved from penetration assays) on the cells viability using MTT assay. 
Results represent mean ± SD for three independent experiments. 
 
 
Figure 3-48: Effect of 30 minutes exposure of DLD-1 cells to gefitinib cumulative 
concentrations (retrieved from penetration assays) on the cells viability using MTT assay. 
Results represent mean ± SD for three independent experiments. 
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3.9 Collagen expression in the MCL using 
immunohistochemistry (IHC): 
Having established that CFF can be generated in our model system, this 
opens the possibility for future studies designed to manipulate tumour cell / 
matrix interactions with the aim of modulating CFF. One example of this would 
be to modulate components of the ECM such as collagen. Preliminary studies 
are reported here to determine whether or not DLD-1 MCL’s secrete collagen. 
Collagen-IV was chosen as an extracellular matrix target to be modified as it 
was expected to be one of the MCL extracellular matrix components if DLD-1 
MCL can form an extracellular matrix. Immunohistochemistry was used to 
detect whether collagen-IV was present in DLD-1 MCLs. Archived DLD-1 
xenograft tissues (formalin fixed and paraffin embedded tumours) were used 
as control. Figure 3-49 A, B, C and D, represent the immunohistochemical 
staining results of collagen-IV expression in DLD-1 xenograft tumours and 
DLD-1 MCL using Rabbit Polyclonal to Collagen-IV as a primary antibody. 
Collagen-IV was expressed in DLD-1 xenograft tissues (figure 3-49, B) and the 
same expression was not detected in the MCLs of DLD-1 (figure 3-49, D).  
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Figure 3-49: Collagen expression in DLD-1 xenograft tumour and in DLD-1 MCL (Day-7). (A) 
DLD-1 xenograft tumour (Control), (B) DLD-1 xenograft tumour with antibody, (C) DLD-1 MCL 
Control and (D) DLD-1 MCL with antibody. 
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4. DISCUSSION AND CONCLUSION: 
Poor drug penetration is now recognised as one of the causes of resistance to 
chemotherapy (Minchinton and Tannock, 2006). The lack of lymphatic 
drainage together with a heterogenous and leaky vascular supply can lead to 
the elevation of interstitial fluid pressure (IFP) in solid tumours. One 
consequence of elevated IFP is that the normal process of convective fluid 
flow (CFF) through tissues is impeded which is considered a major barrier to 
drug uptake. Several studies have been conducted and several approaches 
have been used to study drug penetration into solid tumours. These studies or 
approaches have almost exclusively used in vivo models (Tredan et al., 2007) 
which are time consuming, expensive and are in conflict with policies on 
reduction, refinement and replacement of animal experiments.   
The aim of this study was to develop a simple in vitro model through which 
drug penetration rates through avascular tissues can be calculated with the 
specific aim of assessing the impact of CFF on drug penetration through 
avascular cellular masses. The model is based on the conventional transwell 
model (Phillips et al., 1998) to assess drug penetration across multicell layers 
(MCLs) (Figure 2-1). This model was modified and three different penetration 
models were developed as described below:  
Model-1: Diffusion only (D↓), (Figure 2-1). This is where CFF is zero and the 
drug crosses the MCL via diffusion down a concentration gradient.  
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Model-2: Convection plus diffusion (C↓D↓), (Figure 2-2). This model is 
where both CFF and diffusion are driving the drug across the MCL.     
Model-3: Diffusion opposing convection (D↓C↑), (Figure 2-3). This is a 
model where CFF and diffusion are working in opposite directions  
In all three models, the arrows in the symbols denote the direction of either 
diffusion (D) or convection (C). 
Before discussing the results of penetration and convection through these 
three experimental models, it is important to first discuss the preceding 
experiments which were conducted to characterise and validate the drug 
penetration models. These experiments include the growth characteristics of 
cells on the transwell membranes, developing and evaluating various 
extraction techniques, evaluating analytical methods including limits of 
detection and limits of quantification, evaluating sampling method that will 
allow drug penetration rates to be calculated accurately and reproducibly and 
analysis of the stability of the drugs used under experimental conditions. 
4.1 Growth characteristics of cells in monolayer and MCL 
settings: 
4.1.1 Growth curves in monolayer settings: 
Growth curves of the two main cell lines in this study (DLD-1 and MCF-7) in 
monolayer settings were generated and showed lag, log and plateau phases 
which came in agreement with other studies (Phillips and Clayton, 1997; 
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Sutherland et al., 1983). These studies were conducted in order to be able to 
manage cell cultures effectively by adding defined numbers of cells to flasks 
and subculturing at specified times thereafter. It also allows workers to check 
for abnormalities in cultures such as mycoplasma contamination. Any 
disturbance in the growth curve for instance could indicate a problem in the 
culture. Figure 3-1. 
4.1.2 Growth characteristics of cell lines on the transwell membrane and 
MCL thickness: 
DLD-1 and MCF-7 growth on the transwells was also evaluated (figures 3-2 
and 3-3). Compared to previous studies (Evans et al., 2009; Phillips et al., 
1998) and as expected, DLD-1 and MCF-7 formed MCLs, the thickness of 
which increased as the incubation time increased. Morphologically, the MCLs 
were generally of uniform thickness although some undulations in thickness 
were observed. It was important to carefully look down the light microscope at 
the day 1 cultures to ensure that an even cell layer was present. Any gaps in 
the cell layer can be visualised easily using an objective magnification of X20 
and these transwells were discarded. Electrical impedence devices can be 
used to check the integrity of cell layers but histological analysis of cell layers 
that were checked visually provided a reliable indicator of the integrity of the 
MCL. Furthermore, trypan blue was used to test the ability of DLD-1 MCL to 
form a barrier. The penetration of trypan blue was rapid through blank 
membrane (no cells) but in the presence of a thin MCL of 13.3 µm the 
penetration of trypan blue was significantly impaired. Impaired trypan blue 
penetration through the MCL proved that the MCL formed a good barrier but 
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the blank membrane itself did not. For this reason the MCL can be used to 
measure drug penetration. It also suggests that movement of drug between 
cells is comparatively poor.  
In addition to DLD-1 and MCF-7 cells, the ability of a panel of other cell lines to 
form MCLs was also tested. They were selected based on their ability to form 
spheroids  (Friedrich et al., 2007) and on the basis that cells which formed 
close compact colonies in vitro (determined visually) with each other were 
most likely to form good MCLs. Some of these cells formed MCLs with 
thicknesses ranging from 20 – 120 µm that were morphologically similar to 
MCF-7 and DLD-1 cells. These cell lines included; Panc-1, SK-MEL 23, A-
2780, M14, SiHa and Caski. In contrast, A-549, 7860, HT-29 and PC3 cell 
lines formed thin MCLs with gaps between the cells. Others grew as 
aggregates that were uneven and ‘patchy’ (HT-29 and PC-3 for example). The 
results for HT-29 were surprising as this cell line readily forms multicell 
spheroids that are uniform in shape. In addition, other groups have generated 
MCLs on transwells using the HT-29 cell line (Hicks et al., 2006; Hicks et al., 
2003). The results of this study have shown that whilst several cell lines will 
form MCLs in the transwell system, others will not readily grow or form uniform 
MCLs. It is conceivable that inclusion of a matrix which embeds the cells on 
the transwell could help these cell lines form a MCL but this approach is 
potentially complex as the matrix itself may form a barrier to drug penetration.  
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4.2 Extraction techniques and their efficiencies: 
As it was expected that a wide range of concentrations would be generated 
using the three different penetration models, it was necessary to evaluate 
different extraction techniques. Extraction efficiency, limit of detection, ease of 
use and cost were the requirements for a suitable extraction technique in this 
study. Three different extraction techniques were evaluated based on the 
above requirements. Although SPE is an expensive and time consuming 
procedure, it was the only technique which capable of concentrating large 
volumes of sample. For this reason SPE was selected as the technique which 
gave the lowest limit of detection (Table 3-1), compared to protein precipitation 
with and without evaporation in which there was no concentration step. Protein 
precipitation without evaporation was nevertheless used for samples which 
were expected to give higher concentrations as it was quicker and cheaper. 
4.3 Evaluating and validating sampling methods: 
During the early stages of this study, penetration assays using model 1 were 
conducted according to previously published studies (Phillips et al., 1998). 
Sampling from the bottom chamber occurred by taking 10 µL samples at 
various time intervals after addition of drug to the top chamber. At each time 
point, fresh media replaced the 10 µL sample so that the volume in the bottom 
chamber remained constant. As time progressed, the concentration of drug in 
the top chamber would decrease and this would be matched by an increase in 
drug concentration in the bottom chamber. The concentration gradient across 
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the MCL was variable and this sampling method was called VCG denoting 
variable concentration gradient.  
Using this sampling technique, the ability of doxorubicin to cross MCLs was 
evaluated using an initial concentration of 100, 50 and 25 µM in the top 
chamber. These concentrations were chosen to check that they can be 
detected by the analysis method before going to human peak plasma 
therapeutic level concentrations. Penetration assays were conducted using 
blank membrane as a control and several thicknesses of DLD-1 and MCF-7 
MCLs. Experiments were conducted on days 1, 3, 5, and 7 of DLD-1 growth 
on the membrane. It was noticed that the penetration curves which were 
produced by this method were variable even with blank samples (no cells 
loaded). This level of variability was inconsistent and it made determining the 
rate of penetration challenging. A variety of possible explanations for this 
variability were put forward and tested experimentally. One possible 
explanation was the fact that the transwells used were dehydrated prior to 
being used in cell culture. It was proposed that air bubbles trapped in the 
membrane could cause variations in drug penetration. For this reason the 
experiment was repeated using a hydrated transwell but there was no major 
change in the shape of the curves (Figure 3-19). The second expected cause 
of variation in the shape of the plotted curve was the membrane itself. The 
membrane was collagen coated which could bind doxorubicin and this may be 
variable. To remove the collagen, the membrane was trypsinized prior to 
conducting the penetration assay. Although doxorubicin penetration through a 
trypsinized membrane was faster compared to non-trypsinized which might be 
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due to drug binding to collagen in non-trypsinized membrane, however, 
variations and spikes in the results did not disappear (Figure 3-20). The 
source of error could not be traced despite numerous attempts to resolve this 
problem. It is likely that the main source of error stems from the fact that the 
volume of sample taken for analysis is small (10 µL). Whilst the pipettes were 
routinely calibrated, the error associated with sampling small volumes is 
potentially large and this could be a major contributing factor to the 
experimental variability observed.  
Because of the variability obtained with this sampling technique, it was 
replaced with an alternative method. This method was called the constant 
concentration gradient or CCG-technique. This technique was reproducible, 
less time consuming and samples created with this technique could be 
analysed using any of the previous extraction techniques as the sample 
volume was 500 µL instead of the 10 µL volume used previously. The plotted 
curves using CCG-technique (Figures 3-24 and 3-25), were linear and 
reproducible with r2 of more than 0.95 in all cases. The variability seen in the 
previous methodology was not observed using this method and it was possible 
to calculate the penetration rate of doxorubicin through MCLs. Doxorubicin 
concentrations that are less than 25 µM can be used and different factors that 
influence drug penetration such as modifying IFP or ECM components can be 
quantified using this method. 
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4.4 Evaluating and validating analysis methods: 
Liquid chromatography (LC), liquid chromatography with mass spectrometry 
(LC/MS) and LC/MS/MS were used to analyse the three drugs which were 
used in this study. All the three systems were able to give reasonable limits of 
detection with acceptable precision (Figures 3-8, 3-9 and 3-11 – 3-16 and 
table 3-1). Results of these three systems were in agreement with other 
studies that used liquid chromatography to analyse doxorubicin, imatinib and 
gefitinib in biological samples in spite of the changes in the analysis 
parameters (Storm et al., 1988; Widmer et al., 2004; Zhao et al., 2005). Use of 
internal standard helped reduce the variations that could occur during sample 
extraction from tissue culture medium (Grantab et al., 2006; Zheng et al., 
2001).  Calibration curves from the three different analysis systems were 
reproducible and linear with linear regression coefficients of > 0.98 (Figures 3-
9, 3-15 and 3-16). The methods described here for the analysis of doxorubicin, 
imatinib and gefitinib were sensitive and reproducible and therefore suitable 
for use in the drug penetration assay. 
4.5 Evaluating drugs stability at 37°C: 
Doxorubicin, imatinib and gefitinib stabilities in culture medium were assessed 
at 37°C and the results showed that there was <10% loss after 120 minutes 
incubation period at 37°C (Figures 3-10 and 3-17). The samples are therefore 
stable and this simplified sample collection enormously. Despite this, care was 
always taken when dealing with samples by placing them on ice at all times 
when conducting an experiment to guarantee drug stability. Stability results 
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were in agreement with other published studies (Storm et al., 1988; Widmer et 
al., 2004; Zhao et al., 2005). 
4.6 Impact of convective fluid flow (CFF) and diffusion on 
drug penetration using the three different penetration 
models: 
The ability of drugs to penetrate MCLs of various thicknesses in the presence 
or absence of CFF is the central issue addressed in this thesis. The ability of 
doxorubicin, imatinib and gefitinib to penetrate MCLs using the three 
experimental conditions described above is discussed below. 
4.6.1 Diffusion only penetration assays, model-1 (D↓): 
Diffusion only penetration assays were performed using the variable 
concentration gradient (VCG) and constant concentration gradient (CCG) 
techniques. 
4.6.1.1 Penetration of doxorubicin across MCLs using a variable 
concentration gradient (VCG): 
Despite the problems with this approach with regards to variation, some 
valuable data was obtained that is discussed here. Using the diffusion only 
penetration assays with VCG technique (section 2.7.1), the penetration rate 
was proportional to drug concentration and inversely proportional to the MCL 
thickness. Doxorubicin penetration through membrane alone (no cells seeded) 
was considerably higher compared to its penetration through multicell layers. 
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This finding is in agreement with other studies (Evans et al., 2009; Grantab et 
al., 2006; Phillips et al., 1998; Tunggal et al., 1999). Using this technique, and 
in spite of the “spiky” curves, it was possible to calculate the penetration rates 
through blank transwells and through the MCLs. However, the calculated 
penetration rates using this technique were not reliable because of the noticed 
variations and spiking in the plotted curves (tables 3-2 to 3-4 and figures 3-22 
and 3-23). This approach generated limited data but some general trends 
were obtained. In particular, drug penetration is inversely proportional to the 
thickness of the MCL and proportional to drug concentration.  
4.6.1.2 Penetration of drugs across MCLs using a constant 
concentration gradient (CCG): 
As discussed above, because of the variability observed in the previous assay, 
the sampling and experimental design was changed. At each time point, 
media containing drug in the top chamber was replaced with fresh media 
containing drug at the original concentration. At the same time, the media in 
the bottom chamber was changed and replaced with fresh medium. In this 
way, the concentration gradient between the top and bottom chamber was 
maintained. By keeping the sampling time short (5 minutes maximum), 
concentration gradient would not change significantly during each sample 
point. A further advantage of this technique was that the sample volume used 
to analyse drug concentration increased from 10 µL in the previous method to 
500 µL. The sensitivity of the assay then increased significantly. 
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The results of this modification to the drug penetration assay are presented in 
figures 3-24 and 3-25.  Using this technique, a constant concentration of drug 
crossed the MCL per unit time which when presented as cumulative 
concentration against time gave a linear increase in drug concentration (Figure 
3-24).  The data obtained was significantly better than the previous technique 
with no major variations observed. Linear regression analysis typically gave 
regression coefficient values of >0.98 and rates of drug penetration were 
easily determined from these results. Based on these results, this 
methodology provides a more reproducible and accurate measure of drug 
penetration rates. 
Analysis of doxorubicin penetration across blank membranes, DLD-1 and 
MCF-7 MCLs of different thicknesses are presented in figures 3-24 to 3-31 
and in tables 3-5 to 3-10. Penetration rates ranged from 0.1016 ± 0.009 to 
0.0087 ± 0.0027 nmols/minute for DLD-1 MCLs of 12.91 ± 3.01 and of 69.4 ± 
7.4 µm thick respectively. These results are reproducible and demonstrate that 
an inverse relationship between MCL thickness and doxorubicin penetration 
exists. Whilst this conclusion is not novel, it is to my knowledge the first time it 
has been demonstrated here using the constant concentration gradient 
methodology. The penetration rate of doxorubicin was also concentration 
dependent as shown in figures 3-27 to 3-31. Using DLD-1 MCL of 12.91 ± 3.01 
µm thick, penetration rates of 0.1016 ± 0.0095, 0.0223 ± 0.0071 and 0.0171 ± 
0.0049 were obtained when concentrations of doxorubicin at 100, 50 and 25 
µM were applied respectively (Figures 3-28 and 3-30 and Tables 3-5 to 3-7). 
These results were also reproducible and are consistent with the results of 
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other studies (Evans et al., 2009; Kyle et al., 2004; Kyle and Minchinton, 1999; 
Phillips et al., 1998; Tannock et al., 2002; Tunggal et al., 1999; Wilson and 
Hicks, 1999). Using this methodology, studies were extended to imatinib and 
gefitinib (Figures 3-42 and 3-43). Using DLD-1 MCLs of 13.01 ± 4.23 and 
12.33 ± 2.79 µm thick and 100 µM in the top chamber, the penetration rates of 
imatinib and gefitinib were 0.103 ± 0.04 and 0.18 ± 0.04 nmols/minute 
respectively (Figure 3-44 and 3-45 and table 3-12).   
Using the diffusion only penetration assay model (model 1), the penetration 
rates of the three drugs through one day old DLD-1 MCL were compared 
(table 3-12). It was clear that the penetration rate of gefitinib was almost 2 
times faster than imatinib and doxorubicin which have mainly shown similar 
penetration rates. Whilst there are many potential explanations, Gefitinib 
penetrated faster possibly because it acts on EGFR which is moderately 
expressed in DLD-1 (Prewett et al., 2002), whereas imatinib acts on and may 
be bound to c-kit which is expressed in DLD-1 (Ito et al., 1990). Based on the 
previous results, and as proved by other studies (Minchinton and Tannock, 
2006), the poor penetration of doxorubicin may be due to its binding to DNA 
and the penetration rate decreases as the number of cells (and hence the 
amount of DNA) increases. Doxorubicin is also a substrate for drug efflux 
pumps and poor penetration might be also due to the drug being pumped out 
of cells. Furthermore, cell to cell adhesion forming tight junction or cell to 
matrix adhesion can also limit doxorubicin, imatinib and gefitinib penetration. 
As noticed in the histological sections of the MCLs cells were closely packed 
and previous electron microscopy studies have shown that tight junctions are 
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formed between cells in DLD1 multicell spheroids (Bibby et al., 1993). This 
might have been one of the causes of limited penetration of doxorubicin and is 
in agreement with other studies (Tannock et al., 2002). The other expected 
cause of limited penetration is probably related to the basic character of 
doxorubicin (weak base) and its subsequent accumulation in acidic 
endosomes (Lee and Tannock, 2006; Tunggal et al., 1999). In addition to the 
role of the MCL in limiting the penetration of doxorubicin, imatinib and gefitinib, 
the microporous membrane itself has also shown from control experiments (no 
cells loaded) that it can bind all the three drugs and acts as another barrier 
which came in agreement with other studies (Tannock et al., 2002).  
Whilst the factors that determine drug penetration are complex and varied, 
these studies provided baseline rates of penetration so that the effect of CFF 
on drug penetration can be assessed. 
4.6.2  Convection plus diffusion penetration assays, model-2 (D↓C↓): 
As explained earlier, a drugs ability to leave the blood vessel is dependent on 
both diffusion and convection (Jain, 1998). Because of the poor lymphatic 
drainage system in solid tumours, fluids usually build up and IFP increases. As 
the hydrostatic pressure is variable, there are regions within solid tumours 
where HP is less than IFP and in this case CFF is from the tumour into the 
blood vessel. This forms a barrier to drug uptake in these regions. (Heldin et 
al., 2004). 
In the original apparatus which was used to study diffusion dependent 
penetration, the height of the medium in the top chamber and bottom chamber 
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were identical, i.e. there was no pressure gradient (Figure 2-1). By inserting a 
tube into the transwell (figure 2-2), the fluid level in the top chamber was 
raised above the bottom chamber and a pressure gradient is therefore 
generated. The magnitude of this pressure gradient can change by changing 
the height of media in the tube.  
The influence of MCL thickness on CFF was studied using this model by 
setting the medium height at the top chamber to exert a hydrostatic pressure 
of 28 mmHg which is comparable to arterial hydrostatic pressure in capillaries 
(Jain, 1987a). The weight of the fluid in the bottom chamber was measured as 
a function of time to get the CFF. The results of this study were reproducible 
and demonstrated that an inverse relationship between the CFF and MCL 
thickness exists (Figure 3-33). It was clearly noticed that a 41.1± 3.6 µm thick 
MCL was able to completely prevent CFF. This is an interesting result for 
future studies designed to alter the tumour microenvironment with the aim of 
enhancing CFF and drug delivery. If cell to cell or cell to matrix interactions 
can be manipulated, then this assay would be capable of measuring the effect 
on CFF. This therefore is a novel experimental tool for evaluating such 
therapeutic strategies. The influence of hydrostatic pressure gradient on CFF 
was also studied (Figure 3-32) and CFF was proportional to the hydrostatic 
pressure gradient. These results clearly demonstrate that CFF occurs in the 
experimental model, the magnitude of which varies depending upon both the 
thickness of the MCL and the pressure gradient applied.  
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After checking the ability of this model to create CFF was established, the 
influence of this CFF on the penetration of drugs through MCLs was studied 
using doxorubicin, imatinib and gefitinib. Adding these drugs to the top 
chamber of the model, a physiologically relevant pressure gradient of 28 
mmHg was applied on the MCLs to create CFF of 28.41 ± 2.97, 21.08 ± 9.48 
and 24.04 ± 5.49 µL/min in the case of experiments using doxorubicin, imatinib 
and gefitinib respectively. This result demonstrates that the drugs themselves 
do not induce any major changes in CFF. It was clearly noticed that 
penetration rates were significantly increased in the presence of CFF. Under 
these experimental conditions, penetration rates for doxorubicin, imatinib and 
gefitinib  were 1.53 ± 0.17, 0.9 ± 0.24 and 0.78 ± 0.17 nmoles/min respectively 
(Figure 3-45). There was a 42, 26 and 12 folds increase in the penetration 
rates of doxorubicin, imatinib and gefitinib respectively in the presence of 
convection and diffusion compared with the diffusion only model (D↓). This 
enhancement in drug penetration rates is likely to be caused by CFF ‘carrying’ 
drug down the pressure gradient. It is not known whether it is pushing the drug 
between cells or through cells. This model is similar to what exists in normal 
situation i.e. non-cancerous tissues where there is high drug concentration in 
blood driving diffusion into tissues and a pressure gradient which forces CFF 
from the blood vessel into the tissue. The conclusion here is that the CFF 
significantly increases the penetration rate of drugs through MCLs. This model 
was modified in order to represent the situation in a solid tumour where the 
drug diffusion is opposed by convection coming from solid tumour due to the 
elevated IFP. This model is discussed in the following section. 
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4.6.3  Diffusion opposing convection penetration assays, model-3 
(D↓C↑): 
The above mentioned model was modified to mimic the situation in the solid 
tumour where the direction of CFF is from the tumour back into the blood 
vessel. This was achieved by applying a physiologically relevant hydrostatic 
pressure to the bottom chamber thereby causing CFF to go from the bottom to 
the top chamber. Addition of drug to the top chamber now puts diffusion driven 
drug penetration in opposition to the direction of CFF (figure 2-3). The 
experimental conditions in this model were that one day old DLD-1 MCLs were 
treated with doxorubicin, imatinib and gefitinib (at 100 µM). Drugs were added 
to the top chambers and their diffusion was opposed by hydrostatic pressure 
and CFF (from bottom chamber) of 45.57 ± 6.94, 60.23 ± 11.89 and 44.90 ± 
1.65 µL/min in case of doxorubicin, imatinib and gefitinib respectively (Figure 
3-40). Using this model, penetration rates of doxorubicin, imatinib and gefitinib 
respectively were 0.04±0, 0.04±0 and 0.03±0.01 nmoles/min as presented in 
figure 3-45. The penetration rate of these drugs is therefore significantly 
reduced when CFF opposes drug diffusion.  
Whilst this assay is technically feasible, it is more demanding than models 1 
and 2.  The main disadvantage with this model was that at each sampling 
point, the entire bottom chamber had to be replaced and this was time 
consuming.  In order to simplify this model and reduce the time required to 
obtain samples, it was further modified by adding the drug to the bottom 
chamber and drug concentration in the top chamber was measured (i.e. D↑ 
C↓) as presented in figure 2-4. The hydrostatic pressure from the top to the 
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bottom chamber is applied using 13 mL of medium which exerts a 
physiologically relevant pressure of 28 mmHg similar to that used in the 
convection plus diffusion model. With this model, doxorubicin flowed from the 
bottom chamber to the top chamber at rates of 0.08 ± 0.02 nmoles/min and 
CFF from top to bottom chamber was 26.7 ± 3.9 µL/min. The penetration rate 
with this model was also significantly lower compared to the diffusion only 
model. The advantage of this model is that it reduces the sampling time 
considerably but the main disadvantage of this model is that there is no proper 
stirring in the top chamber.  
The results of the three models have clearly proved that CFF significantly 
affects drug penetration rates. It was clearly noticed that drug penetration was 
enhanced in the presence of CFF. In contrast, drug penetration was 
dramatically limited and hindered when diffusion was opposed by CFF. These 
results came in agreement with the results of the in vivo convection enhanced 
delivery experiments which were conducted by Bobo, Lidar and Mardor (Bobo 
et al., 1994; Lidar et al., 2004; Mardor et al., 2005). Whilst different in vivo 
methodologies were used, the aim of which was studying the influence of 
convection on improving drug delivery was the same. The results of the Bobo, 
Lidar and Mardor studies have also added and proved that convection can 
also be used to enhance drug distribution into solid tumours with the 
advantage of avoiding systemic toxicity. These conclusions can strengthen the 
importance of designing simple in vitro models for studying the impact of CFF 
on drug penetration. 
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Different strategies can be used to improve drug penetration and lethality to 
cells. These strategies include modification of the factors that limit drug 
penetration. For example, the extracellular matrix is significantly altered in 
solid tumours and it may provide a barrier by sequestering drug via protein 
binding mechanisms. It also contributes significantly to increased rigidity of 
tumours thereby preventing the increased interstitial fluid pressure from 
dissipating. There is considerable interest in developing novel strategies that 
target the cellular and/or extracellular microenvironment of tumours. The 
experimental models described in this thesis could be used to evaluate 
therapeutic strategies designed to modify the tumour microenvironment with 
the aim of re-establishing CFF therefore enhancing the delivery of a partner 
therapeutic. This is the first report of an in vitro model that can address this 
issue and further studies to explore other applications (e.g. co-culturing with 
stromal fibroblasts to form more complex MCLs) are warranted. 
4.7  Concentration versus time effect on cell survival: 
Having established that CFF influences drug penetration, an obvious question 
to ask was what impact does CFF have on the sensitivity of cells to the drugs? 
Cells were exposed to concentrations of drugs (Table 3-13) that represent the 
amounts of drugs which penetrated through the MCL in each model. As the 
length of the experiment was 30 minutes, cells were exposed to these 
concentrations for this period of time to determine the concentration versus 
time effect on the cell survival. DLD-1 cells were exposed to doxorubicin, 
imatinib and gefitinib in separate experiments using three different 
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concentrations of each drug, each of which represented the concentration of 
drug which penetrated DLD1 MCLs using the three experimental models. Cells 
were sensitive to the three different concentrations of doxorubicin (Figure 3-
46) however; imatinib and gefitinib (Figures 3-47 and 3-48) did not show 
significant toxicity to the same cell line.  
In the three experimental models, the concentrations of doxorubicin that 
penetrated the MCL in 30 minutes were 112, 2.8 and 0.03 µM for C↓D↓, D↓ 
and D↓C↑ models respectively table 3-13. Using these concentrations, the % 
cell kill was 76.6, 27 and 1% which clearly demonstrates that the direction of 
CFF not only impacts upon drug penetration but it also affects cell response. 
This conclusion is pharmacologically obvious but it clearly demonstrates that 
CFF can have a significant effect on cellular response. The same experiments 
conducted using imatinib and gefitinib were not conclusive as both drugs are 
not very active at the concentrations used. 
4.8 Modifying ECM components as a strategy to improve 
CFF: 
The last two models in this study proved the ability of CFF to enhance drug 
penetration through MCLs. For this reason, thinking of strategies to improve 
CFF would enhance drug penetration through MCL. As stated above, one of 
the strategies to think of was to modify the MCL extracellular matrix (ECM) 
components assuming that the MCL can include an ECM. Collagen is known 
to be one of the components of ECM. In this study, an experiment was 
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conducted to check whether or not DLD-1 MCL can secrete collagen. The 
hypothesis on which this experiment built was that if DLD-1 MCL expresses 
collagen, then if this collagen was degraded enzymatically, that might enhance 
CFF through MCL and hence improve drug penetration. There are several 
types of collagen and collagen type-IV was chosen for this experiment 
(Tannock et al., 2002). Immunohistochemistry was used to detect whether or 
not collagen-IV was present in DLD-1 MCLs. DLD-1 xenograft tissues were 
used as control. Immunohistochemical staining has expressed collagen-IV 
only in DLD-1 xenograft tissues but this expression was not noticed in DLD-1 
MCL as presented in figure 3-49. This suggests that DLD-1 MCL might not be 
secreting this type of collagen or that it might be secreting another ECM 
component such as laminin or fibronectin which needs to be tested using 
another specific antibody. These results can be compared with Tannocks team 
results (Tannock et al., 2002) which have shown the presence of an ECM 
containing both laminin and collagen type-I in the MCLs of MGH-U1 tumour 
(Human bladder carcinoma). However, Tannocks and his team results were in 
agreement with what was achieved in this study through proving the absence 
of collagen-IV in MGH-U1 MCLs although it was present in tumour sections. 
Due to time limitation, this experiment was not further investigated and it can 
be further investigated in the future. Future work should be conducted to 
characterise ECM formation in MCLs using antibody against ECM component 
such as laminin or fibronectin or even another type of collagen. Subsequent 
studies designed to degrade the ECM as a means of enhancing CFF and drug 
delivery would therefore be possible. 
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4.9 Limitations of the study: 
The experimental models described in this study are simple in vitro models 
that are capable of assessing drug penetration through multicell layers and 
assessing the impact of CFF on drug penetration. To my knowledge, no 
previous study has been able to assess CFF or to calculate its effects on 
penetration rates in vitro. These models provide a novel strategy to assess the 
effect of modifying IFP in order to assess the effect of CFF on drug 
penetration. Whilst there are many attractive features to this model, it is true 
that there are limitations. These include the inability to mimic or represent the 
vascular part of the solid tumour and being in vitro models, they are unable to 
represent the full classical PK/PD properties of the used drugs. This especially 
includes drug metabolism process which is considered an essential part of the 
drug PK properties. The preliminary studies reported here also suggest that 
DLD-1 cells cannot form a collagen-IV containing ECM but further studies are 
needed to examine whether other ECM components are secreted. Other 
studies (Tannock et al., 2002) have indeed proved that MCL can form an 
ECM. Despite these limitations, the experimental models described here are 
novel and within the limitations of this approach, can be used to study the 
impact of CFF on drug penetration and its possible therapeutic manipulation. 
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4.10 Conclusion: 
Solid tumour resistance to chemotherapy occurs due to several factors. 
Although cellular and genetic causes of resistance have been proved, 
resistance due to limited drug delivery has also been proved to contribute to 
chemotherapy resistance. Developing strategies to improve drug delivery to 
solid tumours is therefore important and is a fundamental requirement for 
efficacy.   As drug delivery depends mainly on convection and diffusion, one of 
the strategies to be followed is to improve convective fluid flow (CFF) to solid 
tumours but this field is currently limited by the absence of in vitro models 
capable of measuring CFF and its effects on drug penetration. In this study, 
simple in vitro models were developed to study drug penetration through MCL. 
These models were modified to allow CFF and penetration rates to be 
calculated. It was proved in this study that CFF has a significant impact on 
drug penetration. The model itself is flexible and can be modified further to 
incorporate several other features of tumour biology such as the presence of 
an ECM and co-cultures with stromal fibroblasts. It is limited by the fact that it 
does not incorporate the tumour vasculature although it is feasible to culture 
HUVEC or other endothelial cell lines in the transwell. CFF in the presence or 
absence of VEGF could therefore be studied and it is feasible to use such a 
model to study strategies aimed at ‘normalising’ the vascular supply to 
tumours. This proposal clearly requires further study.    
In conclusion, the results of this study illustrate the importance of convective 
fluid flow for effective drug delivery. In tumours where the convective flow is 
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reduced or reversed due to elevated tumour IFP, drug delivery is impaired. 
Strategies designed to enhance convective flow by manipulation of tumour cell 
or tumour/stroma interactions could enhance drug uptake and this model 
provides a ‘tool’ for evaluating such strategies. The limitation of the model is 
that it does not mimic the role played by the microvasculature in generating 
elevated interstitial fluid pressures in tumours.  
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6. APPENDICES: 
6.1 Appendix 1: Chemical structures and molecular weights 
of doxorubicin, imatinib and gefitinib: 
 
Drug Chemical structure  Molecular 
weight (g/L) 
 
Doxorubicin 
C27H29NO11 · HCL 
 
 
579.98 
 
Imatinib 
C29H31N7O 
 
 
493.6 
 
Gefitinib 
C22H24ClFN4O3 
 
 
446.9 
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6.2 Appendix 2: 
Summary of various analysis conditions used for doxorubicin, imatinib and gefitinib in the three 
different penetration systems: 
  Drugs (100µM) 
Variable Model Doxorubicin Imatinib Gefitinib 
Analysed sample 
(µL) + Internal 
standard (µL) 
C↓D↓ 100 + 100 100 + 300 100 + 300 
D↓ 500 + 100 100 + 300 100 + 300 
D↓C↑ 900+100 100+300 900+100 
Internal Standard 
C↓D↓ 50µM 
Epirubicin 
50µM 
Gefitinib 
50µM 
Imatinib 
D↓ 500nM 
Epirubicin 
500nM 
Gefitinib 
500nM 
Imatinib 
D↓C↑ 500nM 
Epirubicin 
500nM 
Gefitinib 
500nM 
Imatinib 
Reconstitution 
volume (µL) 
C↓D↓ 100 400 400 
D↓ 50 400 400 
D↓C↑ 50 400 50 
Injection volume 
(µL) 
C↓D↓ 10 50 30 
D↓ 10 50 10 
D↓C↑ 30 10 10 
Estimated IFP 
(mmHg) 
 
C↓D↓ +28 +28 +28 
D↓ 0 0 0 
D↓C↑ +28 +28 +28 
Analysing Machine 
C↓D↓ HPLC HPLC HPLC 
D↓ HPLC LC/MS LC/MS 
D↓C↑ HPLC LC/MS/MS LC/MS/MS 
Extraction method 
C↓D↓ SPE PPT PPT 
D↓ SPE PPT PPT 
D↓C↑ SPE PPT SPE 
SPE= Solid Phase Extraction, PPT= Protein Precipitation without evaporation. 
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7. CONFERENCE ABSTRACTS: 
7.1 Abstract-1, presented in the BACR 50th Anniversary 
Meeting. “Hallmarks of Cancer: From Mechanisms to 
Therapies” held from 13th to 15th June 2010 at Heriot-Watt 
University, Edinburgh. 
The development and evaluation of a model for assessing convective fluid 
flow through multicell layers in vitro 
H Makeen1, N Periasamy1, PM Loadman1, S Smye2,5, B Sleeman3, P 
Jones4, C Evans5, C Twelves6,1, RM Phillips1 
1Institute of Cancer Therapeutics, University of Bradford, Bradford, West Yorkshire, 
United Kingdom, 2Department of Medical Physics and Engineering, Leeds 
Teaching Hospitals, St James’s University Hospital, Leeds, West Yorkshire, United 
Kingdom, 3Department of Applied Mathematics, University of Leeds, Leeds, West 
Yorkshire, United Kingdom, 4Section of Molecular Gastroenterology, Leeds 
Institute of Molecular Medicine, University of Leeds, St James’s University 
Hospital, Leeds, West Yorkshire, United Kingdom, 5Division of Medical Physics, 
Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds, 
West Yorkshire, United Kingdom, 6Section of Oncology and Clinical Research, 
Leeds Institute of Molecular Medicine, University of Leeds, St James’s University 
Hospital, Leeds, West Yorkshire, United Kingdom 
One consequence of elevated interstitial fluid pressure (IFP) in solid 
tumours is that the normal process of convective fluid flow (CFF) through 
tissues is impeded. This is recognised as a major barrier to drug uptake 
leading to reduced drug efficacy. Studies of IFP have exclusively used in 
vivo models; the aim of this study was to develop an in vitro model that 
could be used to measure CFF. The model consists of a transwell cell 
culture insert which supports the growth of multicell layers (MCL) on 
collagen coated membranes with a pore size of 3 µm. A graduated tube is 
inserted into the transwell and a pressure gradient is applied across the 
membrane by raising the volume of medium in the tube above that of the 
bottom chamber. CFF is determined by measuring the weight of medium in 
the bottom chamber as a function of time. Using a physiologically relevant 
pressure gradient of 28.8 mmHg, CFF progressively decreased as the 
thickness of the MCL increased. DLD-1 MCL with a thickness of 47.6 ± 11.2 
µm completely impeded CFF. Using a MCL of 12.9 ± 3.0 µm and a pressure 
gradient of 28.8 mmHg, CFF was 0.192 mL/min. Under these conditions, 
the rate of penetration of doxorubicin across the MCL was 75 fold greater 
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than when no pressure gradient exists. This model illustrates the 
pharmacological impact that reduced CFF can have on drug delivery; it also 
provides a model for evaluating strategies designed to restore CFF in 
tumours. 
7.2 Abstract-2, Presented in the 5th Saudi International 
Conference, (SIC 2011), 23rd – 26th of June, 2011, the 
University of Warwick, Coventry, UK. 
Influence of convective fluid flow on the penetration of anti-cancer drugs 
through multicell layers.  
Hafiz Makeen1, Nagarajan Periasamy1, Paul M. Loadman1, Pamela F. 
Jones2, Brian D. Sleeman2, Stephen W. Smye2, Chris J. Twelves2, Roger 
M. Phillips1 
1University of Bradford, Bradford, 2University of Leeds, Leeds, United 
Kingdom.  
Background and aims: Elevated interstitial fluid pressure (IFP) is a 
characteristic feature of many solid tumours. One consequence of elevated 
IFP is that the normal process of convective fluid flow through tissues is 
impeded, and this is now recognised as a major barrier to drug uptake. 
Therapeutic approaches designed to reduce tumour IFP with the aim of 
restoring convective fluid flow and hence enhance the delivery of partner 
therapeutics is currently of considerable interest. To date, studies of tumour 
IFP have almost exclusively used in vivo models. The aim of this study was 
to develop an in vitro model that could be used to measure convective fluid 
flow. 
Model Design: The model is based upon the conventional transwell model 
for assessing drug penetration across multicell layers. This model consists 
of a transwell insert that is placed into 1 well of a 24 well plate (panel A). 
The top and bottom chamber is separated by microporous membrane upon 
which cells can be cultured to form multicell layers (panel B). Drugs are 
added to the top chamber and drug concentrations in the bottom chamber 
are measured as a function of time.  
In the conventional apparatus, the level of medium in the top and bottom 
chamber is equal and no pressure gradient exists across the membrane. By 
inserting a graduated tube into the transwell apparatus (panel C), the level 
of medium in the top chamber can be raised above that in the bottom 
chamber and a pressure gradient across the membrane is formed, the 
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magnitude of which can be varied by adjusting the height of medium in the 
tube.  
Analysis of convective fluid flow: DLD-1 human colon carcinoma cells were 
cultured on transwell membranes to various thicknesses and convective 
fluid flow was measured by weighing the bottom chamber at various time 
intervals after applying the pressure gradient. Following the application of a 
physiologically relevant (20.2 mmHg) hydrostatic pressure, convective fluid 
flow decreased as the thickness of the MCL increased. No fluid flow across 
the membrane occurred when the MCL was greater than 47.6 µm. In the 
absence of a MCL, fluid flow was 5.5 mL/min.   
Proof of concept studies: DLD-1 human colon carcinoma cells were cultured 
on transwell membranes for 1 day (12.91 ± 4.50 µm thickness) and 
doxorubicin, gefitinib and imatinib at 100 µM were added to the top chamber 
in the presence or absence of a hydrostatic pressure gradient in individual 
experiments. The concentration of drugs were measured in the bottom 
chamber as a function of time using HPLC. At each sampling point, the 
medium in the top chamber was ‘topped up’ to ensure that both the 
pressure gradient and drug concentration remained constant. Similarly, 
medium in the bottom chamber was replaced at each time point with drug 
free medium. The rate of penetration of doxorubicin is significantly greater 
(approx 42 fold) when hydrostatic pressure of 20.2 mmHg is applied. In 
case of gefitinib and imatinib, the rate of penetration increased by 12 and 26 
fold respectively when convective fluid flow was present. 
Conclusions: The results of this study illustrate the importance of convective 
fluid flow for effective drug delivery. In tumours where the convective flow is 
reduced due to elevated tumour IFP, drug delivery is impaired. Strategies 
designed to enhance convective flow by manipulation of tumour cell or 
tumour/stroma interactions could enhance drug uptake and this model 
provides a ‘tool’ for evaluating such strategies. The limitation of the model is 
that it does not mimic the role played by the microvasculature in generating 
elevated interstitial fluid pressures in tumours.    
 
